# workset high-value-sentences_1 (generated on Wed Aug 3, 2016 at 16:57:43 for user bbadarau)

# ::id PMC_123_4335.0 ::date 2016-07-19T13:05:36 ::authors amoldovan
# ::snt Rapid Estrogen-Induced Phosphorylation of the SRC-3 Coactivator Occurs in an Extranuclear Complex Containing Estrogen Receptor
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_0.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity :name (n / name :op1 "estrogen")
            :xref (x / xref :value "CHEBI:50114"))
      :ARG1 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (p3 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p / phosphorylate-01))
      :location (m2 / macro-molecular-complex))

# ::id PMC_123_4335.2 ::date 2016-07-19T23:15:20 ::authors amoldovan
# ::snt SRC-3/AIB1/ACTR/pCIP/RAC3/TRAM1 is a primary transcriptional coregulator for estrogen receptor (ER).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user amoldovan ::file PMC_123_4335_2.txt
(a / add-modification-00
      :ARG0 (p / protein :name (n / name :op1 "SRC-3")
            :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
      :ARG1 (p2 / protein :name (n2 / name :op1 "estrogen" :op2 "receptor")
            :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN")))

# ::id PMC_123_4335.3 ::date 2016-07-20T22:55:18 ::authors amoldovan
# ::snt Six SRC-3 phosphorylation sites have been identified, and these can be induced by steroids, cytokines, and growth factors, involving multiple kinase signaling pathways.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_3.txt
(s / smr-empty)

# ::id PMC_123_4335.4 ::date 2016-07-20T22:57:52 ::authors amoldovan
# ::snt Using phosphospecific antibodies for six phosphorylation sites, we investigated the mechanisms involved in estradiol (E2)-induced SRC-3 phosphorylation and found that this occurs only when either activated estrogen receptor α (ERα) or activated ERβ is present.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_4.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "estrogen" :op2 "receptor" :op3 "α")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN")
                  :ARG1-of (a / add-modification-00
                        :manner (p2 / phosphorylate-01)))
            :ARG1 (i3 / increase-01
                  :ARG0 (m2 / molecular-physical-entity :name (n2 / name :op1 "estradiol")
                        :xref (x2 / xref :value "CHEBI:50114"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p7 / protein)
                        :ARG1 (p4 / protein :name (n3 / name :op1 "SRC-3")
                              :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner p2)))
      :card2 (i4 / increase-01
            :ARG0 (p5 / protein :name (n4 / name :op1 "estrogen" :op2 "receptor" :op3 "β")
                  :xref (x4 / xref :value "UNIPROT:ESR2_HUMAN")
                  :ARG1-of (a3 / add-modification-00
                        :manner (p6 / phosphorylate-01)))
            :ARG1 (i5 / increase-01
                  :ARG0 (m3 / molecular-physical-entity :name (n5 / name :op1 "estradiol")
                        :xref (x5 / xref :value "CHEBI:50114"))
                  :ARG1 (a4 / add-modification-00
                        :ARG0 (p9 / protein)
                        :ARG1 (p10 / protein :name (n6 / name :op1 "SRC-3")
                              :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner p6))))

# ::id PMC_123_4335.6 ::date 2016-07-21T06:24:51 ::authors amoldovan
# ::snt Mutations in the coactivator binding groove of the ERα ligand binding domain inhibit E2-stimulated SRC-3 phosphorylation, as do mutations in the nuclear receptor-interacting domain of SRC-3, suggesting that ERα must directly contact SRC-3 for this posttranslational modification to take place.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_6.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (m2 / mutate-01
                  :ARG1 (p12 / protein-segment :name (n6 / name :op1 "ligand" :op2 "binding" :op3 "domain")
                        :part-of (p2 / protein :name (n / name :op1 "ERα"))))
            :ARG1 (i2 / increase-01
                  :ARG0 (m4 / molecular-physical-entity :name (n2 / name :op1 "E2")
                        :xref (x / xref :value "CHEBI:50114"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p10 / protein)
                        :ARG1 (p5 / protein :name (n3 / name :op1 "SRC-3"))
                        :manner (p3 / phosphorylate-01))))
      :card2 (d2 / decrease-01
            :ARG0 (m3 / mutate-01
                  :ARG1 (p / protein-segment :name (n7 / name :op1 "receptor-interacting" :op2 "domain")
                        :part-of (p7 / protein :name (n4 / name :op1 "SRC-3"))))
            :ARG1 (i3 / increase-01
                  :ARG0 (p8 / protein :name (n5 / name :op1 "E2")
                        :xref (x2 / xref :value "UNIPROT:DHB1_HUMAN"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p11 / protein)
                        :ARG1 p7
                        :manner (p9 / phosphorylate-01)))))

# ::id PMC_123_4335.7 ::date 2016-07-20T23:20:24 ::authors amoldovan
# ::snt A transcriptionally inactive ERα mutant which localizes to the cytoplasm supports E2-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_7.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "ERα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN")
            :location (c / cytoplasm)
            :ARG2-of (m / mutate-01))
      :ARG1 (i3 / increase-01
            :ARG0 (m2 / molecular-physical-entity :name (n3 / name :op1 "E2")
                  :xref (x3 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (p3 / protein :name (n2 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p2 / phosphorylate-01))))

# ::id PMC_123_4335.8 ::date 2016-07-21T00:44:16 ::authors amoldovan
# ::snt Mutations of the ERα DNA binding domain did not block this rapid E2-dependent SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_8.txt
(d / decrease-01 :polarity -
      :ARG0 (m / mutate-01
            :ARG1 (p / protein-segment
                  :part-of (p2 / protein :name (n / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))))
      :ARG1 (i2 / increase-01
            :ARG0 (m2 / molecular-physical-entity :name (n2 / name :op1 "E2")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p6 / protein)
                  :ARG1 (p5 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_123_4335.10 ::date 2016-07-21T01:17:38 ::authors amoldovan
# ::snt Our results provide evidence for an early nongenomic action of ER on SRC-3 that supports the well-established downstream genomic roles of estrogen and coactivators.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_10.txt
(s / smr-empty)

# ::id PMC_123_4335.12 ::date 2016-07-21T08:24:05 ::authors amoldovan
# ::snt Estradiol induces a mobility change of SRC-3 on SDS-PAGE gels in an ER-dependent manner.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_12.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity :name (n / name :op1 "estradiol")
            :xref (x / xref :value "CHEBI:50114"))
      :ARG1 (p2 / protein :name (n2 / name :op1 "SRC-3")
            :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
      :ARG1-of (i3 / increase-01
            :ARG0 (p4 / protein :name (n3 / name :op1 "ER")
                  :xref (x3 / xref :value "UNIPROT:ESR1_HUMAN"))))

# ::id PMC_123_4335.13 ::date 2016-07-21T10:39:02 ::authors amoldovan
# ::snt It is well known that posttranslational modifications of proteins (e.g., phosphorylation) can change their electrophoretic mobility on SDS-PAGE gels.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user amoldovan ::file PMC_123_4335_13.txt
(s / smr-empty)

# ::id PMC_123_4335.14 ::date 2016-07-21T10:40:08 ::authors amoldovan
# ::snt Protein modification pathways can be activated by various stimuli including hormones and growth factors.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user amoldovan ::file PMC_123_4335_14.txt
(s / smr-empty)

# ::id PMC_123_4335.15 ::date 2016-07-21T10:40:44 ::authors amoldovan
# ::snt To investigate the effect of estradiol (E2) on the migration pattern of SRC-3 on an SDS-PAGE gel, E2 induction (10 nM, 1 h) was performed in HEK293T cells transiently transfected with Flag-tagged wild-type SRC-3 (SRC-3) with or without ERs.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user amoldovan ::file PMC_123_4335_15.txt
(s / smr-empty)

# ::id PMC_123_4335.16 ::date 2016-07-21T10:44:46 ::authors amoldovan
# ::snt As shown in Fig. , E2 treatment caused an upward smearing migration pattern of SRC-3 in the presence of ERα or ERβ (lanes 4 and 6).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_16.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (a2 / and
                  :op1 (m2 / molecular-physical-entity :name (n / name :op1 "E2")
                        :xref (x / xref :value "CHEBI:50114"))
                  :op2 (p4 / protein :name (n3 / name :op1 "ERα")
                        :xref (x3 / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (t / translocate-01
                  :ARG0 (p2 / protein)
                  :ARG1 (p3 / protein :name (n2 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))))
      :card2 (i3 / increase-01
            :ARG0 (a3 / and
                  :op1 (m3 / molecular-physical-entity :name (n4 / name :op1 "E2")
                        :xref (x4 / xref :value "CHEBI:50114"))
                  :op2 (p6 / protein :name (n5 / name :op1 "ERβ")
                        :xref (x5 / xref :value "UNIPROT:ESR2_HUMAN")))
            :ARG1 (t2 / translocate-01
                  :ARG0 (p7 / protein)
                  :ARG1 (p8 / protein :name (n6 / name :op1 "SRC-3")
                        :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN")))))

# ::id PMC_123_4335.17 ::date 2016-07-21T10:56:03 ::authors amoldovan
# ::snt The mobility shift was not observed in the absence of ER (Fig. , lane 2).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user amoldovan ::file PMC_123_4335_17.txt
(s / smr-empty)

# ::id PMC_123_4335.18 ::date 2016-07-21T10:56:37 ::authors amoldovan
# ::snt Treatment with E2 did not change the mobility pattern of an A6 SRC-3 mutated at all six phosphorylation sites (Fig. , lanes 7 and 8).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_18.txt
(i2 / increase-01 :polarity -
      :ARG0 (m2 / molecular-physical-entity :name (n / name :op1 "E2")
            :xref (x / xref :value "CHEBI:50114"))
      :ARG1 (t / translocate-01
            :ARG1 (a2 / amino-acid :name (n4 / name :op1 "alanine")
                  :part-of (p2 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")
                        :ARG2-of (m / mutate-01)))))

# ::id PMC_123_4335.19 ::date 2016-07-21T11:17:34 ::authors amoldovan
# ::snt These results indicated that E2 could alter the electrophoretic mobility of the wild-type SRC-3 but not its phosphorylation-site A6 mutant, implying that the E2-induced mobility change of SRC-3 is the result of SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_19.txt
(m / multi-index-card
      :card1 (t / translocate-01
            :ARG0 (m3 / molecular-physical-entity :name (n / name :op1 "E2")
                  :xref (x / xref :value "CHEBI:50114"))
            :ARG1 (p2 / protein :name (n2 / name :op1 "SRC-3")
                  :mod (w / wild-type)
                  :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")))
      :card2 (t2 / translocate-01 :polarity -
            :ARG0 (m4 / molecular-physical-entity :name (n3 / name :op1 "E2")
                  :xref (x3 / xref :value "CHEBI:50114"))
            :ARG1 (a / amino-acid :name (n4 / name :op1 "alanine")
                  :part-of (p9 / protein :name (n7 / name :op1 "SRC-3")
                        :ARG2-of (m2 / mutate-01)
                        :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))))
      :card3 (i2 / increase-01
            :ARG0 (a3 / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (p6 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p7 / phosphorylate-01))
            :ARG1 (t3 / translocate-01
                  :ARG1 p6
                  :ARG1-of (i3 / increase-01
                        :ARG0 (m5 / molecular-physical-entity :name (n6 / name :op1 "E2")
                              :xref (x5 / xref :value "CHEBI:50114"))))))

# ::id PMC_123_4335.20 ::date 2016-07-21T12:06:44 ::authors amoldovan
# ::snt Since this was observed only in the presence of an ER, the E2-induced SRC-3 mobility shift depends on expression of either ERα or ERβ.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_20.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i3 / increase-01
                  :ARG0 (m2 / molecular-physical-entity :name (n2 / name :op1 "E2")
                        :xref (x2 / xref :value "CHEBI:50114"))
                  :ARG1 (t / translocate-01
                        :ARG1 (p3 / protein :name (n3 / name :op1 "SRC-3")
                              :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN")))))
      :card2 (i4 / increase-01
            :ARG0 (p4 / protein :name (n4 / name :op1 "ERβ")
                  :xref (x4 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i5 / increase-01
                  :ARG0 (m3 / molecular-physical-entity :name (n5 / name :op1 "E2")
                        :xref (x5 / xref :value "CHEBI:50114"))
                  :ARG1 (t2 / translocate-01
                        :ARG1 (p6 / protein :name (n6 / name :op1 "SRC-3")
                              :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))))))

# ::id PMC_123_4335.21 ::date 2016-07-21T12:20:43 ::authors amoldovan
# ::snt Estradiol-induced SRC-3 phosphorylation requires ER.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_21.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "ER")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
      :ARG1 (i3 / increase-01
            :ARG0 (m / molecular-phisycal-entity :name (n2 / name :op1 "estradiol")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (p4 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p2 / phosphorylate-01))))

# ::id PMC_123_4335.22 ::date 2016-07-21T12:51:02 ::authors amoldovan
# ::snt In cells that express ERα, E2 induces SRC-3 phosphorylation at all six phosphorylation sites identified ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_22.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity :name (n / name :op1 "E2")
            :xref (x / xref :value "CHEBI:50114"))
      :ARG1 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (p4 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p3 / phosphorylate-01))
      :location (c / cell))

# ::id PMC_123_4335.23 ::date 2016-07-21T12:55:57 ::authors amoldovan
# ::snt To determine whether E2-induced SRC-3 phosphorylation is dependent on the presence of ER, HEK293T cells transfected with SRC-3 together with or without either ERα or ERβ were treated with E2.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_23.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "ER")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
      :ARG1 (i3 / increase-01
            :ARG0 (m / molecular-physical-entity :name (n2 / name :op1 "E2")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p5 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p3 / phosphorylate-01)))
      :mode (h / hypothesis)
      :location (c / cell-line :name (n4 / name :op1 "HEK293T")
            :xref (x4 / xref :value "RRID:CVCL_0063")))

# ::id PMC_123_4335.25 ::date 2016-07-21T12:57:03 ::authors amoldovan
# ::snt As shown in Fig. , E2 induced SRC-3 phosphorylation at all six sites (T24, S505, S543, S857, S860, and S867) in cells transfected with an expression vector for wild-type ERα (Fig. , lanes 3 and 4, rows 1 to 6) or ERβ (Fig. , rows 1 to 6), but not in cells transfected with an empty expression vector (Fig. , lanes 1 and 2, rows 1 to 6).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_25.txt
(m2 / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (m / molecular-physical-entity :name (n / name :op1 "E2")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p / protein-segment :name (n3 / name :op1 "T24")
                        :part-of (p4 / protein :name (n2 / name :op1 "SRC-3")
                              :xref (x / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p3 / phosphorylate-01))
            :location (c / cell))
      :card2 (i3 / increase-01
            :ARG0 (m3 / molecular-physical-entity :name (n4 / name :op1 "E2")
                  :xref (x3 / xref :value "CHEBI:50114"))
            :ARG1 (a2 / add-modification-00
                  :ARG1 (p10 / protein-segment :name (n9 / name :op1 "S505")
                        :part-of (p15 / protein :name (n14 / name :op1 "SRC-3")
                              :xref (x8 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p5 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (m4 / molecular-physical-entity :name (n5 / name :op1 "E2")
                  :xref (x4 / xref :value "CHEBI:50114"))
            :ARG1 (a3 / add-modification-00
                  :ARG1 (p11 / protein-segment :name (n10 / name :op1 "S543")
                        :part-of (p16 / protein :name (n15 / name :op1 "SRC-3")
                              :xref (x9 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p6 / phosphorylate-01)))
      :card4 (i5 / increase-01
            :ARG0 (m5 / molecular-physical-entity :name (n6 / name :op1 "E2")
                  :xref (x5 / xref :value "CHEBI:50114"))
            :ARG1 (a4 / add-modification-00
                  :ARG1 (p12 / protein-segment :name (n11 / name :op1 "S857")
                        :part-of (p17 / protein :name (n16 / name :op1 "SRC-3")
                              :xref (x10 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p7 / phosphorylate-01)))
      :card5 (i6 / increase-01
            :ARG0 (m6 / molecular-physical-entity :name (n7 / name :op1 "E2")
                  :xref (x6 / xref :value "CHEBI:50114"))
            :ARG1 (a5 / add-modfication-00
                  :ARG1 (p13 / protein-segment :name (n12 / name :op1 "S860")
                        :part-of (p18 / protein :name (n17 / name :op1 "SRC-3")
                              :xref (x11 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p8 / phosphorylate-01)))
      :card6 (i7 / increase-01
            :ARG0 (m7 / molecular-physical-entity :name (n8 / name :op1 "E2")
                  :xref (x7 / xref :value "CHEBI:50114"))
            :ARG1 (a6 / add-modification-00
                  :ARG1 (p14 / protein-segment :name (n13 / name :op1 "S867")
                        :part-of (p19 / protein :name (n18 / name :op1 "SRC-3")
                              :xref (x12 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p9 / phosphorylate-01))))

# ::id PMC_123_4335.26 ::date 2016-07-21T13:11:41 ::authors amoldovan
# ::snt As a negative control, E2-induced SRC-3 phosphorylation was not observed when the SRC-3 phosphorylation mutant A6 was used (Fig. , lanes 5 and 6, rows 1 to 6), even though the A6 form of SRC-3, like wild-type SRC-3, could still bind to ERα in response to E2 (Fig. , lane 6, row 7).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_26.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (m4 / molecular-physical-entity :name (n / name :op1 "E2")
                  :xref (x6 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG1 (a2 / amino-acid :name (n9 / name :op1 "alanine")
                        :part-of (p3 / protein :name (n2 / name :op1 "SRC-3")
                              :ARG2-of (m2 / mutate-01)
                              :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (m5 / molecular-physical-entity :name (n3 / name :op1 "E2")
                  :xref (x / xref :value "CHEBI:50114"))
            :ARG1 (b / bind-01
                  :ARG1 (a3 / amino-acid :name (n10 / name :op1 "alanine")
                        :part-of (p5 / protein :name (n4 / name :op1 "SRC-3")
                              :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")
                              :ARG2-of (m3 / mutate-01)))
                  :ARG2 (p6 / protein :name (n5 / name :op1 "ERα")
                        :xref (x4 / xref :value "UNIPROT:ESR1_HUMAN"))))
      :card3 (i4 / increase-01
            :ARG0 (m6 / molecular-physical-entity :name (n6 / name :op1 "E2")
                  :xref (x5 / xref :value "CHEBI:50114"))
            :ARG1 (b2 / bind-01
                  :ARG1 (p8 / protein :name (n7 / name :op1 "SRC-3")
                        :xref (x7 / xref :value "UNIPROT:NCOA3_HUMAN")
                        :mod (w / wild-type))
                  :ARG2 (p9 / protein :name (n8 / name :op1 "ERα")
                        :xref (x8 / xref :value "UNIPROT:ESR1_HUMAN")))))

# ::id PMC_123_4335.27 ::date 2016-07-21T13:32:14 ::authors amoldovan
# ::snt These results indicated that E2-induced SRC-3 phosphorylation requires either form of ER.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_27.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "ER")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
      :ARG1 (i3 / increase-01
            :ARG0 (m / molecular-physical-entity :name (n2 / name :op1 "E2")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (p5 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p3 / phosphorylate-01))))

# ::id PMC_123_4335.28 ::date 2016-07-21T13:36:24 ::authors amoldovan
# ::snt Estradiol-induced SRC-3 phosphorylation requires the presence of ER.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_28.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "ER")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
      :ARG1 (i3 / increase-01
            :ARG0 (m / molecular-physical-entity :name (n2 / name :op1 "estradiol")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (p5 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p2 / phosphorylate-01))))

# ::id PMC_123_4335.29 ::date 2016-07-21T06:26:01 ::authors amoldovan
# ::snt (A) HEK293T cells were transfected with Flag-tagged SRC-3 (SRC-3) or its phosphorylation mutant (A6), in the absence or presence of ERα.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user amoldovan ::file PMC_123_4335_29.txt
(s / smr-empty)

# ::id PMC_123_4335.30 ::date 2016-07-20T22:59:26 ::authors amoldovan
# ::snt Forty-eight hours later, 10 nM E2 (+) ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user amoldovan ::file PMC_123_4335_30.txt
(s / smr-empty)

# ::id PMC_123_4335.31 ::date 2016-07-21T13:41:23 ::authors amoldovan
# ::snt In order to confirm the ER dependence with endogenous proteins, siRNA against ERα (siERα) was transfected into MCF-7 cells to reduce the expression of endogenous ERα.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user amoldovan ::file PMC_123_4335_31.txt
(s / smr-empty)

# ::id PMC_123_4335.33 ::date 2016-07-21T13:42:26 ::authors amoldovan
# ::snt As shown in Fig. , in the presence of siERα, expression of endogenous ERα was greatly reduced (lanes 3 and 4, row 4), and E2-induced phosphorylation of endogenous SRC-3 was abolished (lanes 3 and 4, rows 1 to 3).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_33.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG1 (p / protein :name (n / name :op1 "ERα")
                  :mod (e / endogenous)
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN")))
      :card2 (d2 / decrease-01
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (p5 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")
                        :mod (e2 / endogenous))
                  :manner (p2 / phosphorylate-01)
                  :ARG1-of (i2 / increase-01
                        :ARG0 (m2 / molecular-physical-entity :name (n4 / name :op1 "E2")
                              :xref (x3 / xref :value "CHEBI:50114"))))))

# ::id PMC_123_4335.34 ::date 2016-07-21T13:58:34 ::authors amoldovan
# ::snt In contrast, SRC-3 phosphorylation was still induced when a control siRNA against luciferase (siLuc) was used (lanes 1 and 2, rows 1 to 3).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_34.txt
(i2 / increase-01
      :ARG1 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (p3 / protein :name (n3 / name :op1 "SRC-3"))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_123_4335.35 ::date 2016-07-21T00:24:24 ::authors amoldovan
# ::snt This confirmed the data from transient-transfection experiments indicating that E2-induced phosphorylation of SRC-3 requires ER.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user amoldovan ::file PMC_123_4335_35.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "ER")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
      :ARG1 (i3 / increase-01
            :ARG0 (m / molecular-physical-entity :name (n2 / name :op1 "E2")
                  :xref (x2 / xref :value "CHEBI:50114"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (p3 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_123_4335.36 ::date 2016-07-23T10:21:35 ::authors nnistor
# ::snt The kinetics of E2-induced SRC-3 phosphorylation also were assessed in HEK293T cells cotransfected with Flag-tagged SRC-3 and ERα.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_36.txt
(i2 / increase-01
      :ARG0 (s / small-molecule :name (n / name :op1 "E2")
            :xref (x / xref :value "PUBCHEM:5757"))
      :ARG1 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (p3 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p4 / phosphorylate-01)))

# ::id PMC_123_4335.37 ::date 2016-07-23T10:35:14 ::authors nnistor
# ::snt As shown in Fig. , SRC-3 phosphorylation could be observed by 15 min after E2 treatment, represented by phosphorylation at sites T24, S505, and S543 (lanes 3 to 7, rows 1 to 3).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_37.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (s / small-molecule :name (n / name :op1 "E2")
                  :xref (x / xref :value "PUBCHEM:5757"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (a2 / amino-acid :mod 24 :name (n2 / name :op1 "threonine")
                        :part-of (p4 / protein :name (n3 / name :op1 "SRC-3")
                              :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p5 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (s2 / small-molecule :name (n4 / name :op1 "E2")
                  :xref (x3 / xref :value "PUBCHEM:5757"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p6 / protein)
                  :ARG1 (a4 / amino-acid :value 505 :name (n5 / name :op1 "serine")
                        :part-of (p7 / protein :name (n6 / name :op1 "SRC-3")
                              :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p8 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (s3 / small-molecule :name (n7 / name :op1 "E2")
                  :xref (x5 / xref :value "PUBCHEM:5757"))
            :ARG1 (a5 / add-modification-00
                  :ARG0 (p9 / protein)
                  :ARG1 (a6 / amino-acid :mod 543 :name (n8 / name :op1 "serine")
                        :part-of (p10 / protein :name (n9 / name :op1 "SRC-3")
                              :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN")))
                  :manner (p / phosphorylate-01))))

# ::id PMC_123_4335.38 ::date 2016-07-23T10:54:52 ::authors nnistor
# ::snt Selectivity of hormones and nuclear receptors for induction of SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_38.txt
(a / add-modification-00
      :ARG0 (p2 / protein)
      :ARG1 (p3 / protein :name (n / name :op1 "SRC-3")
            :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
      :manner (p4 / phosphorylate-01))

# ::id PMC_123_4335.39 ::date 2016-07-23T10:56:59 ::authors nnistor
# ::snt It has been shown that E2 and the synthetic androgen R1881 can induce SRC-3 phosphorylation in the presence of ER and androgen receptor, respectively (Fig. ) ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_39.txt
(m / multi-index-card
      :card1 (i3 / increase-01
            :ARG0 (p5 / protein :name (n3 / name :op1 "ER")
                  :xref (x3 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i2 / increase-01
                  :ARG0 (s / small-molecule :name (n / name :op1 "E2")
                        :xref (x / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p2 / protein)
                        :ARG1 (p3 / protein :name (n2 / name :op1 "SRC-3")
                              :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p4 / phosphorylate-01))))
      :card2 (i4 / increase-01
            :ARG0 (p6 / protein :name (n4 / name :op1 "androgen" :op2 "receptor")
                  :xref (x4 / xref :value "UNIPROT:ANDR_HUMAN"))
            :ARG1 (i5 / increase-01
                  :ARG0 (s2 / small-molecule :name (n5 / name :op1 "E2"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p8 / protein)
                        :ARG1 (p9 / protein :name (n6 / name :op1 "SRC-3")
                              :xref (x5 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p7 / phosphorylate-01))))
      :card3 (i7 / increase-01
            :ARG0 (p13 / protein :name (n9 / name :op1 "ER")
                  :xref (x8 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i6 / increase-01
                  :ARG0 (s3 / small-molecule :name (n7 / name :op1 "R1881")
                        :xref (x6 / xref :value "PUBCHEM:261000"))
                  :ARG1 (a3 / add-modification-00
                        :ARG0 (p11 / protein)
                        :ARG1 (p12 / protein :name (n8 / name :op1 "SRC-3")
                              :xref (x7 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p10 / phosphorylate-01))))
      :card4 (i8 / increase-01
            :ARG0 (p14 / protein :name (n10 / name :op1 "androgen" :op2 "receptor")
                  :xref (x9 / xref :value "UNIPROT:ANDR_HUMAN"))
            :ARG1 (i9 / increase-01
                  :ARG0 (s4 / small-molecule :name (n11 / name :op1 "R1881")
                        :xref (x10 / xref :value "PUBCHEM:261000"))
                  :ARG1 (a4 / add-modification-00
                        :ARG0 (p16 / protein)
                        :ARG1 (p17 / protein :name (n12 / name :op1 "SRC-3")
                              :xref (x11 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p15 / phosphorylate-01)))))

# ::id PMC_123_4335.40 ::date 2016-07-23T11:22:09 ::authors nnistor
# ::snt In order to investigate whether other hormones and their cognate nuclear receptors can induce SRC-3 phosphorylation, HEK293T cells transfected with an SRC-3 expression vector in the absence or presence of progesterone receptor B (PR-B) plasmid were treated with progesterone (P; 10 nM, 1 h).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_40.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity)
      :ARG1 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (p3 / protein :name (n / name :op1 "SRC-3")
                  :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p4 / phosphorylate-01))
      :mode (h / hypothesis))

# ::id PMC_123_4335.41 ::date 2016-07-23T11:25:55 ::authors nnistor
# ::snt As shown in Fig. did not induce SRC-3 phosphorylation in the presence of PR-B (lanes 5 and 6), although in parallel experiments E2 induced ER-dependent SRC-3 phosphorylation (lanes 3 and 4).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Jul 26, 2016 ::user nnistor ::file PMC_123_4335_41.txt
(m / multi-index-card
      :card1 (i3 / increase-01
            :ARG0 (p5 / protein :name (n3 / name :op1 "PR-B")
                  :xref (x3 / xref :value "UNIPROT:PRGR_HUMAN"))
            :ARG1 (i2 / increase-01 :polarity -
                  :ARG0 (s / small-molecule :name (n / name :op1 "progesterone")
                        :xref (x / xref :value "PUBCHEM:5994"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p3 / protein)
                        :ARG1 (p4 / protein :name (n2 / name :op1 "SRC-3")
                              :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p2 / phosphorylate-01))))
      :card2 (i5 / increase-01
            :ARG0 (p / protein :name (n6 / name :op1 "ER")
                  :xref (x6 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i4 / increase-01
                  :ARG0 (s2 / small-molecule :name (n4 / name :op1 "E2")
                        :xref (x4 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p7 / protein)
                        :ARG1 (p8 / protein :name (n5 / name :op1 "SRC-3")
                              :xref (x5 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p6 / phosphorylate-01)))))

# ::id PMC_123_4335.42 ::date 2016-07-23T11:39:37 ::authors nnistor
# ::snt Representative data for SRC-3 phosphorylation at S505 and S867 were shown, and other sites had a similar pattern (data not shown).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_42.txt
(m / multi-index-card
      :card1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (a2 / amino-acid :mod 505 :name (n / name :op1 "serine")
                  :part-of (p4 / protein :name (n2 / name :op1 "SRC-3")
                        :xref (x / xref :value "UNIPROT:NCOA3_HUMAN")))
            :manner (p5 / phosphorylate-01))
      :card2 (a3 / add-modification-00
            :ARG0 (p7 / protein)
            :ARG1 (a4 / amino-acid :mod 867 :name (n3 / name :op1 "serine")
                  :part-of (p8 / protein :name (n4 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")))
            :manner (p6 / phosphorylate-01)))

# ::id PMC_123_4335.43 ::date 2016-07-23T11:44:13 ::authors nnistor
# ::snt As in the case of PR-B, dexamethasone did not induce SRC-3 phosphorylation in cells expressing the glucocorticoid receptor (data not shown).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_43.txt
(i2 / increase-01 :polarity -
      :ARG0 (s / small-molecule :name (n / name :op1 "dexamethasone")
            :xref (x / xref :value "PUBCHEM:5743"))
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p2 / phosphorylate-01))
      :location (c / cell))

# ::id PMC_123_4335.44 ::date 2016-07-23T11:46:45 ::authors nnistor
# ::snt These data indicated that different steroids and their receptors have differential effects on SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_44.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity)
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein :name (n / name :op1 "SRC-3")
                  :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_123_4335.45 ::date 2016-07-23T11:48:38 ::authors nnistor
# ::snt Effects of different agonists and antagonists and their receptors on SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_45.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity)
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein :name (n / name :op1 "SRC-3")
                  :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_123_4335.46 ::date 2016-07-23T11:50:19 ::authors nnistor
# ::snt HEK293T cells were transfected with Flag-tagged wild-type SRC-3 (SRC-3) or its phosphorylation-site mutant (A6) together with either ERα (A and B), ERβ ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_46.txt
(s / smr-empty)

# ::id PMC_123_4335.47 ::date 2016-07-23T11:51:48 ::authors nnistor
# ::snt SERMs do not induce SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_47.txt
(i2 / increase-01 :polarity -
      :ARG0 (m / molecular-physical-entity :name (n / name :op1 "SERM"))
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_123_4335.48 ::date 2016-07-23T11:59:35 ::authors nnistor
# ::snt In order to investigate whether selective estrogen receptor modulators (SERMs) such as 4HT and Ral and pure antagonists such as ICI 182,780 (ICI) can induce SRC-3 phosphorylation, drug treatment (10 nM, 1 h) was performed in HEK293T cells cotransfected with plasmids for Flag-tagged SRC-3 and ERα (Fig. ) or ERβ (Fig. ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user nnistor ::file PMC_123_4335_48.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (s / small-molecule :name (n / name :op1 "4HT")
                  :xref (x / xref :value "PUBCHEM:449459"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (p4 / protein :name (n2 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p2 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (s2 / small-molecule :name (n3 / name :op1 "Ral")
                  :xref (x3 / xref :value "PUBCHEM:5035"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (p7 / protein :name (n4 / name :op1 "SRC-3")
                        :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p6 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (m2 / molecular-physical-entity :name (n5 / name :op1 "ICI" :op2 "182,780")
                  :xref (x5 / xref :value "PUBCHEM:104741"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p9 / protein)
                  :ARG1 (p10 / protein :name (n6 / name :op1 "SRC-3")
                        :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p8 / phosphorylate-01))))

# ::id PMC_123_4335.49 ::date 2016-07-23T12:18:56 ::authors nnistor
# ::snt Tamoxifen and ICI (Fig. ) and 4HT and Ral (Fig. ), unlike E2, did not noticeably induce SRC-3 phosphorylation at sites S505 and S867 in the presence of ERα and ERβ, respectively (lanes 3 and 4, rows 1 and 2).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Jul 26, 2016 ::user nnistor ::file PMC_123_4335_49.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein :name (n / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i3 / increase-01 :polarity -
                  :ARG0 (s / small-molecule :name (n2 / name :op1 "tamoxifen")
                        :xref (x2 / xref :value "PUBCHEM:2733526"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p3 / protein)
                        :ARG1 (a2 / amino-acid :mod 505 :name (n4 / name :op1 "serine")
                              :part-of (p5 / protein :name (n3 / name :op1 "SRC-3")
                                    :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p4 / phosphorylate-01))))
      :card2 (i4 / increase-01
            :ARG0 (p / protein :name (n5 / name :op1 "ERα")
                  :xref (x4 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i5 / increase-01 :polarity -
                  :ARG0 (s2 / small-molecule :name (n6 / name :op1 "tamoxifen")
                        :xref (x5 / xref :value "PUBCHEM:2733526"))
                  :ARG1 (a3 / add-modification-00
                        :ARG0 (p7 / protein)
                        :ARG1 (a4 / amino-acid :mod 867 :name (n7 / name :op1 "serine")
                              :part-of (p8 / protein :name (n8 / name :op1 "SRC-3")
                                    :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p6 / phosphorylate-01))))
      :card3 (i6 / increase-01
            :ARG0 (p9 / protein :name (n10 / name :op1 "ERα")
                  :xref (x8 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i7 / increase-01 :polarity -
                  :ARG0 (m2 / molecular-physical-entity :name (n9 / name :op1 "ICI")
                        :xref (x7 / xref :value "PUBCHEM:104741"))
                  :ARG1 (a5 / add-modification-00
                        :ARG0 (p11 / protein)
                        :ARG1 (a6 / amino-acid :mod 505 :name (n11 / name :op1 "serine")
                              :part-of (p16 / protein :name (n16 / name :op1 "SRC-3")
                                    :xref (x11 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p10 / phosphorylate-01))))
      :card4 (i8 / increase-01
            :ARG0 (p12 / protein :name (n12 / name :op1 "ERα")
                  :xref (x9 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i9 / increase-01 :polarity -
                  :ARG0 (m3 / molecular-physical-entity :name (n13 / name :op1 "ICI")
                        :xref (x10 / xref :value "PUBCHEM:104741"))
                  :ARG1 (a7 / add-modification-00
                        :ARG0 (p14 / protein)
                        :ARG1 (a8 / amino-acid :mod 867 :name (n14 / name :op1 "serine")
                              :part-of (p15 / protein :name (n15 / name :op1 "SRC-3")
                                    :xref (x12 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p13 / phosphorylate-01))))
      :card5 (i10 / increase-01
            :ARG0 (p17 / protein :name (n17 / name :op1 "ERα")
                  :xref (x13 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i11 / increase-01 :polarity -
                  :ARG0 (s3 / small-molecule :name (n18 / name :op1 "4HT")
                        :xref (x14 / xref :value "PUBCHEM:449459"))
                  :ARG1 (a9 / add-modification-00
                        :ARG0 (p18 / protein)
                        :ARG1 (a10 / amino-acid :mod 505 :name (n19 / name :op1 "serine")
                              :part-of (p20 / protein :name (n20 / name :op1 "SRC-3")
                                    :xref (x15 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p19 / phosphorylate-01))))
      :card6 (i12 / increase-01
            :ARG0 (p21 / protein :name (n21 / name :op1 "ERα")
                  :xref (x16 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i13 / increase-01 :polarity -
                  :ARG0 (s4 / small-molecule :name (n22 / name :op1 "4HT")
                        :xref (x17 / xref :value "PUBCHEM:449459"))
                  :ARG1 (a11 / add-modification-00
                        :ARG0 (p23 / protein)
                        :ARG1 (a12 / amino-acid :mod 867 :name (n23 / name :op1 "serine")
                              :part-of (p24 / protein :name (n24 / name :op1 "SRC-3")
                                    :xref (x18 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p22 / phosphorylate-01))))
      :card7 (i14 / increase-01
            :ARG0 (p25 / protein :name (n25 / name :op1 "ERα")
                  :xref (x19 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i15 / increase-01 :polarity -
                  :ARG0 (s5 / small-molecule :name (n26 / name :op1 "Ral")
                        :xref (x20 / xref :value "PUBCHEM:5035"))
                  :ARG1 (a13 / add-modification-00
                        :ARG0 (p27 / protein)
                        :ARG1 (a14 / amino-acid :mod 505 :name (n27 / name :op1 "serine")
                              :part-of (p28 / protein :name (n28 / name :op1 "SRC-3")
                                    :xref (x21 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p26 / phosphorylate-01))))
      :card8 (i16 / increase-01
            :ARG0 (p29 / protein :name (n29 / name :op1 "ERα")
                  :xref (x22 / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG1 (i17 / increase-01 :polarity -
                  :ARG0 (s6 / small-molecule :name (n30 / name :op1 "Ral")
                        :xref (x23 / xref :value "PUBCHEM:5035"))
                  :ARG1 (a15 / add-modification-00
                        :ARG0 (p31 / protein)
                        :ARG1 (a16 / amino-acid :mod 867 :name (n31 / name :op1 "serine")
                              :part-of (p32 / protein :name (n32 / name :op1 "SRC-3")
                                    :xref (x24 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p30 / phosphorylate-01))))
      :card9 (i18 / increase-01
            :ARG0 (p33 / protein :name (n33 / name :op1 "ERβ")
                  :xref (x25 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i19 / increase-01 :polarity -
                  :ARG0 (s7 / small-molecule :name (n34 / name :op1 "tamoxifen")
                        :xref (x26 / xref :value "PUBCHEM:2733526"))
                  :ARG1 (a17 / add-modification-00
                        :ARG0 (p35 / protein)
                        :ARG1 (a18 / amino-acid :mod 505 :name (n35 / name :op1 "serine")
                              :part-of (p36 / protein :name (n36 / name :op1 "SRC-3")
                                    :xref (x27 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p34 / phosphorylate-01))))
      :card10 (i20 / increase-01
            :ARG0 (p37 / protein :name (n37 / name :op1 "ERβ")
                  :xref (x28 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i21 / increase-01 :polarity -
                  :ARG0 (s8 / small-molecule :name (n38 / name :op1 "tamoxifen")
                        :xref (x29 / xref :value "PUBCHEM:2733526"))
                  :ARG1 (a19 / add-modification-00
                        :ARG0 (p39 / protein)
                        :ARG1 (a20 / amino-acid :mod 867 :name (n39 / name :op1 "serine")
                              :part-of (p40 / protein :name (n40 / name :op1 "SRC-3")
                                    :xref (x30 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p38 / phosphorylate-01))))
      :card11 (i22 / increase-01
            :ARG0 (p41 / protein :name (n42 / name :op1 "ERβ")
                  :xref (x32 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i23 / increase-01 :polarity -
                  :ARG0 (m4 / molecular-physical-entity :name (n41 / name :op1 "ICI")
                        :xref (x31 / xref :value "PUBCHEM:104741"))
                  :ARG1 (a21 / add-modification-00
                        :ARG0 (p42 / protein)
                        :ARG1 (a22 / amino-acid :mod 505 :name (n43 / name :op1 "serine")
                              :part-of (p44 / protein :name (n44 / name :op1 "SRC-3")
                                    :xref (x33 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p43 / phosphorylate-01))))
      :card12 (i24 / increase-01
            :ARG0 (p45 / protein :name (n45 / name :op1 "ERβ")
                  :xref (x34 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i25 / increase-01 :polarity -
                  :ARG0 (m5 / molecular-physical-entity :name (n46 / name :op1 "ICI")
                        :xref (x35 / xref :value "PUBCHEM:104741"))
                  :ARG1 (a23 / add-modification-00
                        :ARG0 (p46 / protein)
                        :ARG1 (a24 / amino-acid :mod 867 :name (n47 / name :op1 "serine")
                              :part-of (p48 / protein :name (n48 / name :op1 "SRC-3")
                                    :xref (x36 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p47 / phosphorylate-01))))
      :card13 (i26 / increase-01
            :ARG0 (p49 / protein :name (n49 / name :op1 "ERβ")
                  :xref (x37 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i27 / increase-01 :polarity -
                  :ARG0 (s9 / small-molecule :name (n50 / name :op1 "4HT")
                        :xref (x38 / xref :value "PUBCHEM:449459"))
                  :ARG1 (a25 / add-modification-00
                        :ARG0 (p51 / protein)
                        :ARG1 (a26 / amino-acid :mod 505 :name (n51 / name :op1 "serine")
                              :part-of (p52 / protein :name (n52 / name :op1 "SRC-3")
                                    :xref (x39 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p50 / phosphorylate-01))))
      :card14 (i28 / increase-01
            :ARG0 (p53 / protein :name (n53 / name :op1 "ERβ")
                  :xref (x40 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i29 / increase-01 :polarity -
                  :ARG0 (s10 / small-molecule :name (n54 / name :op1 "4HT")
                        :xref (x41 / xref :value "PUBCHEM:449459"))
                  :ARG1 (a27 / add-modification-00
                        :ARG0 (p54 / protein)
                        :ARG1 (a28 / amino-acid :mod 867 :name (n55 / name :op1 "serine")
                              :part-of (p56 / protein :name (n56 / name :op1 "SRC-3")
                                    :xref (x42 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p55 / phosphorylate-01))))
      :card15 (i30 / increase-01
            :ARG0 (p57 / protein :name (n57 / name :op1 "ERβ")
                  :xref (x43 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i31 / increase-01 :polarity -
                  :ARG0 (s11 / small-molecule :name (n58 / name :op1 "Ral")
                        :xref (x44 / xref :value "PUBCHEM:5035"))
                  :ARG1 (a29 / add-modification-00
                        :ARG0 (p59 / protein)
                        :ARG1 (a30 / amino-acid :mod 505 :name (n59 / name :op1 "serine")
                              :part-of (p60 / protein :name (n60 / name :op1 "SRC-3")
                                    :xref (x45 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p58 / phosphorylate-01))))
      :card16 (i32 / increase-01
            :ARG0 (p61 / protein :name (n61 / name :op1 "ERβ")
                  :xref (x46 / xref :value "UNIPROT:ESR2_HUMAN"))
            :ARG1 (i33 / increase-01 :polarity -
                  :ARG0 (s12 / small-molecule :name (n62 / name :op1 "Ral")
                        :xref (x47 / xref :value "PUBCHEM:5035"))
                  :ARG1 (a31 / add-modification-00
                        :ARG0 (p63 / protein)
                        :ARG1 (a32 / amino-acid :mod 867 :name (n63 / name :op1 "serine")
                              :part-of (p64 / protein :name (n64 / name :op1 "SRC-3")
                                    :xref (x48 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p62 / phosphorylate-01)))))

# ::id PMC_123_4335.50 ::date 2016-07-24T00:38:26 ::authors nnistor
# ::snt ICI treatment significantly reduced the level of total ERα (Fig. , lane 4, row 3) as reported previously (, , ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_50.txt
(d / decrease-01
      :ARG0 (m / molecular-physical-entity :name (n / name :op1 "ICI")
            :xref (x / xref :value "PUBCHEM:104741"))
      :ARG1 (p / protein :name (n2 / name :op1 "ERα")
            :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN")))

# ::id PMC_123_4335.51 ::date 2016-07-24T00:40:25 ::authors nnistor
# ::snt Since SERMs do not promote interaction between SRC coactivators and ER in HEK293T (data not shown) and other cell lines (, ), the data are consistent with a requirement for a direct binding between ER and SRC-3 for induction of coactivator phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Jul 26, 2016 ::user nnistor ::file PMC_123_4335_51.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (m2 / molecular-physical-entity :name (n / name :op1 "SERM"))
            :ARG1 (b / bind-01
                  :ARG1 (p2 / protein
                        :ARG0-of (a / add-modification-00
                              :ARG1 (p4 / protein :name (n2 / name :op1 "SRC")
                                    :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
                              :manner (p3 / phosphorylate-01)))
                  :ARG2 (p5 / protein :name (n3 / name :op1 "ER")
                        :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN")))
            :location (c / cell-line :name (n4 / name :op1 "HEK293T")
                  :xref (x3 / xref :value "HEK:CVCL_0063")))
      :card2 (i3 / increase-01 :polarity -
            :ARG0 (m3 / molecular-physical-entity :name (n5 / name :op1 "SERM"))
            :ARG1 (b2 / bind-01
                  :ARG1 (p6 / protein
                        :ARG0-of (a2 / add-modification-00
                              :ARG1 (p8 / protein :name (n6 / name :op1 "SRC")
                                    :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                              :manner (p7 / phosphorylate-01)))
                  :ARG2 (p9 / protein :name (n7 / name :op1 "ER")
                        :xref (x5 / xref :value "UNIPROT:ESR1_HUMAN")))
            :location (c2 / cell-line))
      :card3 (i4 / increase-01
            :ARG0 (b3 / bind-01
                  :ARG1 (p10 / protein :name (n8 / name :op1 "ER")
                        :xref (x6 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2 (p11 / protein :name (n9 / name :op1 "SRC-3")
                        :xref (x7 / xref :value "UNIPROT:NCOA3_HUMAN")))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p13 / protein)
                  :ARG1 p11
                  :manner (p12 / phosphorylate-01))))

# ::id PMC_123_4335.52 ::date 2016-07-24T00:51:52 ::authors nnistor
# ::snt AF-1 and LBD/AF-2 of ERα are required for maximal induction of SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_52.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein-segment :name (n / name :op1 "AF-1")
                  :part-of (p3 / protein :name (n2 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (a / add-modification-00
                  :ARG0 (p7 / protein)
                  :ARG1 (p8 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p6 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p4 / protein-segment :name (n3 / name :op1 "AF-2")
                  :part-of (p5 / protein :name (n4 / name :op1 "ERα")
                        :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p9 / protein)
                  :ARG1 (p10 / protein :name (n6 / name :op1 "SRC-3")
                        :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p11 / phosphorylate-01))))

# ::id PMC_123_4335.53 ::date 2016-07-24T00:57:26 ::authors nnistor
# ::snt The results above demonstrated that ER is required for E2-induced SRC-3 phosphorylation and implied that an interaction, either direct or indirect, between ER and SRC-3 is required.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_53.txt
(i2 / increase-01
      :ARG0 (p2 / protein :name (n / name :op1 "ER")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n2 / name :op1 "E2")
                  :xref (x2 / xref :value "PUBCHEM:5757"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (p5 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p / phosphorylate-01))))

# ::id PMC_123_4335.54 ::date 2016-07-24T00:59:51 ::authors nnistor
# ::snt In order to investigate the contribution of the AF-1 and AF-2 domains of ERα for E2-induced SRC-3 phosphorylation, wild-type full-length ERα and an ERα truncation mutant, ERα1-282 (N282) lacking AF-2/LBD or ERα179-595 (179C) lacking AF-1, together with Flag-tagged SRC-3, were transfected into HEK293T cells.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_54.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein-segment :name (n / name :op1 "AF-1")
                  :part-of (p3 / protein :name (n2 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (i4 / increase-01
                  :ARG0 (s / small-molecule :name (n5 / name :op1 "E2")
                        :xref (x3 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p7 / protein)
                        :ARG1 (p8 / protein :name (n6 / name :op1 "SRC-3")
                              :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p6 / phosphorylate-01))))
      :card2 (i3 / increase-01
            :ARG0 (p4 / protein-segment :name (n3 / name :op1 "AF-2")
                  :part-of (p5 / protein :name (n4 / name :op1 "ERα")
                        :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (i5 / increase-01
                  :ARG0 (s2 / small-molecule :name (n7 / name :op1 "E2")
                        :xref (x5 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p10 / protein)
                        :ARG1 (p11 / protein :name (n8 / name :op1 "SRC-3")
                              :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p9 / phosphorylate-01)))))

# ::id PMC_123_4335.55 ::date 2016-07-24T01:05:31 ::authors nnistor
# ::snt Cells were then treated, and SRC-3 phosphorylation was examined.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_55.txt
(s / smr-empty)

# ::id PMC_123_4335.56 ::date 2016-07-24T01:06:53 ::authors nnistor
# ::snt As shown in Fig. , N282 did not support E2-induced SRC-3 phosphorylation (lanes 3 and 4), which is not surprising since N282 lacks an LBD and is not responsive to E2.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_56.txt
(i2 / increase-01 :polarity -
      :ARG0 (a / amino-acid :mod 282 :name (n / name :op1 "asparagine"))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n2 / name :op1 "E2")
                  :xref (x / xref :value "PUBCHEM:5757"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (p4 / protein :name (n3 / name :op1 "SRC_3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p / phosphorylate-01))))

# ::id PMC_123_4335.57 ::date 2016-07-24T01:13:31 ::authors nnistor
# ::snt The 179C mutant supported only minimal E2-induced SRC-3 phosphorylation at S505 but not at other sites as represented by T24, S543, and S867 (Fig. , lanes 5 and 6).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_57.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein
                  :ARG2-of (m2 / mutate-01 :value "179C"))
            :ARG1 (i3 / increase-01
                  :ARG0 (s / small-molecule :name (n / name :op1 "E2")
                        :xref (x / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p3 / protein)
                        :ARG1 (a2 / amino-acid :mod 505 :name (n2 / name :op1 "serine")
                              :part-of (p4 / protein :name (n3 / name :op1 "SRC-3")
                                    :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p5 / phosphorylate-01))))
      :card2 (i4 / increase-01 :polarity -
            :ARG0 (p6 / protein
                  :ARG2-of (m3 / mutate-01 :value "179C"))
            :ARG1 (i5 / increase-01
                  :ARG0 (s2 / small-molecule :name (n4 / name :op1 "E2")
                        :xref (x3 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a3 / add-modification-00
                        :ARG0 (p8 / protein)
                        :ARG1 (a4 / amino-acid :mod 54 :name (n5 / name :op1 "threonine")
                              :part-of (p9 / protein :name (n6 / name :op1 "SRC-3")
                                    :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p7 / phosphorylate-01))))
      :card3 (i6 / increase-01 :polarity -
            :ARG0 (p / protein
                  :ARG2-of (m4 / mutate-01 :value "179C"))
            :ARG1 (i7 / increase-01
                  :ARG0 (s3 / small-molecule :name (n7 / name :op1 "E2")
                        :xref (x5 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a5 / add-modification-00
                        :ARG0 (p11 / protein)
                        :ARG1 (a6 / amino-acid :mod 543 :name (n8 / name :op1 "serine")
                              :part-of (p12 / protein :name (n9 / name :op1 "SRC-3")
                                    :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p10 / phosphorylate-01))))
      :card4 (i8 / increase-01 :polarity -
            :ARG0 (p13 / protein
                  :ARG2-of (m5 / mutate-01 :value "179C"))
            :ARG1 (i9 / increase-01
                  :ARG0 (s4 / small-molecule :name (n10 / name :op1 "E2")
                        :xref (x7 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a7 / add-modification-00
                        :ARG0 (p15 / protein)
                        :ARG1 (a8 / amino-acid :mod 867 :name (n11 / name :op1 "serine")
                              :part-of (p16 / protein :name (n12 / name :op1 "SRC-3")
                                    :xref (x8 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p14 / phosphorylate-01)))))

# ::id PMC_123_4335.58 ::date 2016-07-24T01:33:04 ::authors nnistor
# ::snt Similarly, an ERβ truncation mutant, 143C (aa 143 to 530), lacking AF-1, supported only minimal E2-induced SRC-3 phosphorylation at S505 and S543 but not at other sites as represented by T24 and S867 (Fig. ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_58.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein :name (n / name :op1 "ERβ")
                  :xref (x / xref :value "UNIPROT:ESR2_HUMAN")
                  :ARG2-of (m2 / mutate-01 :value "143C"))
            :ARG1 (i3 / increase-01
                  :ARG0 (s / small-molecule :name (n2 / name :op1 "E2")
                        :xref (x2 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p4 / protein)
                        :ARG1 (a2 / amino-acid :mod 505 :name (n4 / name :op1 "serine")
                              :part-of (p5 / protein :name (n3 / name :op1 "SRC-3")
                                    :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p3 / phosphorylate-01))))
      :card2 (i4 / increase-01
            :ARG0 (p6 / protein :name (n5 / name :op1 "ERβ")
                  :xref (x4 / xref :value "UNIPROT:ESR2_HUMAN")
                  :ARG2-of (m4 / mutate-01 :value "143C"))
            :ARG1 (i5 / increase-01
                  :ARG0 (s2 / small-molecule :name (n6 / name :op1 "E2")
                        :xref (x5 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a3 / add-modification-00
                        :ARG0 (p7 / protein)
                        :ARG1 (a4 / amino-acid :mod 543 :name (n7 / name :op1 "serine")
                              :part-of (p8 / protein :name (n8 / name :op1 "SRC-3")
                                    :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p9 / phosphorylate-01))))
      :card3 (i6 / increase-01 :polarity -
            :ARG0 (p10 / protein :name (n9 / name :op1 "ERβ")
                  :xref (x7 / xref :value "UNIPROT:ESR2_HUMAN")
                  :ARG2-of (m3 / mutate-01 :value "143C"))
            :ARG1 (i7 / increase-01
                  :ARG0 (s3 / small-molecule :name (n10 / name :op1 "E2")
                        :xref (x8 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a5 / add-modification-00
                        :ARG0 (p12 / protein)
                        :ARG1 (a6 / amino-acid :mod 24 :name (n11 / name :op1 "threonine")
                              :part-of (p13 / protein :name (n12 / name :op1 "SRC-3")
                                    :xref (x9 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p11 / phosphorylate-01))))
      :card4 (i8 / increase-01 :polarity -
            :ARG0 (p14 / protein :name (n13 / name :op1 "ERβ")
                  :xref (x10 / xref :value "UNIPROT:ESR2_HUMAN")
                  :ARG2-of (m5 / mutate-01 :value "143C"))
            :ARG1 (i9 / increase-01
                  :ARG0 (s4 / small-molecule :name (n14 / name :op1 "E2")
                        :xref (x11 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a7 / add-modification-00
                        :ARG0 (p15 / protein)
                        :ARG1 (a8 / amino-acid :mod 867 :name (n15 / name :op1 "serine")
                              :part-of (p16 / protein :name (n16 / name :op1 "SRC-3")
                                    :xref (x12 / xref :value "UNIPROT:NCOA3_HUMAN")))
                        :manner (p17 / phosphorylate-01)))))

# ::id PMC_123_4335.59 ::date 2016-07-24T02:30:25 ::authors nnistor
# ::snt These data reveal that the AF-1 or LBD/AF-2 domains are required for maximal induction of E2-induced coactivator phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_59.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein-segment :name (n / name :op1 "AF-1"))
            :ARG1 (i3 / increase-01
                  :ARG0 (s / small-molecule :name (n2 / name :op1 "E2")
                        :xref (x / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p4 / protein)
                        :ARG1 (p5 / protein)
                        :manner (p3 / phosphorylate-01))))
      :card2 (i4 / increase-01
            :ARG0 (p / protein-segment :name (n3 / name :op1 "AF-2"))
            :ARG1 (i5 / increase-01
                  :ARG0 (s2 / small-molecule :name (n4 / name :op1 "E2")
                        :xref (x2 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p7 / protein)
                        :ARG1 (p8 / protein)
                        :manner (p6 / phosphorylate-01)))))

# ::id PMC_123_4335.60 ::date 2016-07-24T02:46:26 ::authors nnistor
# ::snt Both AF-1 and LBD/AF-2 domains of ERα are required for maximal induction of SRC-3 phosphorylation in response to E2.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_60.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein-segment :name (n / name :op1 "AF-1")
                  :part-of (p3 / protein :name (n2 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (i3 / increase-01
                  :ARG0 (s / small-molecule :name (n3 / name :op1 "E2")
                        :xref (x2 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p5 / protein)
                        :ARG1 (p6 / protein :name (n4 / name :op1 "SRC-3")
                              :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p4 / phosphorylate-01))))
      :card2 (i4 / increase-01
            :ARG0 (p7 / protein-segment :name (n5 / name :op1 "AF-2")
                  :part-of (p8 / protein :name (n6 / name :op1 "ERα")
                        :xref (x4 / xref :value "UNIPROT:ESR1_HUMAN")))
            :ARG1 (i5 / increase-01
                  :ARG0 (s2 / small-molecule :name (n7 / name :op1 "E2")
                        :xref (x5 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p10 / protein)
                        :ARG1 (p11 / protein :name (n8 / name :op1 "SRC-3")
                              :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p9 / phosphorylate-01)))))

# ::id PMC_123_4335.61 ::date 2016-07-24T02:53:42 ::authors nnistor
# ::snt HEK293T cells were cotransfected with either Flag-SRC-3 (SRC-3) or Flag-SRC-3 phosphorylation mutant (A6) together with either ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_61.txt
(s / smr-empty)

# ::id PMC_123_4335.62 ::date 2016-07-24T02:55:31 ::authors nnistor
# ::snt To further test the role of AF-1 in SRC-3 phosphorylation, an ERα phosphorylation mutant (S104A/S106A/S118A as 3A) was used to determine whether phosphorylation of AF-1 is required.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_62.txt
(i2 / increase-01
      :ARG0 (p2 / protein-segment :name (n / name :op1 "AF-1"))
      :ARG1 (a / add-modification-00
            :ARG0 (p4 / protein)
            :ARG1 (p5 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
            :manner (p3 / phosphorylate-01))
      :mode (h / hypothesis))

# ::id PMC_123_4335.63 ::date 2016-07-24T05:02:51 ::authors nnistor
# ::snt HEK293T cells were transfected with either wild-type ERα or its mutant 3A together with Flag-tagged SRC-3 and treated as described above.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user nnistor ::file PMC_123_4335_63.txt
(s / smr-empty)

# ::id PMC_123_4335.64 ::date 2016-07-24T05:04:42 ::authors nnistor
# ::snt Interestingly, this ERα AF-1 phosphorylation mutant could still induce SRC-3 phosphorylation, at a level comparable to the wild-type ERα (Fig. ), suggesting that phosphorylation of ERα is not a prerequisite for promoting SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Jul 26, 2016 ::user nnistor ::file PMC_123_4335_64.txt
(m2 / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p3 / protein-segment :name (n / name :op1 "AF-1")
                  :part-of (p4 / protein :name (n2 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m / mutate-01)
                  :ARG1-of (a / add-modification-00
                        :manner (p5 / phosphorylate-01)))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p6 / protein)
                  :ARG1 (p7 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p8 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p / protein :name (n4 / name :op1 "ERα")
                  :xref (x3 / xref :value "UNIPROT:ESR1_HUMAN")
                  :mod (w / wild-type))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p9 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN")))))

# ::id PMC_123_4335.65 ::date 2016-07-24T05:08:31 ::authors nnistor
# ::snt The coactivator-binding groove of ERα is required for E2-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Jul 26, 2016 ::user nnistor ::file PMC_123_4335_65.txt
(i2 / increase-01
      :ARG0 (p / protein-segment :name (n4 / name :op1 "coactivator-binding" :op2 "groove")
            :part-of (p2 / protein :name (n / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN")))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n2 / name :op1 "E2")
                  :xref (x2 / xref :value "PUBCHEM:5757"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (p4 / protein :name (n3 / name :op1 "SRC-3")
                        :xref (x3 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p5 / phosphorylate-01))))

# ::id PMC_123_4335.66 ::date 2016-07-20T04:43:34 ::authors epesce
# ::snt It has been shown that the amino acids K362, V376, and L539 of the ERα LBD are among the residues critical for forming a coactivator-binding groove in response to E2 ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_66.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (s / small-molecule :name (n / name :op1 "E2")
                  :xref (v / value :name (n2 / name :op1 "PUBCHEM:5757")))
            :ARG1 (b / bind-01
                  :ARG0 (a / amino-acid :name (n3 / name :op1 "K362")
                        :part-of (p / protein-segment
                              :part-of (p7 / protein-family :name (n10 / name :op1 "ERα"))))
                  :ARG1 (p2 / protein)))
      :card2 (i3 / increase-01
            :ARG0 (s2 / small-molecule :name (n4 / name :op1 "E2")
                  :xref (v2 / value :name (n5 / name :op1 "PUBCHEM:5757")))
            :ARG1 (b2 / bind-01
                  :ARG0 (a2 / amino-acid :name (n6 / name :op1 "V376")
                        :part-of (p3 / protein-segment
                              :part-of (p8 / protein-family :name (n11 / name :op1 "ERα"))))
                  :ARG1 (p4 / protein)))
      :card3 (i4 / increase-01
            :ARG0 (s3 / small-molecule :name (n7 / name :op1 "E2")
                  :xref (v3 / value :name (n8 / name :op1 "PUBCHEM:5757")))
            :ARG1 (b3 / bind-01
                  :ARG0 (a3 / amino-acid :name (n9 / name :op1 "L539")
                        :part-of (p5 / protein-segment
                              :part-of (p9 / protein-family :name (n12 / name :op1 "ERα"))))
                  :ARG1 (p6 / protein))))

# ::id PMC_123_4335.67 ::date 2016-07-20T05:02:43 ::authors epesce
# ::snt In order to investigate whether this surface is essential for E2-induced SRC-3 phosphorylation, several mutations which disrupt the direct interaction of ERα with coactivator were examined for their ability to impact E2 induction of SRC-3 phosphorylation in HEK293T cells.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_67.txt
(m / multi-index-card
      :card1 (a / add-modification-00
            :ARG0 (p2 / protein
                  :ARG0-of (m2 / mutate-01))
            :ARG1 (i2 / increase-01
                  :ARG0 (s2 / small-molecule :name (n / name :op1 "E2")
                        :xref (v / value :name (n2 / name :op1 "PUBCHEM:5757")))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p3 / protein)
                        :ARG1 (p8 / protein :name (n3 / name :op1 "SRC-3")
                              :xref (v2 / value :name (n4 / name :op1 "UNIPROT:SRC-3_HUMAN")))
                        :manner (p / phosphorylate-01)))
            :location (c / cell-line :name (n5 / name :op1 "HEK293T")
                  :xref (v3 / value :name (n6 / name :op1 "HEK293T:CVCL_0063"))))
      :card2 (i3 / increase-01
            :ARG0 (p4 / protein-segment)
            :ARG1 (i4 / increase-01
                  :ARG0 (s / small-molecule :name (n7 / name :op1 "E2")
                        :xref (v4 / value :name (n8 / name :op1 "PUBCHEM:5757")))
                  :ARG1 (a3 / add-modification-00
                        :ARG0 (p5 / protein)
                        :ARG1 (p7 / protein :name (n9 / name :op1 "SRC-3")
                              :xref (v5 / value :name (n10 / name :op1 "UNIPROT:SRC-3_HUMAN")))
                        :manner (p6 / phosphorylate-01)))
            :mode (h / hypothesis)))

# ::id PMC_123_4335.68 ::date 2016-07-20T05:31:26 ::authors epesce
# ::snt The mutants (the single mutants K362D [K], V376D [V], and L539A [L]; the double mutant K362D/V376D [KV]; and the triple mutant K362D/V376D/L539A [KVL]) were transcriptionally impaired as demonstrated in a luciferase reporter assay (Fig. ), consistent with previous reports on the effect of the single mutations ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_68.txt
(s2 / smr-empty)

# ::id PMC_123_4335.69 ::date 2016-07-20T05:41:14 ::authors epesce
# ::snt As shown in Fig. , the ERα single mutants (K, V, or L) were severely compromised in their ability to support E2-induced SRC-3 phosphorylation (lanes 5 to 10, row 1), while the triple mutant (KVL) was unable to induce any phosphorylation of SRC-3 (lanes 3 and 4, row 1).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_69.txt
(i2 / increase-01 :polarity -
      :ARG0 (p2 / protein)
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein :name (n / name :op1 "SRC-3")
                  :xref (v / value :name (n2 / name :op1 "UNIPROT:SRC-3_HUMAN")))
            :manner (p / phosphorylate-01)))

# ::id PMC_123_4335.70 ::date 2016-07-20T05:45:28 ::authors epesce
# ::snt As predicted, the E2-induced interaction between these ERα mutants and SRC-3 was greatly reduced or totally abolished (Fig. , lanes 3 to 10, row 2) in comparison to the positive control (lanes 1 and 2, row 2).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_70.txt
(s2 / smr-empty)

# ::id PMC_123_4335.72 ::date 2016-07-20T05:55:23 ::authors epesce
# ::snt The coactivator-binding groove of ERα is required for estradiol-induced and ER-dependent SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_72.txt
(m / multi-index-card
      :card1 (i6 / increase-01
            :ARG0 (p8 / protein-segment
                  :part-of (p9 / protein-family :name (n8 / name :op1 "ERα")))
            :ARG1 (i3 / increase-01
                  :ARG0 (s / small-molecule :name (n / name :op1 "estradiol")
                        :xref (v / value :name (n2 / name :op1 "PUBCHEM:5757")))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p3 / protein)
                        :ARG1 (p6 / protein :name (n3 / name :op1 "SRC-3")
                              :xref (v2 / value :name (n4 / name :op1 "UNIPROT:SRC-3_HUMAN")))
                        :manner (p / phosphorylate-01))))
      :card2 (i2 / increase-01
            :ARG0 (p10 / protein-segment
                  :part-of (p11 / protein-family :name (n9 / name :op1 "ERα")))
            :ARG1 (i4 / increase-01
                  :ARG0 (a2 / add-modification-00
                        :ARG0 (p4 / protein)
                        :ARG1 (p5 / protein :name (n5 / name :op1 "SRC-3")
                              :xref (v3 / value :name (n6 / name :op1 "UNIPROT:SRC-3_HUMAN")))
                        :manner (p2 / phosphorylate-01))
                  :ARG1 (p7 / protein-family :name (n7 / name :op1 "ER")))))

# ::id PMC_123_4335.73 ::date 2016-07-20T06:06:23 ::authors epesce
# ::snt (A) HEK293T cells were cotransfected with pERE-E1b-Luc and either the empty vector (Vector), the ERα wild type (WT), the ERα ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_73.txt
(s2 / smr-empty)

# ::id PMC_123_4335.74 ::date 2016-07-20T06:07:21 ::authors epesce
# ::snt The LXXLL motifs of SRC-3 are required for E2-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_74.txt
(i2 / increase-01
      :ARG0 (p2 / protein-segment :name (n / name :op1 "LXXLL")
            :part-of (p4 / protein :name (n2 / name :op1 "SRC-3")
                  :xref (v / value :name (n3 / name :op1 "UNIPROT:SRC-3_HUMAN"))))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n4 / name :op1 "E2")
                  :xref (v2 / value :name (n5 / name :op1 "PUBCHEM:5757")))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 p4
                  :manner (p / phosphorylate-01))))

# ::id PMC_123_4335.75 ::date 2016-07-20T06:11:06 ::authors epesce
# ::snt SRC family members contain several LXXLL motifs located in their receptor-interacting domains that mediate their direct binding to the LBD of nuclear receptors such as ERα.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_75.txt
(b / bind-01
      :ARG0 (p / protein-family :name (n / name :op1 "SRC"))
      :ARG1 (p2 / protein-segment
            :part-of (p3 / protein)))

# ::id PMC_123_4335.76 ::date 2016-07-20T06:15:31 ::authors epesce
# ::snt The SRC-3-AAA mutant has two amino acid substitutions within each of its three NR boxes, such that the LXXLL motifs are mutated to LXXAA (); this abolishes the ligand-dependent binding between SRC-3 and the ERα LBD (, , , ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_76.txt
(b / bind-01
      :ARG0 (p / protein :name (n / name :op1 "SRC-3")
            :xref (v / value :name (n2 / name :op1 "UNIPROT:SRC-3_HUMAN")))
      :ARG1 (p2 / protein-segment
            :part-of (p3 / protein-family :name (n3 / name :op1 "ERα"))))

# ::id PMC_123_4335.77 ::date 2016-07-20T06:18:43 ::authors epesce
# ::snt To investigate whether the SRC-3-AAA mutant can be phosphorylated in response to E2, plasmids for the SRC-3 mutant and ERα were transfected into HEK293T cells.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_77.txt
(i3 / increase-01
      :ARG0 (s / small-molecule :name (n / name :op1 "E2")
            :xref (v / value :name (n2 / name :op1 "PUBCHEM:5757")))
      :ARG1 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (p3 / protein :name (n3 / name :op1 "SRC-3-AAA")
                  :ARG2-of (m2 / mutate-01)
                  :xref (v2 / value :name (n4 / name :op1 "UNIPROT:SRC-3-AAA_HUMAN")))
            :manner (p2 / phosphorylate-01))
      :mode (h / hypothesis))

# ::id PMC_123_4335.78 ::date 2016-07-20T06:26:34 ::authors epesce
# ::snt As shown in Fig. , unlike the wild-type SRC-3 (lanes 2 and 3), the AAA mutant could not be phosphorylated in response to E2 treatment (lanes 4 and 5), substantiating the notion that a direct ligand-induced interaction between coactivator and ERα is necessary for E2-dependent SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_78.txt
(i3 / increase-01 :polarity -
      :ARG0 (s / small-molecule :name (n / name :op1 "E2")
            :xref (v / value :name (n2 / name :op1 "PUBCHEM:5757")))
      :ARG1 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (p3 / protein :name (n3 / name :op1 "SRC-3-AAA")
                  :xref (v2 / value :name (n4 / name :op1 "UNIPROT:SRC-3-AAA_HUMAN"))
                  :ARG2-of (m2 / mutate-01))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_123_4335.79 ::date 2016-07-20T06:34:41 ::authors epesce
# ::snt The interaction observed between the AAA mutant and ERα in the absence of E2 (Fig. , lane 4, row 7) likely reflects a hormone- and LXXLL-independent interaction of the ERα AF-1 domain with SRC-3 (), which is inhibited by E2 as a result of ligand-induced interactions of the N and C termini of the receptor ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_79.txt
(s2 / smr-empty)

# ::id PMC_123_4335.80 ::date 2016-07-20T06:36:13 ::authors epesce
# ::snt The receptor-interacting domain of SRC-3 is required for estradiol-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_80.txt
(i2 / increase-01
      :ARG0 (p2 / protein-segment
            :part-of (p4 / protein :name (n / name :op1 "SRC-3")
                  :xref (v / value :name (n2 / name :op1 "UNIPROT:SRC-3_HUMAN"))))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n3 / name :op1 "estradiol")
                  :xref (v2 / value :name (n4 / name :op1 "PUBCHEM:5757")))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 p4
                  :manner (p / phosphorylate-01))))

# ::id PMC_123_4335.81 ::date 2016-07-20T06:38:50 ::authors epesce
# ::snt HEK293T cells were transfected with either wild-type Flag-SRC-3 (SRC-3) or SRC-3 mutant (AAA) having all three LXXLL motifs in the receptor-interacting domain ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_81.txt
(s2 / smr-empty)

# ::id PMC_123_4335.82 ::date 2016-07-20T06:39:31 ::authors epesce
# ::snt Nuclear localization of ERα is not required for E2-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_82.txt
(i2 / increase-01 :polarity -
      :ARG0 (p / protein-family :name (n / name :op1 "ERα")
            :location (n2 / nucleus))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n3 / name :op1 "E2")
                  :xref (v / value :name (n4 / name :op1 "PUBCHEM:5757")))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p3 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (v2 / value :name (n6 / name :op1 "UNIPROT:SRC-3_HUMAN")))
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_123_4335.83 ::date 2016-07-20T06:41:14 ::authors epesce
# ::snt To determine whether phosphorylation of SRC-3 can take place in the cytoplasm, an ERα mutant (ERαΔNLS) lacking amino acids 250 to 303, which encompass the ERα NLS, was used.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_83.txt
(s2 / smr-empty)

# ::id PMC_123_4335.84 ::date 2016-07-20T06:45:59 ::authors epesce
# ::snt This mutant was transcriptionally impaired in a luciferase reporter assay and is localized predominantly in the cytoplasm in the absence of ligand ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_84.txt
(s2 / smr-empty)

# ::id PMC_123_4335.85 ::date 2016-07-20T06:58:19 ::authors epesce
# ::snt In order to determine whether SRC-3 overexpression or ligand would affect the mutant vs subcellular localization, cells were transfected with vectors for Flag-tagged SRC-3 and either wild-type or mutant ERα and then treated with either E2 or vehicle.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_85.txt
(s2 / smr-empty)

# ::id PMC_123_4335.86 ::date 2016-07-20T06:59:21 ::authors epesce
# ::snt In the presence of ligand, GFP-ERαΔNLS was localized in the cytoplasm, as opposed to the wild-type ERα (GFP-hERαWT), which was localized primarily in the nucleus (Fig. ), regardless of the presence or absence (data not shown) of ligand.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_86.txt
(s2 / smr-empty)

# ::id PMC_123_4335.87 ::date 2016-07-20T06:59:52 ::authors epesce
# ::snt Next, the ability of the mutant to promote coactivator phosphorylation was tested.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_87.txt
(i2 / increase-01
      :ARG0 (p2 / protein
            :ARG2-of (m / mutate-01))
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein)
            :manner (p / phosphorylate-01)))

# ::id PMC_123_4335.88 ::date 2016-07-20T07:00:50 ::authors epesce
# ::snt As for wild-type ERα, the mutant was able to induce SRC-3 phosphorylation at all six sites (Fig. ), indicating that nuclear localization of ERα may not be required for inducing SRC-3 phosphorylation in response to E2.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_88.txt
(i2 / increase-01
      :ARG0 (p / protein
            :ARG2-of (m / mutate-01))
      :ARG1 (a2 / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (a / amino-acid
                  :part-of (p4 / protein :name (n / name :op1 "SRC-3")
                        :xref (v / value :name (n2 / name :op1 "UNIPROT:SRC-3_HUMAN"))))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_123_4335.89 ::date 2016-07-20T07:04:47 ::authors epesce
# ::snt Furthermore, the mutant could still bind to SRC-3 in the presence of E2 (Fig. , lanes 5 and 6, row 7).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_89.txt
(b / bind-01
      :ARG0 (p / protein
            :ARG2-of (m / mutate-01))
      :ARG1 (p2 / protein :name (n / name :op1 "SRC-3")
            :xref (v / value :name (n2 / name :op1 "UNIPROT:SRC-3_HUMAN"))))

# ::id PMC_123_4335.90 ::date 2016-07-20T07:06:09 ::authors epesce
# ::snt It is possible that there is a small amount of the ΔNLS mutant receptor localized in the nucleus () which may contribute to SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_90.txt
(i2 / increase-01
      :ARG0 (p2 / protein
            :ARG2-of (m / mutate-01)
            :location (n3 / nucleus))
      :ARG1 (a / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (p4 / protein :name (n / name :op1 "SRC-3")
                  :xref (v / value :name (n2 / name :op1 "UNIPROT:SRC-3_HUMAN")))
            :manner (p / phosphorylate-01))
      :mode (h / hypothesis))

# ::id PMC_123_4335.91 ::date 2016-07-20T07:06:40 ::authors epesce
# ::snt However, it should be noted that, under the conditions used for these assays, there is insufficient nuclear ERαΔNLS to induce the transcription of an ERE-containing reporter gene (data not shown) consistent with a previous report ().
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_91.txt
(s2 / smr-empty)

# ::id PMC_123_4335.92 ::date 2016-07-20T07:07:30 ::authors epesce
# ::snt Nuclear localization of ERα is not required for estradiol-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user epesce ::file PMC_123_4335_92.txt
(i2 / increase-01 :polarity -
      :ARG0 (p3 / protein-family :name (n / name :op1 "ERα")
            :location (n3 / nucleus))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n4 / name :op1 "estradiol")
                  :xref (v2 / value :name (n5 / name :op1 "PUBCHEM:5757")))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p4 / protein :name (n6 / name :op1 "SRC-3")
                        :xref (v3 / value :name (n7 / name :op1 "UNIPROT:SRC-3_HUMAN")))
                  :manner (p / phosphorylate-01))))

# ::id PMC_123_4335.93 ::date 2016-07-20T07:11:04 ::authors epesce
# ::snt (A) HEK293T cells were cotransfected with GFP-tagged wild-type ERα (GFP-WT) or ERα NLS deletion mutant lacking aa 250 to 303 (GFP-ΔNLS), ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 20, 2016 ::user epesce ::file PMC_123_4335_93.txt
(s2 / smr-empty)

# ::id PMC_123_4335.94 ::date 2016-07-20T10:28:04 ::authors tkalman
# ::snt ERα DNA binding activity is not required for E2-induced SRC-3 phosphorylation.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_94.txt
(i2 / increase-01 :polarity -
      :ARG0 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG2 (n2 / nucleic-acid :name (n3 / name :op1 "DNA")
                  :xref (x2 / xref :value "UNIPROT:DNA2_HUMAN")))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n4 / name :op1 "E2")
                  :xref (x3 / xref :value "PUBCHEM:5757"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p3 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_123_4335.95 ::date 2016-07-20T11:00:41 ::authors tkalman
# ::snt Previous data indicated that E2-induced SRC-3 phosphorylation requires the formation of a complex containing SRC-3 and ER.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_95.txt
(i2 / increase-01
      :ARG0 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "SRC-3")
                  :xref (x / xref :value "UNIPROT:NCOA3_HUMAN"))
            :ARG2 (p2 / protein :name (n2 / name :op1 "ER")
                  :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN")))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n3 / name :op1 "E2")
                  :xref (x3 / xref :value "PUBCHEM:5757"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 p
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_123_4335.96 ::date 2016-07-21T11:47:35 ::authors tkalman
# ::snt Assembly of ERα, coactivators, and general transcription factors at target gene promoters is associated with recruitment of protein kinases and receptor phosphorylation (, ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_96.txt
(s / smr-empty)

# ::id PMC_123_4335.97 ::date 2016-07-21T14:04:20 ::authors tkalman
# ::snt Whether E2-dependent SRC-3 phosphorylation requires ERα to be bound to DNA was investigated.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_97.txt
(i2 / increase-01
      :ARG0 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
            :ARG2 (n2 / nucleic-acid :name (n3 / name :op1 "DNA")
                  :xref (x2 / xref :value "UNIPROT:DNA2_HUMAN")))
      :ARG1 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n4 / name :op1 "E2")
                  :xref (x3 / xref :value "PUBCHEM:5757"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p3 / protein :name (n5 / name :op1 "SRC-3")
                        :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p4 / phosphorylate-01)))
      :mode (h / hypothesis))

# ::id PMC_123_4335.98 ::date 2016-07-21T14:20:35 ::authors tkalman
# ::snt The receptor binds directly to estrogen response elements mainly through the P box in the first of the two functionally distinct cysteine-cysteine zinc fingers located within the DBD.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_98.txt
(s / smr-empty)

# ::id PMC_123_4335.99 ::date 2016-07-21T15:34:53 ::authors tkalman
# ::snt Two ERα DBD mutants were tested, ERαCC and ERαEG, each containing a double mutation in different regions of the P box (C202H/C205H as CC and E203A/G204A as EG, respectively).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user tkalman ::file PMC_123_4335_99.txt
(s / smr-empty)

# ::id PMC_123_4335.100 ::date 2016-07-21T15:43:07 ::authors tkalman
# ::snt Neither of the two ERα DBD mutants could activate ERE-dependent transcription in a luciferase reporter assay (Fig. ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user tkalman ::file PMC_123_4335_100.txt
(s / smr-empty)

# ::id PMC_123_4335.101 ::date 2016-07-21T16:24:53 ::authors tkalman
# ::snt However, both of the CC and EG ERα DBD mutants induced SRC-3 phosphorylation, represented by sites S505, S543, and S867 (Fig. , lanes 5 and 6 and lanes 7 and 8, respectively).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_101.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein-segment :name (n / name :op1 "DBD")
                  :part-of (p2 / protein :name (n2 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m2 / mutate-01 :value "CC"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (a2 / amino-acid :mod 505 :name (n3 / name :op1 "serine"))
                  :manner (p4 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p5 / protein-segment :name (n4 / name :op1 "DBD")
                  :part-of (p6 / protein :name (n5 / name :op1 "ERα")
                        :xref (x2 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m3 / mutate-01 :value "CC"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p7 / protein)
                  :ARG1 (a4 / amino-acid :mod 543 :name (n6 / name :op1 "serine"))
                  :manner (p8 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (p9 / protein-segment :name (n7 / name :op1 "DBD")
                  :part-of (p10 / protein :name (n8 / name :op1 "ERα")
                        :xref (x3 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m4 / mutate-01 :value "CC"))
            :ARG1 (a5 / add-modification-00
                  :ARG0 (p11 / protein)
                  :ARG1 (a6 / amino-acid :mod 867 :name (n9 / name :op1 "serine"))
                  :manner (p12 / phosphorylate-01)))
      :card4 (i5 / increase-01
            :ARG0 (p13 / protein-segment :name (n10 / name :op1 "DBD")
                  :part-of (p14 / protein :name (n11 / name :op1 "ERα")
                        :xref (x4 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m5 / mutate-01 :value "EG"))
            :ARG1 (a7 / add-modification-00
                  :ARG0 (p15 / protein)
                  :ARG1 (a8 / amino-acid :mod 505 :name (n12 / name :op1 "serine"))
                  :manner (p16 / phosphorylate-01)))
      :card5 (i6 / increase-01
            :ARG0 (p17 / protein-segment :name (n13 / name :op1 "DBD")
                  :part-of (p18 / protein :name (n14 / name :op1 "ERα")
                        :xref (x5 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m6 / mutate-01 :value "EG"))
            :ARG1 (a9 / add-modification-00
                  :ARG0 (p19 / protein)
                  :ARG1 (a10 / amino-acid :mod 543 :name (n15 / name :op1 "serine"))
                  :manner (p20 / phosphorylate-01)))
      :card6 (i7 / increase-01
            :ARG0 (p21 / protein-segment :name (n16 / name :op1 "DBD")
                  :part-of (p22 / protein :name (n17 / name :op1 "ERα")
                        :xref (x6 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2-of (m7 / mutate-01 :value "EG"))
            :ARG1 (a11 / add-modification-00
                  :ARG0 (p23 / protein)
                  :ARG1 (a12 / amino-acid :mod 867 :name (n18 / name :op1 "serine"))
                  :manner (p24 / phosphorylate-01))))

# ::id PMC_123_4335.102 ::date 2016-07-21T17:14:41 ::authors tkalman
# ::snt The CC mutant appeared to be less effective at supporting SRC-3 phosphorylation than wild-type ERα was (lanes 3 and 4) or the EG mutant, even though the CC mutant binds to SRC-3 as well as does the wild-type receptor.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_102.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (p / protein :name (n / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN")
                  :ARG2-of (m2 / mutate-01 :value "CC"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (p3 / protein :name (n2 / name :op1 "SRC-3")
                        :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
                  :manner (p4 / phosphorylate-01)))
      :card2 (b / bind-01
            :ARG1 (p5 / protein :name (n3 / name :op1 "ERα")
                  :xref (x3 / xref :value "UNIPROT:ESR1_HUMAN")
                  :ARG2-of (m3 / mutate-01 :value "CC"))
            :ARG2 (p6 / protein :name (n4 / name :op1 "SRC-3")
                  :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN")))
      :card3 (b2 / bind-01
            :ARG1 (p7 / protein :name (n5 / name :op1 "ERα")
                  :xref (x5 / xref :value "UNIPROT:ESR1_HUMAN")
                  :mod (w / wild-type))
            :ARG2 (p8 / protein :name (n6 / name :op1 "SRC-3")
                  :xref (x6 / xref :value "UNIPROT:NCOA3_HUMAN"))))

# ::id PMC_123_4335.103 ::date 2016-07-21T17:19:08 ::authors tkalman
# ::snt In contrast, a weaker interaction between the EG mutant and SRC-3 was noted (Fig. , row 4).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_103.txt
(b / bind-01
      :ARG1 (p / protein :name (n / name :op1 "ERα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN")
            :ARG2-of (m / mutate-01 :value "EG"))
      :ARG2 (p2 / protein :name (n2 / name :op1 "SRC-3")
            :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN")))

# ::id PMC_123_4335.104 ::date 2016-07-21T17:20:49 ::authors tkalman
# ::snt It was observed that E2 treatment resulted in decreased SRC-3 levels in cells transfected with either ERα DBD mutant (Fig. , lanes 5 to 8, row 6); the reason for this is unknown, but it does suggest that ERα can exert control over SRC-3 levels in some contexts.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_104.txt
(d / decrease-01
      :ARG0 (s / small-molecule :name (n / name :op1 "E2")
            :xref (x / xref :value "PUBCHEM:5757"))
      :ARG1 (p / protein :name (n2 / name :op1 "SRC-3")
            :xref (x2 / xref :value "UNIPROT:NCOA3_HUMAN"))
      :location (c / cell))

# ::id PMC_123_4335.105 ::date 2016-07-21T17:38:29 ::authors tkalman
# ::snt Estradiol-induced and ER-dependent SRC-3 phosphorylation does not require ER DNA binding.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_105.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (b / bind-01
                  :ARG1 (p / protein :name (n / name :op1 "ER")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2 (n2 / nucleic-acid :name (n3 / name :op1 "DNA")
                        :xref (x2 / xref :value "UNIPROT:DNA2_HUMAN")))
            :ARG1 (i3 / increase-01
                  :ARG0 (s / small-molecule :name (n4 / name :op1 "estradiol")
                        :xref (x3 / xref :value "PUBCHEM:5757"))
                  :ARG1 (a / add-modification-00
                        :ARG0 (p2 / protein)
                        :ARG1 (p3 / protein :name (n5 / name :op1 "SRC-3")
                              :xref (x4 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p4 / phosphorylate-01))))
      :card2 (i4 / increase-01 :polarity -
            :ARG0 (b2 / bind-01
                  :ARG1 (p5 / protein :name (n6 / name :op1 "ER")
                        :xref (x5 / xref :value "UNIPROT:ESR1_HUMAN"))
                  :ARG2 (n7 / nucleic-acid :name (n8 / name :op1 "DNA")
                        :xref (x6 / xref :value "UNIPROT:DNA2_HUMAN")))
            :ARG1 (i5 / increase-01
                  :ARG0 p5
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p6 / protein)
                        :ARG1 (p7 / protein :name (n9 / name :op1 "SRC-3")
                              :xref (x7 / xref :value "UNIPROT:NCOA3_HUMAN"))
                        :manner (p8 / phosphorylate-01)))))

# ::id PMC_123_4335.106 ::date 2016-07-21T18:08:55 ::authors tkalman
# ::snt (A) HEK293T cells were cotransfected with pERE-E1b-Luc, and either the empty vector (Vector), or vectors for wild-type ERα (WT), or the EG (E203A/G204A) ...
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_123_4335_106.txt
(s / smr-empty)

# ::id PMC_317_8447.0 ::date 2016-07-21T18:10:27 ::authors tkalman
# ::snt RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user tkalman ::file PMC_317_8447_0.txt
(i2 / increase-01
      :ARG0 (m / molecular-physical-entity
            :ARG0-of (d / decrease-01
                  :ARG1 (e / enzyme :name (n / name :op1 "RAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN"))))
      :ARG1 (m2 / molecular-physical-entity
            :part e
            :part e)
      :location (c / cell))

# ::id PMC_317_8447.180 ::date 2016-07-21T18:31:13 ::authors tkalman
# ::snt RAF inhibitors rapidly activate MEK/ERK in cells with wild-type BRAF
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_180.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (m2 / molecular-physical-entity
                  :ARG0-of (d / decrease-01
                        :ARG1 (e / enzyme :name (n / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN"))))
            :ARG1 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "MEK")
                        :xref (x2 / xref :value "UNIPROT:MP2K1_HUMAN"))
                  :manner (p2 / phosphorylate-01))
            :location (c / cell))
      :card2 (i3 / increase-01
            :ARG0 (m3 / molecular-physical-entity
                  :ARG0-of (d2 / decrease-01
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "RAF")
                              :xref (x3 / xref :value "UNIPROT:RAF1_HUMAN"))))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (e4 / enzyme :name (n4 / name :op1 "ERK")
                        :xref (x4 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p4 / phosphorylate-01))
            :location (c2 / cell)))

# ::id PMC_317_8447.181 ::date 2016-07-21T21:36:25 ::authors tkalman
# ::snt a , Calu-6 cells (BRAF wild-type /K-RAS Q61K ) were treated with increasing doses of the indicated RAF inhibitors and the effects on ERK signaling were determined by immunoblotting for pMEK and pERK.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_181.txt
(s / smr-empty)

# ::id PMC_317_8447.182 ::date 2016-07-21T23:20:28 ::authors tkalman
# ::snt b , Cells with wild-type BRAF (Calu-6) or mutant BRAF (Malme-3M) were treated with vehicle or PLX4720 (1μM/1 hour).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Fri Jul 22, 2016 ::user tkalman ::file PMC_317_8447_182.txt
(s / smr-empty)

# ::id PMC_317_8447.183 ::date 2016-07-21T23:24:51 ::authors tkalman
# ::snt Phosphorylation and expression of the indicated proteins were assayed by immunoblotting.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_183.txt
(s / smr-empty)

# ::id PMC_317_8447.184 ::date 2016-07-21T23:32:38 ::authors tkalman
# ::snt c , Calu-6 cells treated with 1μM PLX4720 for the indicated time points.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user tkalman ::file PMC_317_8447_184.txt
(s / smr-empty)

# ::id PMC_317_8447.185 ::date 2016-07-21T23:35:21 ::authors tkalman
# ::snt d , Calu-6 cells were treated with 1μM PLX4720 for 60 minutes, then medium was replaced with medium containing 1μM PLX4720 (lanes 3-5) or vehicle (lanes 8-10) for the indicated time points.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 21, 2016 ::user tkalman ::file PMC_317_8447_185.txt
(s / smr-empty)

# ::id PMC_317_8447.186 ::date 2016-07-21T23:38:30 ::authors tkalman
# ::snt MEK/ERK activation requires binding of drug to the catalytic domain of RAF
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user tkalman ::file PMC_317_8447_186.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (b / bind-01
                  :ARG1 (m2 / molecular-physical-entity)
                  :ARG2 (p / protein-segment :name (n / name :op1 "catalytic" :op2 "domain")
                        :part-of (e / enzyme :name (n2 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN"))))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (e2 / enzyme :name (n3 / name :op1 "MEK")
                        :xref (x2 / xref :value "UNIPROT:MP2K1_HUMAN"))
                  :manner (p3 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (b2 / bind-01
                  :ARG1 (m3 / molecular-physical-entity)
                  :ARG2 (p4 / protein-segment :name (n4 / name :op1 "catalytic" :op2 "domain")
                        :part-of (e3 / enzyme :name (n5 / name :op1 "RAF")
                              :xref (x3 / xref :value "UNIPROT:RAF1_HUMAN"))))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (e4 / enzyme :name (n6 / name :op1 "ERK")
                        :xref (x4 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p6 / phosphorylate-01))))

# ::id PMC_317_8447.187 ::date 2016-07-21T23:48:27 ::authors tkalman
# ::snt a , 293H cells transfected with EGFP (control), HA-tagged RAS G12V , the catalytic domain of CRAF (V5-tagged catC) and catC carrying a mutation at the gatekeeper residue (V5-tagged catC T421M ), treated with vehicle or PLX4720 (1μM/1 hour).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_187.txt
(s / smr-empty)

# ::id PMC_317_8447.188 ::date 2016-07-21T23:50:07 ::authors tkalman
# ::snt Lysates were subjected to immunoblot analysis for pMEK and pERK.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Fri Jul 22, 2016 ::user tkalman ::file PMC_317_8447_188.txt
(s / smr-empty)

# ::id PMC_317_8447.189 ::date 2016-07-21T23:51:48 ::authors tkalman
# ::snt b , Wild-type (+/+), BRAF knock-out (BRAF −/−) or CRAF knock-out (CRAF −/−) mouse embryonic fibroblasts (MEFs) were treated with the indicated concentrations of PLX4720 for 1 hour.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Fri Jul 22, 2016 ::user tkalman ::file PMC_317_8447_189.txt
(s / smr-empty)

# ::id PMC_317_8447.190 ::date 2016-07-21T23:55:35 ::authors tkalman
# ::snt c , Sorafenib inhibits the gatekeeper mutant catC T421M protein in vitro ( Supplementary Fig. 8c ) and activates MEK/ERK in cells expressing it.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_190.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (m2 / molecular-physical-entity :name (n / name :op1 "Sorafenib"))
            :ARG1 (p / protein :name (n2 / name :op1 "catC")
                  :ARG2-of (m3 / mutate-01 :value "T421M")
                  :xref (v / value :name (n3 / name :op1 "UNIPROT:catC_HUMAN"))))
      :card2 (i2 / increase-01
            :ARG0 (m4 / molecular-physical-entity :name (n4 / name :op1 "Sorafenib"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (e / enzyme :name (n5 / name :op1 "MEK")
                        :xref (x / xref :value "UNIPROT:MP2K1_HUMAN"))
                  :manner (p3 / phosphorylate-01))
            :location (c / cell))
      :card3 (i3 / increase-01
            :ARG0 (m5 / molecular-physical-entity :name (n6 / name :op1 "Sorafenib"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (e2 / enzyme :name (n7 / name :op1 "ERK")
                        :xref (x2 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p5 / phosphorylate-01))
            :location (c2 / cell)))

# ::id PMC_317_8447.191 ::date 2016-07-22T00:09:03 ::authors tkalman
# ::snt 293H cells overexpressing catC T421M were treated with the indicated concentrations of sorafenib for 1 hour.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_191.txt
(s / smr-empty)

# ::id PMC_317_8447.192 ::date 2016-07-22T00:09:31 ::authors tkalman
# ::snt Lysates were subjected to analysis for pMEK and pERK.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Fri Jul 22, 2016 ::user tkalman ::file PMC_317_8447_192.txt
(s / smr-empty)

# ::id PMC_317_8447.193 ::date 2016-07-22T00:09:55 ::authors tkalman
# ::snt RAF inhibitor induces the active, phosphorylated state of wild-type and kinase-dead RAF
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_193.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (m2 / molecular-physical-entity
                  :ARG0-of (d / decrease-01
                        :ARG1 (e / enzyme :name (n / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN"))))
            :ARG1 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "RAF")
                        :xref (x2 / xref :value "UNIPROT:RAF1_HUMAN"))
                  :manner (p2 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (m3 / molecular-physical-entity
                  :ARG0-of (d2 / decrease-01
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "RAF")
                              :xref (x3 / xref :value "UNIPROT:RAF1_HUMAN"))))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (e4 / enzyme :name (n4 / name :op1 "RAF")
                        :xref (x4 / xref :value "UNIPROT:RAF1_HUMAN")
                        :ARG2-of (m4 / mutate-01 :mod "-/-"))
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_317_8447.194 ::date 2016-07-22T00:44:17 ::authors tkalman
# ::snt a , 293H cells over-expressing catC were treated with the indicated amounts of PLX4720 for 1 hour.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_194.txt
(s / smr-empty)

# ::id PMC_317_8447.196 ::date 2016-07-22T00:46:10 ::authors tkalman
# ::snt Kinase activity was determined by immunoblotting for pMEK.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user tkalman ::file PMC_317_8447_196.txt
(s / smr-empty)

# ::id PMC_317_8447.199 ::date 2016-07-30T08:33:05 ::authors aduvocelle
# ::snt c , Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user aduvocelle ::file PMC_317_8447_199.txt
(i2 / increase-01
      :ARG0 (e / enzyme :name (n2 / name :op1 "Raf")
            :ARG0-of (d / decrease-01))
      :ARG1 (a2 / add-modification-00
            :manner (p3 / phosphorylate-01)
            :location (e2 / enzyme :name (n3 / name :op1 "Raf"))))

# ::id PMC_317_8447.200 ::date 2016-07-30T09:13:02 ::authors aduvocelle
# ::snt V5-tagged wild-type CRAF or kinase-dead CRAF D486N were overexpressed in 293H cells.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user aduvocelle ::file PMC_317_8447_200.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG1 (e / enzyme :name (n / name :op1 "CRAF")
                  :mod (w / wild-type)))
      :card2 (i3 / increase-01
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "CRAF")))
      :location (c2 / cell :name (n2 / name :op1 "293H")))

# ::id PMC_317_8447.206 ::date 2016-07-30T09:28:49 ::authors aduvocelle
# ::snt MEK/ERK induction occurs via transactivation of RAF dimers
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user aduvocelle ::file PMC_317_8447_206.txt
(i2 / increase-01
      :ARG0 (e / enzyme :name (n3 / name :op1 "RAF"))
      :ARG1 (m / macro-molecular-complex
            :part (e2 / enzyme :name (n5 / name :op1 "MEK"))
            :part (e3 / enzyme :name (n6 / name :op1 "ERK"))))

# ::id PMC_317_8447.207 ::date 2016-07-30T09:31:33 ::authors aduvocelle
# ::snt a , Similarly to RAF inhibitors, JAB34 inhibits MEK/ERK at higher concentrations.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user aduvocelle ::file PMC_317_8447_207.txt
(d / decrease-01
      :ARG0 (m2 / molecular-physical-entity :name (n3 / name :op1 "JAB34"))
      :ARG1 (m3 / macro-molecular-complex
            :part (e / enzyme :name (n4 / name :op1 "MEK"))
            :part (e2 / enzyme :name (n5 / name :op1 "ERK"))))

# ::id PMC_369_0480.3 ::date 2016-07-30T10:19:38 ::authors aduvocelle
# ::snt RAS proteins are important direct activators of p110α, p110γ, and p110δ type I phosphoinositide 3-kinases (PI3Ks), interacting via an amino-terminal RAS-binding domain (RBD).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_3.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein :name (n2 / name :op1 "RAS"))
            :ARG1 (e / enzyme :name (n3 / name :op1 "p110α")))
      :card2 (i3 / increase-01
            :ARG0 (p3 / protein :name (n5 / name :op1 "RAS"))
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "p110γ")))
      :card3 (i4 / increase-01
            :ARG0 (p4 / protein :name (n6 / name :op1 "RAS"))
            :ARG1 (e3 / enzyme :name (n7 / name :op1 "PI3Ks"))))

# ::id PMC_369_0480.5 ::date 2016-07-31T07:23:58 ::authors aduvocelle
# ::snt Unexpectedly, RAS is unable to interact with p110β, but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_5.txt
(m / multi-index-card
      :card1 (b3 / bind-01 :polarity -
            :ARG1 (p2 / protein :name (n2 / name :op1 "RAS"))
            :ARG2 (e / enzyme :name (n3 / name :op1 "p110β")))
      :card2 (b / bind-01
            :ARG0 (p3 / protein :name (n4 / name :op1 "RAC1")
                  :part-of (p / protein-family :name (n / name :op1 "RHO" :op2 "GTPase")))
            :ARG1 (e2 / enzyme :name (n5 / name :op1 "p110β")))
      :card3 (b2 / bind-01
            :ARG0 (p4 / protein :name (n6 / name :op1 "CDC42")
                  :part-of (p7 / protein-family :name (n12 / name :op1 "RHO" :op2 "GTPase")))
            :ARG1 (e3 / enzyme :name (n7 / name :op1 "p110β")))
      :card4 (a2 / add-modification-00
            :ARG0 (p5 / protein :name (n8 / name :op1 "RAC1")
                  :part-of (p8 / protein-family :name (n13 / name :op1 "RHO" :op2 "GTPase")))
            :ARG1 (e4 / enzyme :name (n9 / name :op1 "p110β")))
      :card5 (a3 / add-modification-00
            :ARG0 (p6 / protein :name (n10 / name :op1 "CDC42")
                  :part-of (p9 / protein-family :name (n14 / name :op1 "RHO" :op2 "GTPase")))
            :ARG1 (e5 / enzyme :name (n11 / name :op1 "p110β"))))

# ::id PMC_369_0480.6 ::date 2016-07-31T07:35:33 ::authors aduvocelle
# ::snt In fibroblasts, GPCRs couple to PI3K through Dock180/Elmo1-mediated RAC activation and subsequent interaction with p110β.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_6.txt
(b2 / bind-01
      :ARG0 (p3 / protein :name (n3 / name :op1 "RAC")
            :ARG1-of (a / add-modification-00)
            :ARG1-of (b / bind-01
                  :ARG2 (e / enzyme :name (n4 / name :op1 "p110β"))))
      :ARG1 (p / protein :name (n / name :op1 "GPCRs"))
      :ARG2 (p2 / protein :name (n2 / name :op1 "PI3K"))
      :location (f / fibroblast))

# ::id PMC_369_0480.7 ::date 2016-07-31T07:45:41 ::authors aduvocelle
# ::snt Cells from mice carrying mutations in the p110β RBD show reduced PI3K activity and defective chemotaxis, and these mice are resistant to experimental lung fibrosis.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_7.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG1 (p / protein :name (n / name :op1 "PI3K")
                  :ARG1-of (a / add-modification-00))
            :location (c / cell
                  :ARG1-of (m2 / mutate-01)
                  :part-of (m3 / mouse)))
      :card2 (d2 / decrease-01
            :ARG1 (c3 / chemotaxis)
            :location (c2 / cell
                  :ARG1-of (m4 / mutate-01)
                  :part-of (m5 / mouse))))

# ::id PMC_369_0480.8 ::date 2016-07-31T08:08:29 ::authors aduvocelle
# ::snt These findings revise our understanding of the regulation of type I PI3K by showing that both RAS and RHO family GTPases directly regulate distinct ubiquitous PI3K isoforms and that RAC activates p110β downstream of GPCRs.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_8.txt
(m / multi-index-card
      :card1 (a / add-modification-00
            :ARG0 (p2 / protein :name (n2 / name :op1 "RAS"))
            :ARG1 (p3 / protein :name (n3 / name :op1 "PI3K")
                  :mod (i2 / isoform)))
      :card2 (a2 / add-modification-00
            :ARG0 (p4 / protein-family :name (n5 / name :op1 "RHO" :op2 "GTPase"))
            :ARG1 (p5 / protein :name (n4 / name :op1 "PI3K")
                  :mod (i3 / isoform)))
      :card3 (a3 / add-modification-00
            :ARG0 (p / protein :name (n / name :op1 "RAC"))
            :ARG1 (e / enzyme :name (n6 / name :op1 "p110β")
                  :ARG1-of (b / bind-01
                        :ARG2 (p6 / protein :name (n7 / name :op1 "GPCR"))
                        :direction (d / downstream)))))

# ::id PMC_369_0480.13 ::date 2016-07-31T08:19:06 ::authors aduvocelle
# ::snt Unlike p110α, p110γ, and p110δ PI3K isoforms, RAS is unable to interact with p110β
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_13.txt
(m / multi-index-card
      :card1 (b / bind-01 :polarity -
            :ARG1 (p2 / protein :name (n2 / name :op1 "RAS"))
            :ARG2 (e / enzyme :name (n3 / name :op1 "p110β")))
      :card2 (b2 / bind-01
            :ARG1 (p3 / protein :name (n4 / name :op1 "RAS"))
            :ARG2 (e2 / enzyme :name (n7 / name :op1 "p110α")))
      :card3 (b3 / bind-01
            :ARG1 (p4 / protein :name (n5 / name :op1 "RAS"))
            :ARG2 (e3 / enzyme :name (n8 / name :op1 "p110γ")))
      :card4 (b4 / bind-01
            :ARG1 (p5 / protein :name (n6 / name :op1 "RAS"))
            :ARG2 (e5 / enzyme :name (n10 / name :op1 "p110δ" :op2 "PI3K")
                  :mod (i2 / isoform))))

# ::id PMC_369_0480.14 ::date 2016-07-31T08:26:19 ::authors aduvocelle
# ::snt The RHO family GTPases RAC1 and CDC42 directly bind and activate p110β via its RBD
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_14.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "RAC1")
                  :part-of (p2 / protein-family :name (n2 / name :op1 "RHO" :op2 "GTPase")))
            :ARG2 (e / enzyme :name (n3 / name :op1 "p110β"))
            :location (p5 / protein-segment :name (n6 / name :op1 "RBD")))
      :card2 (b2 / bind-01
            :ARG1 (p3 / protein :name (n4 / name :op1 "CDC42")
                  :part-of (p4 / protein-family :name (n5 / name :op1 "RHO" :op2 "GTPase")))
            :ARG2 (e2 / enzyme :name (n8 / name :op1 "p110β"))
            :location (p6 / protein-segment :name (n7 / name :op1 "RBD")))
      :card3 (a / add-modification-00
            :ARG0 (p7 / protein :name (n9 / name :op1 "RAC1")
                  :part-of (p9 / protein-family :name (n11 / name :op1 "RHO" :op2 "GTPase")))
            :ARG1 (e3 / enzyme :name (n13 / name :op1 "p110β")))
      :card4 (a2 / add-modification-00
            :ARG0 (p8 / protein :name (n10 / name :op1 "CDC42")
                  :part-of (p10 / protein-family :name (n12 / name :op1 "RHO" :op2 "GTPase")))
            :ARG1 (e5 / enzyme :name (n15 / name :op1 "p110β"))))

# ::id PMC_369_0480.15 ::date 2016-07-31T08:34:37 ::authors aduvocelle
# ::snt GPCRs couple to PI3K via Dock180/Elmo1-mediated RAC activation and binding to p110β
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_15.txt
(b / bind-01
      :ARG1 (p / protein :name (n / name :op1 "GPCR"))
      :ARG2 (p2 / protein :name (n2 / name :op1 "PI3K")))

# ::id PMC_369_0480.16 ::date 2016-07-31T08:39:22 ::authors aduvocelle
# ::snt Mice with RBD mutant p110β are resistant to experimental lung fibrosis
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_16.txt
(a / add-modification-00 :polarity -
      :ARG0 (f / fibrosis
            :part-of (l / lung)
            :mod (e / experimental))
      :ARG1 (p / protein-segment :name (n / name :op1 "RBD")
            :ARG1-of (m2 / mutate-01
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "p110β")))
            :part-of (m3 / mouse)))

# ::id PMC_369_0480.18 ::date 2016-07-31T08:42:44 ::authors aduvocelle
# ::snt RAS proteins bind and activate multiple PI3K isoforms.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_18.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p2 / protein :name (n2 / name :op1 "RAS"))
            :ARG2 (p3 / protein :name (n3 / name :op1 "PI3K")
                  :mod (i2 / isoform)))
      :card2 (a / add-modification-00
            :ARG0 (p4 / protein :name (n4 / name :op1 "RAS"))
            :ARG2 (p5 / protein :name (n5 / name :op1 "PI3K")
                  :mod (i3 / isoform))))

# ::id PMC_369_0480.19 ::date 2016-07-31T08:45:29 ::authors aduvocelle
# ::snt The p110β isoform of PI3K, however, is instead activated by the binding of RHO family members RAC and CDC42.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user aduvocelle ::file PMC_369_0480_19.txt
(m / multi-index-card
      :card1 (a / add-modification-00
            :ARG0 (b / bind-01
                  :ARG1 (p / protein :name (n / name :op1 "RAC")
                        :part-of (p2 / protein-family :name (n2 / name :op1 "RHO")))
                  :ARG2 e)
            :ARG1 (e / enzyme :name (n3 / name :op1 "p110β")))
      :card2 (a2 / add-modification-00
            :ARG0 (b2 / bind-01
                  :ARG1 (p3 / protein :name (n4 / name :op1 "CDC42")
                        :part-of (p4 / protein-family :name (n5 / name :op1 "RHO")))
                  :ARG2 e2)
            :ARG1 (e2 / enzyme :name (n6 / name :op1 "p110β"))))

# ::id PMC_369_0480.48 ::date 2016-07-23T08:27:47 ::authors arus
# ::snt To investigate the role of RAS in regulating p110β, we set out to characterize the biochemical interaction between the two in vitro.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 23, 2016 ::user arus ::file PMC_369_0480_48.txt
(s / smr-empty)

# ::id PMC_369_0480.49 ::date 2016-07-23T12:25:08 ::authors arus
# ::snt In glutathione S-transferase (GST) pull-down studies using recombinant, GTPγS-loaded HRAS, KRAS, and NRAS as baits, we found strong and specific interaction between all three RAS proteins and p110α ( Figure 1 A).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user arus ::file PMC_369_0480_49.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG0 (e / enzyme :name (n2 / name :op1 "HRAS")
                  :xref (x / xref :value "UNIPROT:RASH_HUMAN"))
            :ARG1 (e4 / enzyme :name (n3 / name :op1 "p110α")
                  :xref (x2 / xref :value "UNIPROT:PK3CA_HUMAN")))
      :card2 (b2 / bind-01
            :ARG0 (e3 / enzyme :name (n6 / name :op1 "KRAS")
                  :xref (x5 / xref :value "UNIPROT:RASK_HUMAN"))
            :ARG1 (e5 / enzyme :name (n7 / name :op1 "p110α")
                  :xref (x6 / xref :value "UNIPROT:PK3CA_HUMAN")))
      :card3 (b3 / bind-01
            :ARG0 (e2 / enzyme :name (n4 / name :op1 "NRAS")
                  :xref (x3 / xref :value "UNIPROT:RASN_HUMAN"))
            :ARG1 (e6 / enzyme :name (n5 / name :op1 "p110α")
                  :xref (x4 / xref :value "UNIPROT:PK3CA_HUMAN"))))

# ::id PMC_369_0480.50 ::date 2016-07-23T12:48:38 ::authors arus
# ::snt In contrast, p110β bound to none of the RAS proteins, but did bind to RAB5, a previously identified GTPase interactor of p110β ( Christoforidis et al., 1999 ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user arus ::file PMC_369_0480_50.txt
(m / multi-index-card
      :card1 (b / bind-01 :polarity -
            :ARG1 (e / enzyme :name (n3 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (p / protein-family :name (n / name :op1 "Ras")))
      :card2 (b2 / bind-01
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (p5 / protein :name (n5 / name :op1 "RAB5")
                  :xref (x3 / xref :value "UNIPROT:RAB5A_HUMAN"))))

# ::id PMC_369_0480.51 ::date 2016-07-23T12:58:16 ::authors arus
# ::snt Mutating key residues within the RBD of p110α (T208D/K227A) abrogated RAS binding, whereas introduction of analogous mutations (see below for details) into p110β did not affect RAB5 binding.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_51.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (m2 / mutate-01
                  :ARG1 (p2 / protein-segment :name (n2 / name :op1 "RBD")
                        :part-of (p3 / protein :name (n3 / name :op1 "p110α")
                              :xref (x / xref :value "UNIPROT:PK3CA_HUMAN"))))
            :ARG1 (b / bind-01
                  :ARG1 (p / protein-family :name (n / name :op1 "Ras"))))
      :card2 (i2 / increase-01 :polarity -
            :ARG0 (p4 / protein :name (n4 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG1 (b2 / bind-01
                  :ARG1 (p5 / protein :name (n5 / name :op1 "RAB5")
                        :xref (x3 / xref :value "UNIPROT:RAB5A_HUMAN")))))

# ::id PMC_369_0480.52 ::date 2016-07-24T02:04:15 ::authors arus
# ::snt Similar results were obtained when we used recombinant full-length GST-p110/p85 complexes to pull down active RAS or RAB5 proteins ( Figure 1 B).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_52.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (m2 / macro-molecular-complex
                  :part (p2 / protein :name (n2 / name :op1 "GST-p110")
                        :xref (x / xref :value "UNIPROT:GSTP1_HUMAN"))
                  :part (p3 / protein :name (n3 / name :op1 "p85")
                        :xref (x2 / xref :value "UNIPROT:P85A_HUMAN")))
            :ARG1 (p4 / protein :name (n4 / name :op1 "RAS")
                  :ARG1-of (a / add-modification-00
                        :manner (p5 / phosphorylate-01))))
      :card2 (d2 / decrease-01
            :ARG0 (m3 / macro-molecular-complex
                  :part (p6 / protein :name (n5 / name :op1 "GST-p110")
                        :xref (x3 / xref :value "UNIPROT:GSTP1_HUMAN"))
                  :part (p7 / protein :name (n6 / name :op1 "p85")
                        :xref (x4 / xref :value "UNIPROT:P85A_HUMAN")))
            :ARG1 (p8 / protein :name (n7 / name :op1 "RAB5")
                  :xref (x5 / xref :value "UNIPROT:RAB5A_HUMAN"))))

# ::id PMC_369_0480.53 ::date 2016-07-24T02:14:21 ::authors arus
# ::snt Moreover, when we expressed constitutively active RAS or RAB5, along with p110α/p85 or p110β/p85 in COS7 cells, and measured PIP 3 -levels ( Figure 1 C) or steady-state phospho-AKT ( Figure S1 A available online) as indicators of PI3K activity, HRAS and KRAS strongly enhanced p110α activity, whereas p110β was not stimulated by either RAS proteins or RAB5.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_53.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (e / enzyme :name (n2 / name :op1 "HRAS")
                  :xref (x / xref :value "UNIPROT:RASH_HUMAN"))
            :ARG1 (p2 / protein :name (n3 / name :op1 "p110α")
                  :xref (x2 / xref :value "UNIPROT:PK3CA_HUMAN")
                  :ARG1-of (a / add-modification-00
                        :manner (p3 / phosphorylate-01))))
      :card2 (i3 / increase-01
            :ARG0 (e2 / enzyme :name (n4 / name :op1 "KRAS")
                  :xref (x3 / xref :value "UNIPROT:RASK_HUMAN"))
            :ARG1 (p4 / protein :name (n5 / name :op1 "p110α")
                  :xref (x4 / xref :value "UNIPROT:PK3CA_HUMAN")
                  :ARG1-of (a2 / add-modification-00
                        :manner (p5 / phosphorylate-01))))
      :card3 (i4 / increase-01 :polarity -
            :ARG0 (p6 / protein :name (n6 / name :op1 "RAS"))
            :ARG1 (p7 / protein :name (n7 / name :op1 "p110β")
                  :xref (x5 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card3 (i5 / increase-01 :polarity -
            :ARG0 (p8 / protein :name (n8 / name :op1 "RAB5")
                  :xref (x6 / xref :value "UNIPROT:RAB5A_HUMAN"))
            :ARG1 (p9 / protein :name (n9 / name :op1 "p110β")
                  :xref (x7 / xref :value "UNIPROT:PK3CB_HUMAN"))))

# ::id PMC_369_0480.54 ::date 2016-07-24T02:25:43 ::authors arus
# ::snt An Intact RBD Is Essential for p110β Activity in Cells
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_54.txt
(s / smr-empty)

# ::id PMC_369_0480.55 ::date 2016-07-24T02:28:42 ::authors arus
# ::snt The modest RBD sequence similarity among the four paralogs of type I PI3K is shown in Figure 1 D.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_55.txt
(s / smr-empty)

# ::id PMC_369_0480.56 ::date 2016-07-24T02:31:06 ::authors arus
# ::snt Even though the overall structural organization of the p110β RBD is conserved ( Zhang et al., 2011 ), we speculated that because we cannot detect any interaction with RAS, it might have lost or altered its function.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_56.txt
(s / smr-empty)

# ::id PMC_369_0480.57 ::date 2016-07-24T02:34:16 ::authors arus
# ::snt We therefore mutated two highly conserved key residues within the p110β RBD to generate a p110β-S205D/K224A double mutant (p110β-RBD-DM; Figure 1 E).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_57.txt
(s / smr-empty)

# ::id PMC_369_0480.58 ::date 2016-07-24T02:38:19 ::authors arus
# ::snt Analogous mutations in p110α and p110γ disrupt RAS binding ( Gupta et al., 2007 ; Pacold et al., 2000 ).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_58.txt
(m2 / multi-index-card
      :card1 (d3 / decrease-01
            :ARG0 (m / mutate-01
                  :ARG1 (p2 / protein :name (n2 / name :op1 "p110α")
                        :xref (x / xref :value "UNIPROT:PK3CA_HUMAN")))
            :ARG1 (b / bind-01
                  :ARG1 (p3 / protein :name (n3 / name :op1 "RAS"))))
      :card2 (d4 / decrease-01
            :ARG0 (m3 / mutate-01
                  :ARG1 (p4 / protein :name (n4 / name :op1 "p110γ")
                        :xref (x2 / xref :value "UNIPROT:PK3CG_HUMAN")))
            :ARG1 (b2 / bind-01
                  :ARG1 (p5 / protein :name (n5 / name :op1 "RAS")))))

# ::id PMC_369_0480.59 ::date 2016-07-24T03:48:52 ::authors arus
# ::snt In vitro, the basal lipid kinase activity of purified recombinant p110β-RBD-DM protein was indistinguishable from its wild-type counterpart prepared in parallel ( Figure 1 F).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_59.txt
(s / smr-empty)

# ::id PMC_369_0480.60 ::date 2016-07-24T03:49:54 ::authors arus
# ::snt Moreover, p110β-RBD-DM was still stimulated by the addition of purified recombinant Gβγ subunits, alone or in combination with a platelet-derived growth factor receptor (PDGFR)-derived phosphotyrosine peptide (pY740), indicating that the RBD mutations had no intrinsic effect on p110β lipid kinase activity or RBD-independent stimulatory input ( Figure 1 G).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_60.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (s / small-molecule :name (n3 / name :op1 "Gβγ")
                  :xref (x2 / xref :value "PUBCHEM:274122"))
            :ARG1 (p / protein-segment :name (n / name :op1 "RBD")
                  :part-of (p2 / protein :name (n2 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))))
      :card2 (i3 / increase-01
            :ARG0 (a / and
                  :op1 (s2 / small-molecule :name (n6 / name :op1 "Gβγ")
                        :xref (x4 / xref :value "PUBCHEM:274122"))
                  :op2 (s3 / small-molecule :name (n7 / name :op1 "PDGFR")
                        :xref (x5 / xref :value "PUBCHEM:10907042")))
            :ARG1 (p3 / protein-segment :name (n4 / name :op1 "RBD")
                  :part-of (p4 / protein :name (n5 / name :op1 "p110β")
                        :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN"))))
      :card3 (i4 / increase-01 :polarity -
            :ARG0 (p5 / protein-segment :name (n8 / name :op1 "RBD")
                  :ARG1-of (m2 / mutate-01))
            :ARG1 (p6 / protein :name (n9 / name :op1 "p110β")
                  :xref (x6 / xref :value "UNIPROT:PK3CB_HUMAN")
                  :ARG1-of (a2 / add-modification-00
                        :manner (p7 / phosphorylate-01))))
      :card4 (i5 / increase-01 :polarity -
            :ARG0 (p8 / protein-segment :name (n10 / name :op1 "RBD")
                  :ARG1-of (m3 / mutate-01))
            :ARG1 (i6 / increase-01
                  :ARG0 (p9 / protein-segment :name (n11 / name :op1 "RBD")))))

# ::id PMC_369_0480.61 ::date 2016-07-24T04:08:37 ::authors arus
# ::snt However, RBD mutant p110β was much less active than wild-type when expressed in COS7 cells ( Figures 1 H and S1 B) even when Gβγ subunits were coexpressed or a myristoylation signal was added, pointing to a critical role of the RBD for p110β activity in living cells.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_61.txt
(s / smr-empty)

# ::id PMC_369_0480.62 ::date 2016-07-24T04:33:20 ::authors arus
# ::snt p110β Interacts with Distinct RAS Subfamily GTPases
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_62.txt
(b / bind-01
      :ARG0 (p / protein :name (n / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
      :ARG1 (p2 / protein-family :name (n2 / name :op1 "GTPases")))

# ::id PMC_369_0480.63 ::date 2016-07-24T04:34:21 ::authors arus
# ::snt To identify RBD interactors of p110β, we probed all 34 murine members of the RAS subfamily of small GTPases (RFGs) for binding to p110β/p85 ( Figure S1 C).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_63.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p / protein-family :name (n / name :op1 "GTPases"))
            :ARG2 (p2 / protein :name (n2 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
            :mode (h / hypothesis))
      :card2 (b2 / bind-01
            :ARG1 (p3 / protein-family :name (n3 / name :op1 "GTPases"))
            :ARG2 (p4 / protein :name (n4 / name :op1 "p85")
                  :xref (x2 / xref :value "UNIPROT:P85A_HUMAN"))
            :mode (h2 / hypothesis)))

# ::id PMC_369_0480.64 ::date 2016-07-24T04:35:16 ::authors arus
# ::snt Parallel experiments were performed with p110α/p85, p110γ/p101, and p110δ/p85, respectively ( Figure S1 D).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_64.txt
(s / smr-empty)

# ::id PMC_369_0480.65 ::date 2016-07-24T04:35:47 ::authors arus
# ::snt Strikingly, whereas all non-β isoforms interacted with the three prototypical RAS proteins and a partially overlapping subset of closely related RFGs (RRAS1, RRAS2, MRAS, and ERAS), p110β bound to none of those ( Figure 2 A).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_65.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p2 / protein :name (n2 / name :op1 "non-β" :op2 "isoform"))
            :ARG2 (p3 / protein :name (n3 / name :op1 "RAS")))
      :card2 (b2 / bind-01
            :ARG1 (p4 / protein :name (n4 / name :op1 "non-β" :op2 "isoform"))
            :ARG2 (e / enzyme :name (n5 / name :op1 "RRAS1")
                  :xref (x / xref :value "UNIPROT:Q25284_LOLFO")))
      :card3 (b3 / bind-01
            :ARG1 (p5 / protein :name (n6 / name :op1 "non-β" :op2 "isoform"))
            :ARG2 (e2 / enzyme :name (n7 / name :op1 "RRAS2")
                  :xref (x2 / xref :value "UNIPROT:RRAS2_HUMAN")))
      :card4 (b4 / bind-01
            :ARG1 (p6 / protein :name (n8 / name :op1 "non-β" :op2 "isoform"))
            :ARG2 (e3 / enzyme :name (n9 / name :op1 "MRAS")
                  :xref (x3 / xref :value "UNIPROT:RASM_HUMAN")))
      :card5 (b5 / bind-01
            :ARG1 (p7 / protein :name (n10 / name :op1 "non-β" :op2 "isoform"))
            :ARG2 (e4 / enzyme :name (n11 / name :op1 "ERAS")
                  :xref (x4 / xref :value "UNIPROT:RASE_HUMAN")))
      :card6 (b6 / bind-01 :polarity -
            :ARG1 (p8 / protein :name (n12 / name :op1 "p110β")
                  :xref (x5 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (e5 / enzyme :name (n13 / name :op1 "RRAS1")
                  :xref (x6 / xref :value "UNIPROT:Q25284_LOLFO")))
      :card7 (b7 / bind-01 :polarity -
            :ARG1 (p9 / protein :name (n14 / name :op1 "p110β")
                  :xref (x7 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (e6 / enzyme :name (n15 / name :op1 "RRAS2")
                  :xref (x8 / xref :value "UNIPROT:RRAS2_HUMAN")))
      :card8 (b8 / bind-01 :polarity -
            :ARG1 (p10 / protein :name (n16 / name :op1 "p110β")
                  :xref (x9 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (e7 / enzyme :name (n17 / name :op1 "MRAS")
                  :xref (x10 / xref :value "UNIPROT:RASM_HUMAN")))
      :card9 (b9 / bind-01 :polarity -
            :ARG1 (p11 / protein :name (n18 / name :op1 "p110β")
                  :xref (x11 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (e8 / enzyme :name (n19 / name :op1 "ERAS")
                  :xref (x12 / xref :value "UNIPROT:RASE_HUMAN"))))

# ::id PMC_369_0480.66 ::date 2016-07-24T05:19:21 ::authors arus
# ::snt Instead, p110β exclusively bound to the more distantly related DIRAS1 and DIRAS2 proteins in a GTP-dependent manner ( Figure S1 C).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_66.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (e / enzyme :name (n2 / name :op1 "DIRAS1")
                  :xref (x2 / xref :value "UNIPROT:DIRA1_HUMAN")))
      :card2 (b2 / bind-01
            :ARG1 (p2 / protein :name (n3 / name :op1 "p110β")
                  :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (e2 / enzyme :name (n4 / name :op1 "DIRAS2")
                  :xref (x4 / xref :value "UNIPROT:DIRA2_HUMAN"))))

# ::id PMC_369_0480.67 ::date 2016-07-24T05:24:54 ::authors arus
# ::snt DIRAS selectively bound wild-type and not RBD mutant p110β ( Figure S2 B), suggesting binding to the RBD.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_67.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (e2 / enzyme :name (n / name :op1 "DIRAS"))
            :ARG2 (p2 / protein :name (n2 / name :op1 "p110β")
                  :mod (w / wild-type)
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card2 (b2 / bind-01 :polarity -
            :ARG1 (e / enzyme :name (n3 / name :op1 "DIRAS"))
            :ARG2 (p4 / protein-segment :name (n4 / name :op1 "RBD")
                  :ARG1-of (m2 / mutate-01)
                  :part-of (p5 / protein :name (n5 / name :op1 "p110β")
                        :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN")))))

# ::id PMC_369_0480.68 ::date 2016-07-24T09:15:05 ::authors arus
# ::snt However, DIRAS failed to stimulate p110β lipid kinase activity in vitro ( Figure 2 C) and in cells, where constitutively active DIRAS proteins seemed to repress rather than elevate phospho-AKT when coexpressed along with p110β ( Figure 2 B), making DIRAS an unlikely in vivo activator of p110β.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_68.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (e / enzyme :name (n / name :op1 "DIRAS"))
            :ARG1 (p / protein :name (n2 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN")
                  :ARG1-of (a2 / add-modification-00
                        :manner (p2 / phosphorylate-01))))
      :card2 (d / decrease-01
            :ARG0 (e2 / enzyme :name (n3 / name :op1 "DIRAS")
                  :ARG1-of (a3 / add-modification-00
                        :manner (p3 / phosphorylate-01)))
            :ARG1 (e3 / enzyme :name (n4 / name :op1 "AKT"))
            :location (c / cell)))

# ::id PMC_369_0480.69 ::date 2016-07-24T09:17:30 ::authors arus
# ::snt p110β Is a Direct RAC/CDC42 Target Protein
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_69.txt
(s / smr-empty)

# ::id PMC_369_0480.70 ::date 2016-07-24T09:32:36 ::authors arus
# ::snt When comparing DIRAS with RAS, an obvious difference is the substitution of Asp33 within the G2 box of RAS with Ile37 in DIRAS ( Figure 2 D).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_70.txt
(s / smr-empty)

# ::id PMC_369_0480.71 ::date 2016-07-24T09:36:44 ::authors arus
# ::snt This substitution is relevant to PI3K binding because an HRAS-D33I mutant showed attenuated binding to p110α and DIRAS1-I37D showed reduced binding to p110β, even though exchange of this residue did not enable RAS binding to p110β or DIRAS binding to p110α ( Figure S2 A), pointing to additional, G2-box-independent determinants of PI3K isoform specificity.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_71.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (e / enzyme :name (n2 / name :op1 "HRAS")
                  :ARG2-of (m2 / mutate-01 :value "D33I")
                  :xref (x / xref :value "UNIPROT:RASH_HUMAN"))
            :ARG2 (p2 / protein :name (n3 / name :op1 "p110α")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card2 (b2 / bind-01
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "DIRAS1")
                  :xref (x3 / xref :value "UNIPROT:DIRA1_HUMAN")
                  :ARG2-of (m3 / mutate-01 :value "I37D"))
            :ARG2 (p3 / protein :name (n5 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card3 (i2 / increase-01 :polarity -
            :ARG0 (p4 / protein)
            :ARG1 (b3 / bind-01
                  :ARG1 (p5 / protein :name (n6 / name :op1 "RAS"))
                  :ARG2 (p6 / protein :name (n7 / name :op1 "p110β")
                        :xref (x5 / xref :value "UNIPROT:PK3CB_HUMAN"))))
      :card4 (i3 / increase-01 :polarity -
            :ARG0 (p7 / protein)
            :ARG1 (b4 / bind-01
                  :ARG1 (e3 / enzyme :name (n8 / name :op1 "DIRAS"))
                  :ARG2 (p8 / protein :name (n9 / name :op1 "p110α")
                        :xref (x6 / xref :value "UNIPROT:PK3CA_HUMAN")))))

# ::id PMC_369_0480.72 ::date 2016-07-24T10:19:45 ::authors arus
# ::snt Several members of the RHO subfamily of small GTPases harbor a hydrophobic isoleucine or valine residue in this position ( Figure S2 C), which prompted us to test p110β for binding to representative RHO family GTPases ( Figure S2 D).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_72.txt
(b / bind-01
      :ARG1 (p2 / protein :name (n / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
      :ARG2 (p3 / protein-family :name (n2 / name :op1 "RHO" :op2 "GTPase")))

# ::id PMC_369_0480.74 ::date 2016-07-24T10:22:57 ::authors arus
# ::snt Weaker binding to RHOG and minimal binding to RHOA was also observed ( Figure 2 E).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_74.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p / protein)
            :ARG2 (p2 / protein :name (n / name :op1 "RHOG")
                  :xref (x / xref :value "UNIPROT:RHOG_HUMAN")))
      :card2 (b2 / bind-01
            :ARG1 (p3 / protein)
            :ARG2 (p4 / protein :name (n2 / name :op1 "RHOA")
                  :xref (x2 / xref :value "UNIPROT:RHOA_HUMAN"))))

# ::id PMC_369_0480.75 ::date 2016-07-24T10:27:07 ::authors arus
# ::snt Importantly, RAC1, CDC42, RHOG, and RHOA preparations bound similar amounts of GTP, indicating proper folding and functionality ( Figure 2 E, right lower graph), and a RAC1-I33D mutant showed reduced binding to p110β ( Figure S2 E), confirming a key role of this residue in GTPase binding to p110β.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_75.txt
(m2 / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p2 / protein :name (n3 / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG2 (s / small-molecule :name (n / name :op1 "GTP")
                  :xref (x2 / xref :value "PUBCHEM:6830")))
      :card2 (b2 / bind-01
            :ARG1 (p3 / protein :name (n4 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG2 (s2 / small-molecule :name (n5 / name :op1 "GTP")
                  :xref (x4 / xref :value "PUBCHEM:6830")))
      :card3 (b3 / bind-01
            :ARG1 (p4 / protein :name (n6 / name :op1 "RHOG")
                  :xref (x5 / xref :value "UNIPROT:RHOG_HUMAN"))
            :ARG2 (s3 / small-molecule :name (n7 / name :op1 "GTP")
                  :xref (x6 / xref :value "PUBCHEM:6830")))
      :card4 (b4 / bind-01
            :ARG1 (p5 / protein :name (n8 / name :op1 "RHOA")
                  :xref (x7 / xref :value "UNIPROT:RHOA_HUMAN"))
            :ARG2 (s4 / small-molecule :name (n9 / name :op1 "GTP")
                  :xref (x8 / xref :value "PUBCHEM:6830")))
      :card5 (b5 / bind-01
            :ARG1 (p6 / protein :name (n10 / name :op1 "RAC1")
                  :xref (x9 / xref :value "UNIPROT:RAC1_HUMAN")
                  :ARG2-of (m3 / mutate-01 :value "I33D"))
            :ARG2 (p7 / protein :name (n11 / name :op1 "p110β")
                  :xref (x10 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card6 (b6 / bind-01
            :ARG1 (p8 / protein-family :name (n12 / name :op1 "GTPase"))
            :ARG2 (p9 / protein :name (n13 / name :op1 "p110β")
                  :xref (x11 / xref :value "UNIPROT:PK3CB_HUMAN"))))

# ::id PMC_369_0480.76 ::date 2016-07-24T10:42:47 ::authors arus
# ::snt The RAC1/CDC42-p110β interaction was isoform specific because neither RAC1 nor CDC42 significantly bound non-β isoforms under parallel conditions ( Figures 2 F and S2 F).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_76.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG2 (p2 / protein :name (n2 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card2 (b2 / bind-01
            :ARG1 (p3 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG2 (p4 / protein :name (n4 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card3 (b3 / bind-01
            :ARG1 (p5 / protein :name (n5 / name :op1 "RAC1")
                  :xref (x5 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG2 (p6 / protein :name (n6 / name :op1 "non-β" :op2 "isoform")))
      :card4 (b4 / bind-01
            :ARG1 (p7 / protein :name (n7 / name :op1 "CDC42")
                  :xref (x6 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG2 (p8 / protein :name (n8 / name :op1 "non-β" :op2 "isoform"))))

# ::id PMC_369_0480.77 ::date 2016-07-24T10:51:55 ::authors arus
# ::snt Strikingly, GTPγS-loaded RAC1 or CDC42 strongly stimulated p110β lipid kinase activity in vitro ( Figure 2 G), alone and in cooperation with a phosphotyrosine peptide (pY740), or when p110β was complexed with a less inhibitory, truncated p85 (Δp85 schematic in Figure 3 C).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_77.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG1 (p2 / protein :name (n2 / name :op1 "p110β")
                        :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :manner (p3 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p4 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a2 / add-modification-00
                  :ARG1 (p6 / protein :name (n4 / name :op1 "p110β")
                        :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :manner (p5 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (a3 / and
                  :op1 (p7 / protein :name (n5 / name :op1 "RAC1")
                        :xref (x5 / xref :value "UNIPROT:RAC1_HUMAN"))
                  :op2 (a4 / amino-acid :mod 740 :name (n6 / name :op1 "tyrosine")
                        :ARG1-of (p8 / phosphorylate-01)))
            :ARG1 (p9 / protein :name (n7 / name :op1 "p110β")
                  :xref (x6 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card4 (i5 / increase-01
            :ARG0 (a5 / and
                  :op1 (p10 / protein :name (n8 / name :op1 "CDC42")
                        :xref (x7 / xref :value "UNIPROT:CDC42_HUMAN"))
                  :op2 (a6 / amino-acid :mod 740 :name (n9 / name :op1 "tyrosine")
                        :ARG1-of (p11 / phosphorylate-01)))))

# ::id PMC_369_0480.78 ::date 2016-07-24T11:09:24 ::authors arus
# ::snt Stimulation of p110β by active RAC1 and CDC42 was dose dependent ( Figure 2 H).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 24, 2016 ::user arus ::file PMC_369_0480_78.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN")
                  :ARG1-of (a2 / add-modification-00
                        :manner (p4 / phosphorylate-01)))
            :ARG1 (p3 / protein :name (n3 / name :op1 "p110β")
                  :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n2 / name :op1 "CDC42")
                  :xref (x2 / xref :value "UNIPROT:CDC42_HUMAN")
                  :ARG1-of (a / add-modification-00
                        :manner (p5 / phosphorylate-01)))
            :ARG1 (p6 / protein :name (n4 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN"))))

# ::id PMC_369_0480.79 ::date 2016-07-22T14:56:50
# ::snt Coexpression of constitutively active RAC1 or CDC42 ( Figure S2 G, lanes 4–6), but not RHOA ( Figure S2 H), along with p110β/p85 in COS7 cells strongly elevated cellular phospho-AKT and PIP 3 levels ( Figure 2 I), indicating that both GTPases activate p110β in transfected cells.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_79.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (c / coexpress-00
                  :ARG1 (o / or
                        :op1 (p2 / protein :name (n3 / name :op1 "RAC1")
                              :xref (x / xref :value "UNIPROT"))
                        :op2 (p3 / protein :name (n4 / name :op2 "CDC42")
                              :xref (x2 / xref :value "UNIPROT")))
                  :ARG1-of (d / describe-01
                        :ARG0 (a2 / and
                              :op1 (f / figure :mod "S2 G")
                              :op2 (l / lane
                                    :mod (v / value-interval :op1 4 :op2 6)))))
            :ARG1 (e3 / enzyme :name (n7 / name :op1 "PIP" :op2 "3")
                  :ARG1-of (a6 / add-modification-00
                        :ARG0 (p11 / protein)
                        :manner (p9 / phosphorylate-01))
                  :xref (x4 / xref :value "UNIPROT"))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f3 / figure :mod "2 I")))
      :card2 (i3 / increase-01
            :ARG0 (c2 / coexpress-00
                  :ARG1 (o2 / or
                        :op1 (p / protein :name (n2 / name :op1 "RAC1")
                              :xref (x5 / xref :value "UNIPROT"))
                        :op2 (p4 / protein :name (n5 / name :op1 "CDC42")
                              :xref (x6 / xref :value "UNIPROT")))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a / and
                              :op1 (f2 / figure :mod "S2 G")
                              :op2 (l2 / lane
                                    :mod (v2 / value-interval :op1 4 :op2 6)))))
            :ARG1 (e / enzyme :name (n / name :op1 "AKT")
                  :ARG1-of (a7 / add-modification-00
                        :ARG0 (p12 / protein)
                        :manner (p10 / phosphorylate-01))
                  :xref (x3 / xref :value "UNIPROT"))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f4 / figure :mod "2 I"))))

# ::id PMC_369_0480.80 ::date 2016-07-23T01:09:32
# ::snt PIP 3 levels were further enhanced by coexpression of Gβ 1 /Gγ 2 subunits or by myristoylation of p110β ( Figure 2 I).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_80.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (c / coexpress-00
                  :ARG1 (m2 / macro-molecular-complex
                        :part (g / gene :name (n2 / name :op1 "Gβ1")
                              :xref (x / xref :value "HGNC"))
                        :part (g2 / gene :name (n3 / name :op1 "Gγ2")
                              :xref (x2 / xref :value "HGNC"))))
            :ARG1 (e / enzyme :name (n / name :op1 "PIP 3")
                  :xref (x3 / xref :value "UNIPROT")))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2 I")))

# ::id PMC_369_0480.81 ::date 2016-07-23T02:10:49
# ::snt In contrast, GTPγS-loaded RAC1/CDC42 did not stimulate p110α in vitro ( Figure S2 I), nor did V12-RAC1/CDC42 cooperate with p110α, p110γ, or p110δ to elevate cellular phospho-AKT levels ( Figure S2 J).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_81.txt
(m / multi-index-card
      :card1 (i3 / increase-01 :polarity -
            :ARG0 (m2 / macro-molecular-complex
                  :part (p4 / protein :name (n3 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT"))
                  :part (p5 / protein :name (n4 / name :op1 "CDC42")
                        :xref (x2 / xref :value "UNIPROT")))
            :ARG1 (p3 / protein :name (n2 / name :op1 "p110α"))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "S2 I")))
      :card2 (i2 / increase-01
            :ARG1 (a / add-modification-00
                  :ARG0 (m3 / macro-molecular-complex
                        :part (p6 / protein :name (n5 / name :op1 "V12-RAC1")
                              :xref (x3 / xref :value "UNIPROT"))
                        :part (p7 / protein :name (n6 / name :op1 "CDC42")
                              :xref (x4 / xref :value "UNIPROT")))
                  :ARG1 (e2 / enzyme :name (n / name :op1 "AKT"))
                  :manner (p2 / phosphorylate-01))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure :mod "S2 J"))))

# ::id PMC_369_0480.83 ::date 2016-07-23T02:23:21
# ::snt RAC and CDC42 Are RBD Interactors of p110β
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_83.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT"))
            :ARG1 (p3 / protein :name (n3 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT")))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n2 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT"))
            :ARG1 (p4 / protein :name (n4 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT"))))

# ::id PMC_369_0480.84 ::date 2016-07-23T02:30:54
# ::snt We next aimed to confirm that RAC and CDC42 are RBD interactors of p110β.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_84.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT"))
            :ARG1 (p3 / protein :name (n3 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT")))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n2 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT"))
            :ARG1 (p4 / protein :name (n4 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT")))
      :mode (h / hypotheses))

# ::id PMC_369_0480.85 ::date 2016-07-23T02:36:21
# ::snt Purified recombinant wild-type p110β/p85 bound to RAC1 and CDC42 in a concentration-dependent manner, whereas p110β-RBD-DM/p85 complexes showed no binding ( Figure 3 A).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_85.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (m2 / macro-molecular-complex
                  :mod (w / wild-type)
                  :part (p3 / protein :name (n / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT"))
                  :part (p4 / protein :name (n6 / name :op1 "p85")
                        :xref (x2 / xref :value "UNIPROT")))
            :ARG2 (p / protein :name (n2 / name :op1 "RAC")))
      :card2 (b2 / bind-01
            :ARG1 (m3 / macro-molecular-complex
                  :mod (w2 / wild-type)
                  :part (p5 / protein :name (n3 / name :op1 "p110β")
                        :xref (x4 / xref :value "UNIPROT"))
                  :part (p6 / protein :name (n5 / name :op1 "p85")
                        :xref (x5 / xref :value "UNIPROT")))
            :ARG2 (p2 / protein :name (n4 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT")))
      :card3 (b3 / bind-01 :polarity -
            :ARG1 (m4 / macro-molecular-complex
                  :part (p7 / protein :name (n7 / name :op1 "p110β-RBD-DM")
                        :xref (x6 / xref :value "UNIPROT"))
                  :part (p8 / protein :name (n8 / name :op1 "p85")
                        :xref (x7 / xref :value "UNIPROT"))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3 A")))

# ::id PMC_369_0480.86 ::date 2016-07-23T02:47:48
# ::snt Similarly, RBD mutant p110β was not stimulated by active RAC1 or CDC42 in vitro ( Figure 3 B) or in cells ( Figure S2 E, lanes 7–9).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_86.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :ARG1-of (a / add-modification-00
                        :ARG0 (p7 / protein)
                        :manner (p5 / phosphorylate-01))
                  :xref (x / xref :value "UNIPROT"))
            :ARG1 (p2 / protein :name (n2 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT"))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure :mod "3 B")))
      :card2 (i3 / increase-01 :polarity -
            :ARG0 (p3 / protein :name (n3 / name :op1 "CDC42")
                  :ARG1-of (a2 / add-modification-00
                        :ARG0 (p8 / protein)
                        :manner (p6 / phosphorylate-01))
                  :xref (x3 / xref :value "UNIPROT"))
            :ARG1 (p4 / protein :name (n4 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT")))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3 B")))

# ::id PMC_369_0480.88 ::date 2016-07-23T03:20:34
# ::snt Intriguingly, binding was unaffected by removal of the BHD but completely disrupted when full-length p85 was in complex with RBD mutant p110β, strongly arguing for the RBD as the RAC/CDC42-binding site.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_88.txt
(m2 / multi-index-card
      :card1 (c / complex-with-00
            :ARG1 (a / and
                  :op1 (p / protein :name (n / name :op1 "p85")
                        :xref (x / xref :value "UNIPROT"))
                  :op2 (p2 / protein :name (n2 / name :op2 "p110β")
                        :ARG1-of (m / mutate-01)
                        :xref (x2 / xref :value "UNIPROT"))))
      :card2 (b / bind-01
            :ARG1 (p3 / protein :name (n3 / name :op1 "RAC")
                  :xref (x3 / xref :value "UNIPROT"))
            :ARG2 (p4 / protein :name (n4 / name :op1 "CDC42")
                  :xref (x4 / xref :value "UNIPROT"))))

# ::id PMC_369_0480.90 ::date 2016-07-23T03:30:41
# ::snt Of those, 17 mutations of 14 RBD residues affected binding to both GTPases without affecting p110β protein stability.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_90.txt
(b / bind-01
      :ARG1 (p2 / protein :name (n2 / name :op1 "p110β")
            :xref (x2 / xref :value "UNIPROT"))
      :ARG2 (p / protein :name (n / name :op1 "GTPase")
            :xref (x / xref :value "UNIPROT")))

# ::id PMC_369_0480.92 ::date 2016-07-23T07:18:22
# ::snt Finally, we employed isothermal titration calorimetry (ITC) to study thermodynamics of the RAC1/CDC42-p110β interaction.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_92.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC1"))
            :ARG1 (p3 / protein :name (n3 / name :op1 "p110β")))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n2 / name :op1 "CDC42"))
            :ARG1 (p4 / protein :name (n4 / name :op1 "p110β"))))

# ::id PMC_369_0480.93 ::date 2016-07-23T07:29:54
# ::snt In solution, RAC1⋅GTPγS bound to p110β/Δp85 with a molar ratio close to 1 and an average K d of 1.42 μM, whereas the affinity measured for CDC42⋅GTPγS was 3.1 μM ( Figures 3 E and 3F).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_93.txt
(b / bind-01
      :ARG1 (m / macro-molecular-complex
            :part (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT"))
            :part (m2 / molecular-physical-entity :name (n2 / name :op1 "GTPγS")
                  :xref (x2 / xref :value "PUBCHEM")))
      :ARG2 (m3 / macro-molecular-complex
            :part (p2 / protein :name (n3 / name :op1 "p110β")
                  :xref (x3 / xref :value "UNIPROT"))
            :part (p3 / protein :name (n4 / name :op1 "Δp85")
                  :xref (x4 / xref :value "UNIPROT")))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f / figure :name (n5 / name :op1 "3 E"))
                  :op2 (f2 / figure :name (n6 / name :op1 "3 F")))))

# ::id PMC_369_0480.94 ::date 2016-07-23T07:43:40
# ::snt Similar affinities have been reported for the RAS-p110α and RAS-p110γ interactions ( Pacold et al., 2000 ; Rodriguez-Viciana et al., 1996 ), indicating that RAC1 and CDC42 are plausible RBD interactors of p110β.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_94.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT"))
            :ARG1 (p2 / protein :name (n2 / name :op1 "p110α")
                  :xref (x2 / xref :value "UNIPROT")))
      :card2 (i3 / increase-01
            :ARG0 (p3 / protein :name (n3 / name :op1 "RAS")
                  :xref (x3 / xref :value "UNIPROT"))
            :ARG1 (p4 / protein :name (n4 / name :op1 "p110γ")
                  :xref (x4 / xref :value "UNIPROT")))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (p5 / publication-91
                        :ARG0 (p7 / person :name (n5 / name :op1 "Pacold"))
                        :time (d2 / date-entity :time 2000))
                  :op1 (p6 / publication-91
                        :ARG0 (p8 / person :name (n6 / name :op1 "Rodriguez-Viciana"))
                        :time (d3 / date-entity :time 1996)))))

# ::id PMC_369_0480.95 ::date 2016-07-23T07:46:04
# ::snt No binding was observed between GTPγS-loaded RAC1/CDC42 and p110α or p110β-RBD-DM, respectively ( Figure S3 C).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_95.txt
(m / multi-index-card
      :card1 (b / bind-01 :polarity -
            :ARG1 (m2 / macro-molecular-complex
                  :part (p / protein :name (n / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT"))
                  :part (p2 / protein :name (n2 / name :op1 "CDC42")
                        :xref (x2 / xref :value "UNIPROT")))
            :ARG2 (p3 / protein :name (n3 / name :op1 "p110α")
                  :xref (x3 / xref :value "UNIPROT")))
      :card2 (b2 / bind-01 :polarity -
            :ARG1 (m3 / macro-molecular-complex
                  :part (p4 / protein :name (n4 / name :op1 "RAC1")
                        :xref (x4 / xref :value "UNIPROT"))
                  :part (p5 / protein :name (n5 / name :op1 "CDC42")
                        :xref (x5 / xref :value "UNIPROT")))
            :ARG2 (m4 / macro-molecular-complex
                  :part (p6 / protein :name (n6 / name :op1 "p110β")
                        :xref (x6 / xref :value "UNIPROT"))
                  :part (p7 / protein :name (n7 / name :op1 "RBD-DM")
                        :xref (x7 / xref :value "UNIPROT"))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "S3 C")))

# ::id PMC_369_0480.96 ::date 2016-07-23T08:08:48
# ::snt p110β-RBD-DM Mice Show Signs of Reduced PI3K Activity
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_96.txt
(i2 / increase-01
      :ARG1 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (m / macro-molecular-complex :name (n / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT"))
            :manner (p / phosphorylate-01)))

# ::id PMC_369_0480.98 ::date 2016-07-23T08:12:13
# ::snt Homologous recombination in embryonic stem (ES) cells was employed to replace exon 6 of the murine Pik3cb gene ( Figure S4 A), and germline transmission was achieved by eight-cell embryo injection ( Figures S4 B and S4C).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_98.txt
(t / translocate-01
      :ARG0 (c / cell :name (n / name :op1 "ES"))
      :ARG1 (p / protein-segment :name (n2 / name :op1 "exon 6")
            :part-of (g / gene :name (n3 / name :op1 "murine" :op2 "Pik3" :op3 "cb")
                  :xref (x / xref :value "GO")))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "S4 A")))

# ::id PMC_369_0480.103 ::date 2016-07-23T08:18:40
# ::snt Moreover, p110β-RBD-DM MEFs showed lower steady-state phospho-AKT levels ( Figure 4 F), suggesting that stimulatory signaling to p110β via its RBD contributes to PI3K activity in vivo.
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_103.txt
(m2 / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p2 / protein :name (n2 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT"))
            :ARG1 (a2 / add-modification-00
                  :ARG1 (m3 / macro-molecular-complex :name (n7 / name :op1 "PI3K")
                        :xref (x3 / xref :value "UNIPROT:P85A_HUMAN"))
                  :manner (p6 / phosphorylate-01)))
      :card2 (i4 / increase-01
            :ARG0 (c / cell :name (n3 / name :op1 "MEF")
                  :location-of (p3 / protein :name (n4 / name :op1 "p110β-RBD-DM"))
                  :xref (x2 / xref :value "MEF-1"))
            :ARG1 (a / add-modification-00
                  :ARG1 (e / enzyme :name (n6 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p5 / phosphorylate-01))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "4 F"))))

# ::id PMC_369_0480.104 ::date 2016-07-23T01:10:43
# ::snt Expression levels of p110β, p110α, and p85 were indistinguishable among the genotypes ( Figure S4 D), and the stoichiometry of p110 subunit binding to p85 was undisturbed ( Figure S4 E).
# ::save-date Sun Jul 24, 2016 ::user ipuiulet ::file PMC_369_0480_104.txt
(b / bind-01
      :ARG1 (p3 / protein :name (n / name :op1 (p / p110) :op2 "subunit")
            :xref (x / xref :value "UNIPROT"))
      :ARG2 (p4 / protein :name (n2 / name :op1 (p2 / p85))
            :xref (x2 / xref :value "UNIPROT"))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "S4 E")))

# ::id PMC_369_0480.105 ::date 2016-07-22T23:29:01
# ::snt RAC and CDC42 Regulate p110β In Vivo
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_105.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:RAC_HUMAN"))
            :ARG1 (e / enzyme :name (n2 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "p110β")
                  :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN"))))

# ::id PMC_369_0480.106 ::date 2016-07-22T23:29:16
# ::snt To determine whether RAC and CDC42 are upstream activators of p110β in vivo, we transfected wild-type and p110β-RBD-DM MEFs with small interfering RNA (siRNA) pools (Dharmacon On-target plus) targeting these GTPases ( Figure 4 G).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_106.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (e / enzyme :name (n2 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :mode (h / hypothesis))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "p110β")
                  :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :mode (h2 / hypothesis)))

# ::id PMC_369_0480.107 ::date 2016-07-23T00:44:41
# ::snt Although single knockdowns had only minor effects, combined knockdown of RAC1 and CDC42 significantly lowered phospho-AKT levels in wild-type, but not in p110β-RBD-DM cells, closing the gap in steady-state phospho-AKT levels between the genotypes and suggesting that endogenous RAC1 and CDC42 cooperatively activate p110β via its RBD.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_107.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (a2 / and
                  :op1 (p / protein :name (n / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN")
                        :ARG1-of (a / add-modification-00
                              :manner (k / knock-down-02)))
                  :op2 (p2 / protein :name (n2 / name :op1 "CDC42")
                        :ARG1-of a
                        :xref (x2 / xref :value "UNIPROT:CDC42_HUMAN")))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p9 / protein)
                  :ARG1 (e / enzyme :name (n3 / name :op1 "AKT")
                        :xref (x3 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p3 / phosphorylate-01))
            :location (c / cell
                  :mod (w / wild-type)))
      :card2 (d2 / decrease-01 :polarity -
            :ARG0 (a4 / and
                  :op1 (p4 / protein :name (n4 / name :op1 "RAC1")
                        :xref (x4 / xref :value "UNIPROT:RAC1_HUMAN"))
                  :op2 (p5 / protein :name (n5 / name :op1 "CDC42")
                        :xref (x5 / xref :value "UNIPROT:CDC42_HUMAN")))
            :ARG1 (a5 / add-modification-00
                  :ARG0 (p10 / protein)
                  :ARG1 (e3 / enzyme :name (n10 / name :op1 "AKT")
                        :xref (x9 / xref :value "UNIPROT:AKT1_HUMAN")))
            :location (c2 / cell
                  :mod (m2 / macro-molecular-complex
                        :part (e4 / enzyme :name (n11 / name :op1 "p110β")
                              :xref (x10 / xref :value "UNIPROT:PK3CB_HUMAN")))))
      :card3 (i2 / increase-01
            :ARG0 (a6 / and
                  :op1 (p6 / protein :name (n6 / name :op1 "RAC1")
                        :xref (x6 / xref :value "UNIPROT:RAC1_HUMAN"))
                  :op2 (p7 / protein :name (n7 / name :op1 "CDC42")
                        :xref (x7 / xref :value "UNIPROT:CDC42_HUMAN")))
            :ARG1 (p8 / protein-segment :name (n8 / name :op1 "RBD")
                  :part-of (e2 / enzyme :name (n9 / name :op1 "p110β")
                        :xref (x8 / xref :value "UNIPROT:PK3CB_HUMAN")
                        :ARG0-of (a7 / activity-06)))))

# ::id PMC_369_0480.108 ::date 2016-07-24T08:37:42
# ::snt We next acutely expressed constitutively active mutants of RAC1 and CDC42 in wild-type, p110α-, and p110β-knockout MEFs ( Figures 4 H and S4 F).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_108.txt
(s / smr-empty)

# ::id PMC_369_0480.109 ::date 2016-07-24T08:40:17
# ::snt Both RAC1 and CDC42 increased steady-state phospho-AKT levels in wild-type and p110α-deleted cells but not in p110β-knockout MEFs.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_109.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (e / enzyme :name (n2 / name :op1 "AKT")
                        :xref (x2 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p11 / phosphorylate-01))
            :location (c / cell
                  :mod (w / wild-type)))
      :card2 (i3 / increase-01
            :ARG0 (p3 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (e2 / enzyme :name (n4 / name :op1 "AKT")
                        :xref (x4 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p12 / phosphorylate-01))
            :location (c2 / cell
                  :mod (w2 / wild-type)))
      :card3 (i4 / increase-01 :polarity -
            :ARG0 (p5 / protein :name (n5 / name :op1 "RAC1")
                  :xref (x5 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p6 / protein)
                  :ARG1 (e3 / enzyme :name (n6 / name :op1 "AKT")
                        :xref (x6 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p7 / phosphorylate-01))
            :location (c3 / cell-line :name (n7 / name :op1 "MEF")
                  :xref (x10 / xref :value "RRID:CVCL_4240")))
      :card4 (i5 / increase-01 :polarity -
            :ARG0 (p8 / protein :name (n8 / name :op1 "CDC42")
                  :xref (x7 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (p9 / protein)
                  :ARG1 (e4 / enzyme :name (n9 / name :op1 "AKT")
                        :xref (x8 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p10 / phosphorylate-01))
            :location (c4 / cell-line :name (n10 / name :op1 "MEF")
                  :xref (x9 / xref :value "RRID:CVCL_4240"))))

# ::id PMC_369_0480.110 ::date 2016-07-24T09:29:30
# ::snt Moreover, expression of V12-RAC1 and V12-CDC42 failed to elevate phospho-AKT levels in p110β-RBD-DM MEFs, whereas V12-HRAS did so in both wild-type and p110β-RBD-DM MEFs ( Figure 4 I).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_110.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :ARG1-of (m2 / mutate-01 :value "V12")
                  :xref (x2 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (e / enzyme :name (n2 / name :op1 "AKT")
                        :xref (x7 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p3 / phosphorylate-01))
            :location (c / cell-line :name (n3 / name :op1 "MEF")
                  :xref (x3 / xref :value "RRID:CVCL_M515")))
      :card2 (i3 / increase-01 :polarity -
            :ARG0 (p4 / protein :name (n4 / name :op1 "CDC42")
                  :ARG1-of (m3 / mutate-01 :value "V12")
                  :xref (x11 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (e2 / enzyme :name (n5 / name :op1 "AKT")
                        :xref (x8 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p6 / phosphorylate-01))
            :location (c2 / cell-line :name (n6 / name :op1 "MEF")
                  :xref (x4 / xref :value "RRID:CVCL_M515")))
      :card3 (i4 / increase-01
            :ARG0 (p7 / protein :name (n7 / name :op1 "HRAS")
                  :xref (x / xref :value "UNIPROT:RASH_HUMAN")
                  :ARG1-of (m4 / mutate-01 :value "V12"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p8 / protein)
                  :ARG1 (e3 / enzyme :name (n8 / name :op1 "AKT")
                        :xref (x9 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p9 / phosphorylate-01))
            :location (c3 / cell-line :name (n9 / name :op1 "MEF")
                  :mod (w / wild-type)
                  :xref (x5 / xref :value "RRID:CVCL_L690")))
      :card4 (i5 / increase-01
            :ARG0 (p10 / protein :name (n10 / name :op1 "HRAS")
                  :ARG1-of (m5 / mutate-01 :value "V12"))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (p11 / protein)
                  :ARG1 (e4 / enzyme :name (n11 / name :op1 "AKT")
                        :xref (x10 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p12 / phosphorylate-01))
            :location (c4 / cell-line :name (n12 / name :op1 "MEF")
                  :xref (x6 / xref :value "RRID:CVCL_4240"))))

# ::id PMC_369_0480.111 ::date 2016-07-24T10:28:10
# ::snt Taken together, these findings indicate that RAC1 and CDC42 activate PI3K in living cells by isoform-specific regulation of p110β through its RBD.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_111.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (e / enzyme :name (n2 / name :op1 "PI3K")
                  :xref (x2 / xref :value "UNIPROT:PK3CA_HUMAN"))
            :location (c / cell))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "PI3K")
                  :xref (x4 / xref :value "UNIPROT:PK3CA_HUMAN"))))

# ::id PMC_369_0480.112 ::date 2016-07-24T10:39:34
# ::snt Activation of p110β Downstream of GPCRs Requires an Intact RBD
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_112.txt
(i2 / increase-01
      :ARG0 (p / protein-segment :name (n / name :op1 "RBD")
            :part-of (e / enzyme :name (n2 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN")))
      :ARG1 e)

# ::id PMC_369_0480.113 ::date 2016-07-24T10:47:59
# ::snt To study whether the p110β RBD is required for coupling p110β to GPCRs, we stimulated wild-type and p110β-RBD-DM MEFs with the lipid growth factors and GPCR agonists LPA and S1P.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_113.txt
(i2 / increase-01
      :ARG0 (p / protein-segment :name (n / name :op1 "RBD")
            :part-of (e / enzyme :name (n2 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN")))
      :ARG1 (b / bind-01
            :ARG1 e
            :ARG2 (p2 / potein :name (n3 / name :op1 "GPCR")
                  :xref (x2 / xref :value "UNUPROT:GP160_HUMAN")))
      :mode (h / hypothesis))

# ::id PMC_369_0480.114 ::date 2016-07-24T10:59:09
# ::snt LPA and S1P dose-dependently induced both AKT and ERK phosphorylation in wild-type cells ( Figures 5 A and S5 A).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_114.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (s / small-molecule :name (n / name :op1 "LPA")
                  :xref (x / xref :value "CHEBI:74330"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (e / enzyme :name (n2 / name :op1 "AKT")
                        :xref (x2 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p2 / phosphorylate-01))
            :location (c / cell
                  :mod (w / wild-type)))
      :card2 (i3 / increase-01
            :ARG0 (s2 / small-molecule :name (n3 / name :op1 "LPA")
                  :xref (x3 / xref :value "CHEBI:74330"))
            :ARG1 (a2 / add-modifiction-00
                  :ARG0 (p3 / protein)
                  :ARG1 (e2 / enzyme :name (n4 / name :op1 "ERK")
                        :xref (x4 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p4 / phosphorylate-01))
            :location (c2 / cell
                  :mod (w2 / wild-type)))
      :card3 (i4 / increase-01
            :ARG0 (s3 / small-molecule :name (n5 / name :op1 "S1P")
                  :xref (x5 / xref :value "CHEBI:37550"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (e3 / enzyme :name (n6 / name :op1 "AKT")
                        :xref (x6 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p8 / phosphorylate-01))
            :location (c3 / cell
                  :mod (w3 / wild-type)))
      :card4 (i5 / increase-01
            :ARG0 (s4 / small-molecule :name (n7 / name :op1 "S1P")
                  :xref (x7 / xref :value "CHEBI:37550"))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (p6 / protein)
                  :ARG1 (e4 / enzyme :name (n8 / name :op1 "ERK")
                        :xref (x8 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p7 / phosphorylate-01))
            :location (c4 / cell
                  :mod (w4 / wild-type))))

# ::id PMC_369_0480.115 ::date 2016-07-24T11:23:20
# ::snt These responses were sensitive to pertussis toxin ( Figure S5 B), confirming GPCR involvement.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_115.txt
(s / smr-empty)

# ::id PMC_369_0480.116 ::date 2016-07-24T11:59:09
# ::snt In p110β-RBD-DM MEFs, LPA- and S1P-induced phosphorylation of AKT was strongly diminished, whereas ERK phosphorylation was undisturbed ( Figures 5 A and S5 A).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_116.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG1 (a / add-modification-00
                  :ARG0 (s / small-molecule :name (n / name :op1 "LPA")
                        :xref (x / xref :value "CHEBI:74330"))
                  :ARG1 (e / enzyme :name (n2 / name :op1 "AKT")
                        :xref (x2 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p / phosphorylate-01))
            :location (c / cell-line :name (n5 / name :op1 "MEF")
                  :xref (x5 / xref :value "RRID:CVCL_4240")))
      :card2 (d2 / decrease-01
            :ARG1 (a2 / add-modification-00
                  :ARG0 (s2 / small-molecule :name (n3 / name :op1 "S1P")
                        :xref (x3 / xref :value "CHEBI:37550"))
                  :ARG1 (e2 / enzyme :name (n4 / name :op1 "AKT")
                        :xref (x4 / xref :value "UNIPROT:AKT1_HUMAN")))
            :location (c2 / cell-line :name (n6 / name :op1 "MEF")
                  :xref (x6 / xref :value "RRID:CVCL_4240")))
      :card3 (d3 / decrease-01 :polarity -
            :ARG1 (a3 / add-modification-00
                  :ARG0 (s3 / small-molecule :name (n7 / name :op1 "LPA")
                        :xref (x7 / xref :value "CHEBI:74330"))
                  :ARG1 (e3 / enzyme :name (n8 / name :op1 "ERK")
                        :xref (x8 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p2 / phosphorylate-00))
            :location (c3 / cell-line :name (n9 / name :op1 "MEF")
                  :xref (x9 / xref :value "CHEBI:74330")))
      :card4 (d4 / decrease-01 :polarity -
            :ARG1 (a4 / add-modification-00
                  :ARG0 (s4 / small-molecule :name (n10 / name :op1 "S1P")
                        :xref (x10 / xref :value "CHEBI:37550"))
                  :ARG1 (e4 / enzyme :name (n11 / name :op1 "ERK")
                        :xref (x11 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p3 / phosphorylate-01))
            :location (c4 / cell-line :name (n12 / name :op1 "MEF")
                  :xref (x12 / xref :value "RRID:CVCL_4240"))))

# ::id PMC_369_0480.117 ::date 2016-07-24T12:34:46
# ::snt Also, in time course experiments, AKT phosphorylation was more transient when the p110β RBD was mutated ( Figure 5 B and not shown).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_117.txt
(i2 / increase-01
      :ARG0 (m / mutate-01
            :ARG1 (p / protein-segment :name (n / name :op1 "RBD")
                  :part-of (e / enzyme :name (n2 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))))
      :ARG1 (a / add-modification-00
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "AKT")
                  :xref (x2 / xref :value "UNIPROT:AKT1_HUMAN"))
            :manner (p2 / phosphorylate-01)))

# ::id PMC_369_0480.118 ::date 2016-07-24T12:43:04
# ::snt In contrast, p110β-RBD-DM MEFs responded normally to epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and insulin in dose-response ( Figure S5 C) and time course experiments (data not shown).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_118.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN"))
            :ARG1 (c / cell-line :name (n2 / name :op1 "MEF")
                  :xref (x2 / xref :value "RRID:CVCL_4240")))
      :card2 (i3 / increase-01
            :ARG0 (p2 / protein :name (n3 / name :op1 "PDGF")
                  :xref (x3 / xref :value "UNIPROT:PDGFB_HUMAN"))
            :ARG1 (c2 / cell-line :name (n4 / name :op1 "MEF")
                  :xref (x4 / xref :value "RRID:CVCL_4240")))
      :card3 (i4 / increase-01
            :ARG0 (s / small-molecule :name (n5 / name :op1 "insulin")
                  :xref (x5 / xref :value "CHEBI:5931"))
            :ARG1 (c3 / cell-line :name (n6 / name :op1 "MEF")
                  :xref (x6 / xref :value "RRID:CVCL_4240"))))

# ::id PMC_369_0480.119 ::date 2016-07-24T12:56:41
# ::snt Notably, in p110β-knockout cells, AKT phosphorylation in response to LPA was completely abolished ( Figure 5 C), indicating that the RBD is essential for much but not all p110β activation downstream of GPCRs.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_119.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG1 (a / add-modification-00
                  :ARG0 (s / small-molecule :name (n / name :op1 "LPA")
                        :xref (x / xref :value "CHEBI:74330"))
                  :ARG1 (e / enzyme :name (n2 / name :op1 "AKT")
                        :xref (x2 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p / phosphorylate-01))
            :location (c / cell
                  :part (e2 / enzyme :name (n3 / name :op1 "p110β")
                        :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN"))))
      :card2 (i2 / increase-01
            :ARG0 (p2 / protein-sement :name (n4 / name :op1 "RBD")
                  :part-of (e3 / enzyme :name (n5 / name :op1 "p110β")
                        :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN")))
            :ARG1 (e4 / enzyme :name (n6 / name :op1 "p110β")
                  :xref (x5 / xref :value "UNIPROT:PK3CB_HUMAN")
                  :ARG0-of (a2 / activity-06))))

# ::id PMC_369_0480.120 ::date 2016-07-24T13:14:05
# ::snt Activation of p110β Downstream of GPCRs Requires RAC
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_120.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "RAC")
            :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
      :ARG1 (e / enzyme :name (n2 / name :op1 "p110β")
            :xref (x2 / xref :value "UNIPROT:PK3CA_HUMAN")
            :ARG0-of (a / activity-06)))

# ::id PMC_369_0480.121 ::date 2016-07-24T13:18:14
# ::snt To test whether the identified p110β RBD interactors are required for linking p110β to GPCRs, we knocked down RAC1 and CDC42 in wild-type MEFs.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_121.txt
(i2 / increase-01
      :ARG0 (p / potein-segment :name (n / name :op1 "RBD")
            :part-of (e / enzyme :name (n2 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN")))
      :ARG1 (b / bind-01
            :ARG1 e
            :ARG2 (p2 / protein-family :name (n3 / name :op1 "GPCR")))
      :mode (h / hypothesis))

# ::id PMC_369_0480.122 ::date 2016-07-24T13:30:05
# ::snt Knockdown of RAC1 strongly impacted LPA/S1P-induced AKT phosphorylation, knockdown of CDC42 had only minor effects, and combination knockdown of both RAC1 and CDC42 had little additional effect compared to RAC1 knockdown alone ( Figure 5 D).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_122.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG0 (s / small-molecule :name (n2 / name :op1 "LPA")
                        :xref (x2 / xref :value "CHEBI:74330"))
                  :ARG1 (e / enzyme :name (n3 / name :op1 "AKT")
                        :xref (x3 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p2 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p3 / protein :name (n4 / name :op1 "RAC1")
                  :xref (x4 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (s2 / small-molecule :name (n5 / name :op1 "S1P")
                        :xref (x6 / xref :value "CHEBI:37550"))
                  :ARG1 (e2 / enzyme :name (n6 / name :op1 "AKT")
                        :xref (x5 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p4 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (p5 / protein :name (n7 / name :op1 "CDC42")
                  :xref (x7 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (s3 / small-molecule :name (n8 / name :op1 "LPA")
                        :xref (x8 / xref :value "CHEBI:74330"))
                  :ARG1 (e3 / enzyme :name (n9 / name :op1 "AKT")
                        :xref (x9 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p6 / phosphorylate-01)))
      :card4 (i5 / increase-01
            :ARG0 (p7 / protein :name (n10 / name :op1 "CDC42")
                  :xref (x10 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (s4 / small-molecule :name (n11 / name :op1 "S1P")
                        :xref (x11 / xref :value "CHEBI:37550"))
                  :ARG1 (e4 / enzyme :name (n12 / name :op1 "AKT")
                        :xref (x12 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p8 / phosphorylate-01)))
      :card5 (i6 / increase-01
            :ARG0 (a5 / and
                  :op1 (p9 / protein :name (n13 / name :op1 "RAC1")
                        :xref (x13 / xref :value "UNIPROT:RAC1_HUMAN"))
                  :op2 (p10 / protein :name (n14 / name :op1 "CDC42")
                        :xref (x14 / xref :value "UNIPROT:CDC42_HUMAN")))
            :ARG1 (a6 / add-modification-00
                  :ARG0 (s5 / small-molecule :name (n15 / name :op1 "LPA")
                        :xref (x15 / xref :value "CHEBI:74330"))
                  :ARG1 (e5 / enzyme :name (n16 / name :op1 "AKT")
                        :xref (x16 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p11 / phosphorylate-01)))
      :card6 (i7 / increase-01
            :ARG0 (a7 / and
                  :op1 (p12 / protein :name (n17 / name :op1 "RAC1")
                        :xref (x17 / xref :value "UNIPROT:RAC1_HUMAN"))
                  :op2 (p13 / protein :name (n18 / name :op1 "CDC42")
                        :xref (x18 / xref :value "UNIPROT:CDC42_HUMAN")))
            :ARG1 (a8 / add-modification-00
                  :ARG0 (s6 / small-molecule :name (n19 / name :op1 "S1P")
                        :xref (x19 / xref :value "CHEBI:37550"))
                  :ARG1 (e6 / enzyme :name (n20 / name :op1 "AKT")
                        :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN")))
            :manner (p14 / phosphorylate-01)))

# ::id PMC_369_0480.123 ::date 2016-07-24T14:02:21
# ::snt Deconvolution experiments using single siRNA oligonucleotides confirmed the leading role of RAC1 in this pathway ( Figure S5 D).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_123.txt
(s / smr-empty)

# ::id PMC_369_0480.124 ::date 2016-07-24T14:05:25
# ::snt Neither RAC1 nor CDC42 knockdown affected LPA/S1P-induced phosphorylation of ERK or activation of either pathway induced by tyrosine kinase receptor agonists (EGF, PDGF, and insulin; Figure S5 E).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_124.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG0 (s / small-molecule :name (n2 / name :op1 "LPA")
                        :xref (x2 / xref :value "CHEBI:74330"))
                  :ARG1 (e / enzyme :name (n3 / name :op1 "ERK")
                        :xref (x3 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p2 / phosphorylate-01)))
      :card2 (i3 / increase-01 :polarity -
            :ARG0 (p3 / protein :name (n4 / name :op1 "RAC1")
                  :xref (x4 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (s2 / smal-molecule :name (n5 / name :op1 "S1P")
                        :xref (x5 / xref :value "CHEBI:37550"))
                  :ARG1 (e2 / enzyme :name (n6 / name :op1 "ERK")
                        :xref (x6 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p4 / phosphorylate-01)))
      :card3 (i4 / increase-01 :polarity -
            :ARG0 (p5 / protein :name (n7 / name :op1 "CDC42")
                  :xref (x7 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (s3 / small-molecule :name (n8 / name :op1 "LPA")
                        :xref (x8 / xref :value "CHEBI:74330"))
                  :ARG1 (e3 / enzyme :name (n9 / name :op1 "ERK")
                        :xref (x9 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p6 / phosphorylate-01)))
      :card4 (i5 / increase-01
            :ARG0 (p7 / protein :name (n10 / name :op1 "CDC42")
                  :xref (x10 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (s4 / small-molecule :name (n11 / name :op1 "S1P")
                        :xref (x11 / xref :value "CHEBI:37550"))
                  :ARG1 (e4 / enzyme :name (n12 / name :op1 "ERK")
                        :xref (x12 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p8 / phosphorylate-01)))
      :card5 (i6 / increase-01 :polarity -
            :ARG0 (p9 / protein :name (n13 / name :op1 "RAC1")
                  :xref (x13 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (i7 / increase-01
                  :ARG0 (m2 / molecular-physical-entity)
                  :ARG1 (p10 / pathway)))
      :card6 (i8 / increase-01 :polarity -
            :ARG0 (p11 / protein :name (n14 / name :op1 "CDC42")
                  :xref (x14 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (i9 / increase-01
                  :ARG0 (m3 / molecular-physical-entity)
                  :ARG1 (p12 / pathway))))

# ::id PMC_369_0480.125 ::date 2016-07-24T14:30:09
# ::snt Similarly, EHT1864, a direct inhibitor of RAC but not CDC42 activation, dose-dependently inhibited AKT phosphorylation induced by LPA/S1P ( Figure 5 E), but not EGF, PDGF, or insulin ( Figure S5 F).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_125.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (s / small-molecule :name (n / name :op1 "EHT1864"))
            :ARG1 (a / add-modification-00
                  :ARG0 (s2 / small-molecule :name (n2 / name :op1 "LPA")
                        :xref (x / xref :value "CHEBI:74330"))
                  :ARG1 (e / enzyme :name (n3 / name :op1 "AKT")
                        :xref (x2 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p / phosphorylate-01)))
      :card2 (d2 / decrease-01
            :ARG0 (s4 / small-molecule :name (n5 / name :op1 "EHT1864"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (s3 / small-molecule :name (n4 / name :op1 "S1P")
                        :xref (x3 / xref :value "CHEBI:37550"))
                  :ARG1 (e2 / enzye :name (n6 / name :op1 "AKT")
                        :xref (x4 / xref :value "UNIPROT:AKT1_HUMAN")))
            :manner (p2 / phosphorylate-01))
      :card3 (d3 / decrease-01 :polarity -
            :ARG0 (s5 / small-molecule :name (n7 / name :op1 "EHT1864"))
            :ARG1 (p3 / protein :name (n8 / name :op1 "EGF")
                  :xref (x5 / xref :value "UNIPROT:EGF_HUMAN")))
      :card4 (d4 / decrease-01 :polarity -
            :ARG0 (s6 / small-molecule :name (n9 / name :op1 "EHT1864"))
            :ARG1 (p4 / propetin :name (n10 / name :op1 "PDGF")
                  :xref (x6 / xref :value "UNIPROT:PDGFB_HUMAN")))
      :card5 (d5 / decrease-01 :polarity -
            :ARG0 (s7 / small-molecule :name (n11 / name :op1 "EHT1864"))
            :ARG1 (s8 / small-molecule :name (n12 / name :op1 "insulin")
                  :xref (x7 / xref :value "CHEBI:5931"))))

# ::id PMC_369_0480.126 ::date 2016-07-24T14:53:18
# ::snt Therefore, acute loss or inhibition of RAC phenocopied the signaling defect observed in p110β-RBD-DM MEFs.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_126.txt
(a / add-modification-00
      :ARG0 (d / decrease-01
            :ARG1 (p / protein :name (n / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN")))
      :ARG1 (c / cell-line :name (n2 / name :op1 "MEF")
            :xref (x2 / xref :value "RRID:CVCL_4240")))

# ::id PMC_369_0480.127 ::date 2016-07-24T15:00:41
# ::snt In line with this, RAC was activated very rapidly upon LPA stimulation, reaching its peak activity within 20 s ( Figure 5 F).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_127.txt
(i2 / increase-01
      :ARG0 (s / small-molecule :name (n / name :op1 "LPA")
            :xref (x / xref :value "CHEBI:74330"))
      :ARG1 (p / protein :name (n2 / name :op1 "RAC")
            :xref (x2 / xref :value "UNIPROT:RAC1_HUMAN")))

# ::id PMC_369_0480.128 ::date 2016-07-24T15:08:23
# ::snt Dock180/Elmo1 Activates RAC Downstream of GPCRs and Upstream of p110β
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_128.txt
(i2 / increase-01
      :ARG0 (m2 / macro-molecular-complex
            :part (p2 / protein :name (n2 / name :op1 "Elmo1")
                  :xref (x2 / xref :value "UNIPROT:ELMO1_HUMAN"))
            :part (p / protein :name (n / name :op1 "Dock180")
                  :xref (x / xref :value "UNIPROT:DOCK1_HUMAN")))
      :ARG1 (p3 / protein :name (n3 / name :op1 "RAC")
            :xref (x3 / xref :value "UNIPROT:RAC1_HUMAN")))

# ::id PMC_369_0480.129 ::date 2016-07-24T15:23:03
# ::snt To provide further mechanistic insight into the GPCR-RAC-p110β pathway, we performed a small candidate siRNA screen to identify the guanine nucleotide exchange factor (RAC-GEF) involved.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_129.txt
(s / smr-empty)

# ::id PMC_369_0480.131 ::date 2016-07-24T15:29:52
# ::snt In contrast, knockdown of the Dock family RAC-GEF Dock180 or its adaptor protein Elmo1 interfered with AKT phosphorylation induced by LPA and S1P ( Figure 6 B and S6 B), but not by EGF, PDGF, and insulin ( Figure S6 C).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_131.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "Dock180")
                  :xref (x / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG0 (s / small-molecule :name (n2 / name :op1 "LPA")
                        :xref (x2 / xref :value "CHEBI:74330"))
                  :ARG1 (e / enzyme :name (n3 / name :op1 "AKT")
                        :xref (x3 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p2 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p3 / protein :name (n4 / name :op1 "Dock180")
                  :xref (x4 / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (s2 / small-molecule :name (n5 / name :op1 "S1P")
                        :xref (x5 / xref :value "CHEBI:37550"))
                  :ARG1 (e2 / enzyme :name (n6 / name :op1 "AKT")
                        :xref (x6 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p4 / phosphorylate-01)))
      :card3 (i4 / increase-01
            :ARG0 (p5 / protein :name (n7 / name :op1 "Elmo1")
                  :xref (x7 / xref :value "UNIPROT:ELMO1_HUMAN"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (s3 / small-molecule :name (n8 / name :op1 "LPA")
                        :xref (x8 / xref :value "CHEBI:74330"))
                  :ARG1 (e3 / enzyme :name (n9 / name :op1 "AKT")
                        :xref (x9 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p6 / phosphorylate-01)))
      :card4 (i5 / increase-01
            :ARG0 (p7 / protein :name (n10 / name :op1 "Elmo1")
                  :xref (x10 / xref :value "UNIPROT:ELMO1_HUMAN"))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (s4 / small-molecule :name (n11 / name :op1 "S1P")
                        :xref (x11 / xref :value "CHEBI:37550"))
                  :ARG1 (e4 / enzyme :name (n12 / name :op1 "AKT")
                        :xref (x12 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p8 / phosphorylate-00)))
      :card5 (i6 / increase-01 :polarity -
            :ARG0 (p9 / protein :name (n13 / name :op1 "Dock180")
                  :xref (x13 / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (a5 / add-modification-00
                  :ARG0 (p10 / protein :name (n14 / name :op1 "EGF")
                        :xref (x14 / xref :value "UNIPROT:EGF_HUMAN"))
                  :ARG1 (e5 / enzyme :name (n15 / name :op1 "AKT")
                        :xref (x15 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p11 / phosphorylate-01)))
      :card6 (i7 / increase-01 :polarity -
            :ARG0 (p12 / protein :name (n16 / name :op1 "Dock180")
                  :xref (x16 / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (a6 / add-modification-00
                  :ARG0 (p13 / protein :name (n17 / name :op1 "PDGF")
                        :xref (x17 / xref :value "UNIPROT:PDGFB_HUMAN"))
                  :ARG1 (e6 / enzyme :name (n18 / name :op1 "AKT")
                        :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p14 / phosphorylate-01)))
      :card7 (i8 / increase-01 :polarity -
            :ARG0 (p15 / protein :name (n19 / name :op1 "Dock180")
                  :xref (x19 / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (a7 / add-modification-00
                  :ARG0 (s5 / small-molecule :name (n20 / name :op1 "insulin")
                        :xref (x20 / xref :value "CHEBI:5931"))
                  :ARG1 (e7 / enzyme :name (n21 / name :op1 "AKT")
                        :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p16 / phosphorylate-01)))
      :card8 (i9 / increase-01 :polarity -
            :ARG0 (p17 / protein :name (n22 / name :op1 "Elmo1")
                  :xref (x22 / xref :value "UNIPROT:ELMO1_HUMAN"))
            :ARG1 (a8 / add-modification-00
                  :ARG0 (p18 / protein :name (n23 / name :op1 "EGF")
                        :xref (x23 / xref :value "UNIPROT:EGF_HUMAN"))
                  :ARG1 (e8 / enzyme :name (n24 / name :op1 "AKT")
                        :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner (p19 / phosphorylate-01)))
      :card9 (i10 / increase-01 :polarity -
            :ARG0 (p20 / protein :name (n25 / name :op1 "Elmo1"))
            :ARG1 (a9 / add-modification-00
                  :ARG0 (p21 / protein :name (n26 / name :op1 "PDGF")
                        :xref (x25 / xref :value "UNIPROT:PDGFB_HUMAN"))
                  :ARG1 (e9 / enzyme :name (n27 / name :op1 "AKT")
                        :xref (x26 / xref :value "UNIPROT:AKT1_HUMAN")))
            :manner (p22 / phosphorylate-01))
      :card10 (i11 / increase-01 :polarity -
            :ARG0 (p23 / protein :name (n28 / name :op1 "Elmo1")
                  :xref (x27 / xref :value "UNIPROT:ELMO1_HUMAN"))
            :ARG1 (a10 / add-modification-00
                  :ARG0 (s6 / small-molecule :name (n29 / name :op1 "insulin")
                        :xref (x28 / xref :value "CHEBI:5931"))
                  :ARG1 (e10 / enzyme :name (n30 / name :op1 "AKT")
                        :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN")))
            :manner (p24 / phosphorylate-01)))

# ::id PMC_369_0480.132 ::date 2016-07-24T15:32:00
# ::snt Specificity of results was confirmed in deconvolution experiments using individual siRNA oligonucleotides targeting Dock180 and Elmo1 ( Figures S6 D and S6E).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_132.txt
(s / smr-empty)

# ::id PMC_369_0480.133 ::date 2016-07-24T15:35:22
# ::snt Knockdown of Elmo2 had no effect ( Figure S6 F).
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_133.txt
(s / smr-empty)

# ::id PMC_369_0480.134 ::date 2016-07-24T15:38:53
# ::snt Moreover, knockdown of Dock180 abolished LPA- but not EGF-induced RAC activation ( Figure 6 C), firmly placing Dock180/Elmo1 downstream of the LPA receptor and upstream of RAC and p110β.
# ::save-date Sun Jul 24, 2016 ::user imaftei ::file PMC_369_0480_134.txt
(m / muti-index-card
      :card1 (d / decrease-01
            :ARG0 (p / protein :name (n / name :op1 "Dock180")
                  :xref (x / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (i2 / increase-01
                  :ARG0 (s / small-molecule :name (n4 / name :op1 "LPA")
                        :xref (x4 / xref :value "CHEBI:74330"))
                  :ARG1 (p3 / protein :name (n3 / name :op1 "RAC")
                        :xref (x3 / xref :value "UNIPROT:RAC1_HUMAN"))))
      :card2 (d2 / decrease-01 :polarity -
            :ARG0 (p4 / protein :name (n5 / name :op1 "Dock180")
                  :xref (x5 / xref :value "UNIPROT:DOCK1_HUMAN"))
            :ARG1 (i3 / increase-01
                  :ARG0 (p2 / protein :name (n2 / name :op1 "EGF")
                        :xref (x2 / xref :value "UNIPROT:EGF_HUMAN"))
                  :ARG1 (p5 / protein :name (n6 / name :op1 "RAC")
                        :xref (x6 / xref :value "UNIPROT:RAC1_HUMAN")))))

# ::id PMC_369_0480.244 ::date 2016-07-23T08:47:55
# ::snt Reagents and Antibodies
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_244.txt
(s / smr-empty)

# ::id PMC_369_0480.249 ::date 2016-07-23T08:53:30
# ::snt Plasmids and Cloning
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_249.txt
(s / smr-empty)

# ::id PMC_369_0480.278 ::date 2016-07-23T08:53:58
# ::snt Lipid Kinase Assays
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_278.txt
(s / smr-empty)

# ::id PMC_369_0480.282 ::date 2016-07-23T08:54:56
# ::snt Lipid Extraction and PIP 3 Quantification
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_282.txt
(s / smr-empty)

# ::id PMC_369_0480.294 ::date 2016-07-23T08:55:27
# ::snt Generation of p110β-RBD-DM Mice
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_294.txt
(s / smr-empty)

# ::id PMC_369_0480.308 ::date 2016-07-23T08:58:15
# ::snt Mouse Embryonic Fibroblasts
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_308.txt
(s / smr-empty)

# ::id PMC_369_0480.316 ::date 2016-07-23T08:59:07
# ::snt Cell Culture, Plasmid, and siRNA Transfections
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_316.txt
(s / smr-empty)

# ::id PMC_369_0480.333 ::date 2016-07-23T09:12:49
# ::snt Quantitative Real-Time PCR
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_333.txt
(s / smr-empty)

# ::id PMC_369_0480.337 ::date 2016-07-23T09:13:41
# ::snt Growth Factor and Lysophospholipid Signaling Assays
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_337.txt
(s / smr-empty)

# ::id PMC_369_0480.353 ::date 2016-07-23T09:14:55
# ::snt RAC Activation Assay
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_353.txt
(s / smr-empty)

# ::id PMC_369_0480.364 ::date 2016-07-23T09:15:32
# ::snt Histology and Morphometric Analysis
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_364.txt
(s / smr-empty)

# ::id PMC_369_0480.374 ::date 2016-07-23T09:16:01
# ::snt Article plus Supplemental Information
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_374.txt
(s / smr-empty)

# ::id PMC_369_0480.375 ::date 2016-07-23T09:16:27
# ::snt PI 3-Kinase p110β Is Unable to Interact with RAS
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_375.txt
(b / bind-01 :polarity -
      :ARG1 (e / enzyme :name (n / name :op1 "PI" :op2 "3-Kinase" :op3 "p110β"))
      :ARG2 (e2 / enzyme :name (n2 / name :op1 "RAS")))

# ::id PMC_369_0480.376 ::date 2016-07-23T09:29:37
# ::snt Purified recombinant, GTPγS-loaded HRAS, KRAS, NRAS, and RAB5 were incubated with lysates from COS7 cells expressing FLAG-p110α/p85 or FLAG-p110β/p85, wild-type (WT), or RBD double mutant (DM).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_376.txt
(s / smr-empty)

# ::id PMC_369_0480.377 ::date 2016-07-23T09:50:27
# ::snt Purified recombinant GST-p110α/p85 and GST-p110β/p85 were incubated with lysates from COS7 cells expressing Myc-tagged, constitutively active HRAS, KRAS, NRAS, and RAB5.
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_377.txt
(i2 / increase-01
      :ARG1 (a2 / and
            :op1 (p / protein :mod "p110α/p85" :name (n / name :op1 "GST"))
            :op2 (p5 / protein :mod "p110β/p85" :name (n5 / name :op1 "GST")))
      :ARG2 (p2 / protein :name (n2 / name :op1 "lysate")
            :ARG0-of (a / add-modification-00
                  :manner (p3 / phosphorylate-01
                        :ARG1 (p4 / protein :name (n3 / name :op1 "Myc"))
                        :location (c / cell :name (n4 / name :op1 "COS7"))))))

# ::id PMC_369_0480.378 ::date 2016-07-23T10:18:42
# ::snt Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active mutants of HRAS, KRAS, NRAS, and RAB5, alone or in combination with p110α/p85 or p110β/p85 (n = 3; mean with SD; one-way ANOVA).
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_378.txt
(s / smr-empty)

# ::id PMC_369_0480.379 ::date 2016-07-23T10:26:55
# ::snt Alignment of amino acid sequences of all four type I PI3K RBDs (PIK3CB = p110β, PIK3CD = p110δ, PIK3CA = p110α, PIK3CG = p110γ).
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_379.txt
(s / smr-empty)

# ::id PMC_369_0480.380 ::date 2016-07-23T10:27:29
# ::snt Orange represents RAS-binding residues in p110γ, and arrows represent conserved “RAS-binding” residues.
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_380.txt
(s / smr-empty)

# ::id PMC_369_0480.381 ::date 2016-07-23T10:28:13
# ::snt The two point mutations are shown together with hypothetical interactor residues modeled on the RAS-p110γ interaction.
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_381.txt
(s / smr-empty)

# ::id PMC_369_0480.382 ::date 2016-07-23T10:29:56
# ::snt Lipid kinase assay assessing basal activities of purified recombinant p110β/p85 complexes (n = 3; mean with SEM).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_382.txt
(i2 / increase-01
      :ARG1 (c / complexe :name (n / name :op1 "p110β/p85")
            :ARG1-of (p / pure-02))
      :mode (h / hypothesis))

# ::id PMC_369_0480.383 ::date 2016-07-23T10:49:12
# ::snt A representative lipid kinase assay assessing effect of recombinant Gβγ and a PDGFR-derived phosphotyrosine peptide (pY740) on the activity of purified recombinant p85/p110β-WT and p85/p110β-RBD-DM is shown.
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_383.txt
(s / smr-empty)

# ::id PMC_369_0480.384 ::date 2016-07-23T10:55:10
# ::snt Lipids were extracted and PIP 3 levels measured from COS7 cells expressing wild-type or RBD mutant p110β/p85.
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_384.txt
(i2 / increase-01
      :ARG1 (m / mutant :name (n / name :op1 "RBD")
            :mod (w / wild-type))
      :location (c / cell :name (n2 / name :op1 "COS7")))

# ::id PMC_369_0480.385 ::date 2016-07-23T13:14:02
# ::snt Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr, myristoylated p110β (n = 3; mean with SEM; paired t test).
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_385.txt
(s / smr-empty)

# ::id PMC_369_0480.386 ::date 2016-07-23T13:15:00
# ::snt See also Figure S1 .
# ::save-date Sat Jul 23, 2016 ::user adobreanschi ::file PMC_369_0480_386.txt
(s / smr-empty)

# ::id PMC_369_0480.387 ::date 2016-07-23T13:16:09
# ::snt RAC and CDC42 Directly Bind and Active p110β
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_387.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "RAC"))
            :ARG2 (p / protein :name (n2 / name :op1 "CDC42")))
      :card2 (a / add-modification-00
            :manner (a2 / activate-01
                  :ARG0 (a3 / and
                        :op1 (e2 / enzyme :name (n3 / name :op1 "RAC"))
                        :op2 (p2 / protein :name (n4 / name :op1 "CDC42")))
                  :ARG1 (e3 / enzyme :name (n5 / name :op1 "p110β")))))

# ::id PMC_369_0480.388 ::date 2016-07-24T05:01:01
# ::snt Table summarizes results from GST pull-down assays ( Figures S1 C and S1D) probing 34 murine RAS subfamily GTPases for GTP-dependent binding of type I PI3K isoforms (−, no binding; +, specific binding; ++, strong binding; +++, very strong binding).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_388.txt
(s / smr-empty)

# ::id PMC_369_0480.389 ::date 2016-07-24T05:02:43
# ::snt Constitutively active DIRAS1 or DIRAS2 were coexpressed with FLAG-p110β/p85 in COS7 cells.
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_389.txt
(m / multi-index-card
      :card1 (a / add-modification-00
            :manner (c / coexpress-01
                  :ARG1 (e / enzyme :name (n / name :op1 "DIRAS1"))
                  :ARG2 (p / protein-segment :mod "p110β/p85" :name (n2 / name :op1 "FLAG"))
                  :ARG3 (c2 / cell :name (n3 / name :op1 "COS7"))))
      :card2 (a2 / add-modification-00
            :manner (c3 / coexpress-01
                  :ARG1 (e2 / enzyme :name (n4 / name :op1 "DIRAS2"))
                  :ARG2 (p2 / protein-segment :mod "p110β/p85" :name (n5 / name :op1 "FLAG"))
                  :ARG3 (c4 / cell :name (n6 / name :op1 "COS7")))))

# ::id PMC_369_0480.390 ::date 2016-07-24T05:21:06
# ::snt Shown is a lipid kinase assay assessing the effect of purified recombinant, GTPγS-loaded DIRAS1 on p85/p110β (WT) and p85/p110β-RBD-DM (DM) activity (n = 3; mean with SEM).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_390.txt
(s / smr-empty)

# ::id PMC_369_0480.391 ::date 2016-07-24T05:21:53
# ::snt Color-coded amino acid sequence alignment of the N termini of indicated small GTPases.
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_391.txt
(s / smr-empty)

# ::id PMC_369_0480.392 ::date 2016-07-24T05:27:48
# ::snt A square frame highlights the G2 box sequence, and the variant residue (D33 in RAS) is shown in gray.
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_392.txt
(s / smr-empty)

# ::id PMC_369_0480.393 ::date 2016-07-24T05:28:24
# ::snt Purified recombinant, GDP/GTPγS-loaded RHO GTPases were incubated with purified recombinant p110β/p85 (50 nM).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_393.txt
(s / smr-empty)

# ::id PMC_369_0480.394 ::date 2016-07-24T05:31:02
# ::snt Top: representative experiment; left: quantification (n = 2; mean with SEM); right: 3 [H]-GTP uptake of GTPase preparations (n = 2; mean with SEM).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_394.txt
(s / smr-empty)

# ::id PMC_369_0480.395 ::date 2016-07-24T05:31:43
# ::snt Purified recombinant GDP/GTPγS-loaded RAC1 and CDC42 were incubated with lysates from COS7 cells expressing FLAG-tagged p110α/p85, p110β/p85, p110γ/p101, and p110δ/p85.
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_395.txt
(s / smr-empty)

# ::id PMC_369_0480.396 ::date 2016-07-24T05:35:34
# ::snt Purified recombinant GTPγS-loaded RAC1/CDC42 (1 μM) were added to purified recombinant p110β/p85, and lipid kinase activity was assessed in vitro.
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_396.txt
(s / smr-empty)

# ::id PMC_369_0480.397 ::date 2016-07-24T05:36:37
# ::snt pTyr, phosphotyrosine peptide (pY740, 10 μM); Δp85, truncated p85, schematic in Figure 3 C (n = 2; mean with SD).
# ::save-date Sun Jul 24, 2016 ::user adobreanschi ::file PMC_369_0480_397.txt
(s / smr-empty)

# ::id PMC_369_0480.398 ::date 2016-07-27T11:13:16 ::authors ssirca
# ::snt Increasing concentrations of purified recombinant GTPγS-loaded RAC1/CDC42 were added to purified recombinant p110β/Δp85, and lipid kinase activity was assessed in vitro (n = 3; mean with SEM).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_398.txt
(s / smr-empty)

# ::id PMC_369_0480.399 ::date 2016-07-27T11:57:06 ::authors ssirca
# ::snt Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active RAC1 or CDC42, alone or in combination with FLAG-p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_399.txt
(s / smr-empty)

# ::id PMC_369_0480.400 ::date 2016-07-27T12:35:42 ::authors ssirca
# ::snt Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr, myristoylated p110β (n = 2; mean with SD).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_400.txt
(s / smr-empty)

# ::id PMC_369_0480.401 ::date 2016-07-27T14:17:56 ::authors ssirca
# ::snt Western blots show expression levels of FLAG-p110β and Myc-tagged GTPases.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_401.txt
(s / smr-empty)

# ::id PMC_369_0480.402 ::date 2016-07-27T14:44:51 ::authors ssirca
# ::snt See also Figure S2 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_402.txt
(s / smr-empty)

# ::id PMC_369_0480.403 ::date 2016-07-27T14:54:36 ::authors ssirca
# ::snt RAC and CDC42 Are Interactors of the p110β RAS-Binding Domain
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_403.txt
(b / bind-01
      :ARG0 (p3 / protein-family :name (n3 / name :op1 "RAS")
            :part (p4 / protein :name (n4 / name :op1 "p110β")
                  :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :ARG1 (p / protein :name (n / name :op1 "RAC")
            :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
      :ARG2 (p2 / protein :name (n2 / name :op1 "CDC42")
            :xref (x2 / xref :value "UNIPROT:CDC42_HUMAN")))

# ::id PMC_369_0480.404 ::date 2016-07-27T15:25:44 ::authors ssirca
# ::snt Purified recombinant p85/p110β (WT) and p85/p110β-RBD-DM (DM) protein complexes, at the indicated concentrations, were incubated with GST-tagged, GDP/GTPγS-loaded RAC1 and CDC42.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_404.txt
(s / smr-empty)

# ::id PMC_369_0480.405 ::date 2016-07-27T15:27:05 ::authors ssirca
# ::snt Purified recombinant GTPγS-loaded RAC1/CDC42 (1 μM) were added to purified recombinant p85/p110β-WT or p85/p110β-RBD-DM in lipid kinase assays (n = 2; mean with SD).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_405.txt
(s / smr-empty)

# ::id PMC_369_0480.406 ::date 2016-07-27T15:30:19 ::authors ssirca
# ::snt Data are part of experiment shown in Figure 2 G.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_406.txt
(s / smr-empty)

# ::id PMC_369_0480.407 ::date 2016-07-27T15:31:36 ::authors ssirca
# ::snt Purified recombinant p110β/p85 protein complexes were incubated with GST-tagged, GDP/GTPγS-loaded RAC1, CDC42 and RAB5.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_407.txt
(s / smr-empty)

# ::id PMC_369_0480.408 ::date 2016-07-27T15:32:16 ::authors ssirca
# ::snt Lanes 1/2: p85/p110β-WT; lanes 3/4: Δp85/p110β-WT; lanes 5/6: p85/p110β-RBD-DM.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_408.txt
(s / smr-empty)

# ::id PMC_369_0480.409 ::date 2016-07-27T15:32:56 ::authors ssirca
# ::snt Δp85 is detailed in the schematic.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_409.txt
(s / smr-empty)

# ::id PMC_369_0480.410 ::date 2016-07-27T15:33:56 ::authors ssirca
# ::snt Amino acid alignment of type I PI3K RBDs with secondary structure elements of p110β (H, helix; E, β sheet) and color coding to illustrate effect of residue mutation on p110β binding to RAC1/CDC42.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_410.txt
(t / translocate-01
      :ARG0 (m2 / mutate-01
            :ARG1 (s / small-molecule))
      :ARG1 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "p110β")
                  :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :ARG2 (m / macro-molecular-complex
                  :part (p2 / protein :name (n2 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
                  :part (p3 / protein :name (n3 / name :op1 "CDC42")
                        :xref (x2 / xref :value "UNIPROT:CDC42_HUMAN")))))

# ::id PMC_369_0480.411 ::date 2016-07-27T15:59:27 ::authors ssirca
# ::snt Green, unaltered binding; red, reduced/abolished binding; blue, unstable protein; yellow, p110β-RBD-DM residues; black, not mutated ( Figures S3 A and S3B for pull-down assays and table).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_411.txt
(s / smr-empty)

# ::id PMC_369_0480.412 ::date 2016-07-27T16:00:17 ::authors ssirca
# ::snt Binding of purified recombinant GTPγS-loaded RAC1 and CDC42 to purified recombinant p110β/Δ85 in solution was studied.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_412.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (p / protein :name (n / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG2 (m2 / macro-molecular-complex
                  :part (p2 / protein :name (n2 / name :op1 "p110β")
                        :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :part (p3 / protein :name (n3 / name :op1 "p85")
                        :xref x2)))
      :card2 (b2 / bind-01
            :ARG1 (p4 / protein :name (n4 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG2 (m3 / macro-molecular-complex
                  :part (p5 / protein :name (n5 / name :op1 "p110β")
                        :xref (x4 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :part (p6 / protein :name (n6 / name :op1 "p85")
                        :xref x4))))

# ::id PMC_369_0480.413 ::date 2016-07-27T16:02:31 ::authors ssirca
# ::snt Top: differential power over time; bottom: thermal energy (H) over molar ratio.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_413.txt
(s / smr-empty)

# ::id PMC_369_0480.414 ::date 2016-07-27T16:02:58 ::authors ssirca
# ::snt Numbers represent K d values determined in independent experiments.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_414.txt
(s / smr-empty)

# ::id PMC_369_0480.415 ::date 2016-07-27T16:03:35 ::authors ssirca
# ::snt n.b., no binding.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_415.txt
(s / smr-empty)

# ::id PMC_369_0480.416 ::date 2016-07-27T16:04:02 ::authors ssirca
# ::snt See also Figure S3 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_416.txt
(s / smr-empty)

# ::id PMC_369_0480.417 ::date 2016-07-27T16:04:28 ::authors ssirca
# ::snt RAC/CDC42 Binding to p110β Regulates PI3K Activity In Vivo
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_417.txt
(i2 / increase-01
      :ARG0 (b / bind-01
            :ARG1 (m / macro-molecular-complex
                  :part (p / protein :name (n / name :op1 "RAC")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
                  :part (p2 / protein :name (n2 / name :op1 "CDC42")))
            :ARG2 (p3 / protein :name (n3 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :ARG1 (a / add-modification-00
            :ARG0 (m2 / macro-molecular-complex :name (n4 / name :op1 "PI3K")
                  :xref (x3 / xref :value "UNIPROT:P85A_HUMAN"))
            :manner (p4 / phosphorylate-01)))

# ::id PMC_369_0480.418 ::date 2016-07-27T16:30:54 ::authors ssirca
# ::snt Offspring from HET × HET crosses was genotyped at 2 weeks of age (n = 389; p < 0.02, chi-square analysis).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_418.txt
(s / smr-empty)

# ::id PMC_369_0480.419 ::date 2016-07-27T16:32:24 ::authors ssirca
# ::snt Newborn pups from HET × HET crosses were collected on the morning of birth, weighed, and genotyped (n = 31; mean ±SEM; p = 0.011, t test).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_419.txt
(s / smr-empty)

# ::id PMC_369_0480.420 ::date 2016-07-27T16:33:20 ::authors ssirca
# ::snt Weights of adult homozygous p110β-RBD-DM mice (12–30 weeks old) were compared to same-cage wild-type littermates (n = 39; mean ±SEM; paired t test).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user ssirca ::file PMC_369_0480_420.txt
(s / smr-empty)

# ::id PMC_369_0480.421 ::date 2016-07-27T23:48:37 ::authors ssirca
# ::snt Early passage primary MEFs were grown in culture following a modified 3T3 protocol (n = 2 per genotype).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_421.txt
(s / smr-empty)

# ::id PMC_369_0480.422 ::date 2016-07-28T00:08:34 ::authors ssirca
# ::snt Population doubling rate was calculated as PDR = log ( n ( d a y 3 ) / n ( s e e d e d ) ) / l o g 2 (mean ±SEM; p < 0.001, two-way ANOVA).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_422.txt
(s / smr-empty)

# ::id PMC_369_0480.423 ::date 2016-07-28T00:09:40 ::authors ssirca
# ::snt Cell-cycle profiles of early passage wild-type and homozygous p110β-RBD-DM primary MEFs growing in 1% or 10% FCS (n = 4, means; SEM in the Results section).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_423.txt
(s / smr-empty)

# ::id PMC_369_0480.424 ::date 2016-07-28T00:11:54 ::authors ssirca
# ::snt Wild-type and p110β-RBD-DM MEFs were maintained in cell culture medium supplemented with 0%, 1%, or 10% FCS and harvested for western blot analysis.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_424.txt
(s / smr-empty)

# ::id PMC_369_0480.425 ::date 2016-07-28T00:13:34 ::authors ssirca
# ::snt Wild-type and p110β-RBD-DM MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1, CDC42, or both and harvested for western blot analysis 30 hr after transfection.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_425.txt
(s / smr-empty)

# ::id PMC_369_0480.426 ::date 2016-07-28T00:35:59 ::authors ssirca
# ::snt Graph shows phospho-AKT normalized to total AKT (n = 3; mean with SEM, one-way ANOVA).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_426.txt
(s / smr-empty)

# ::id PMC_369_0480.427 ::date 2016-07-28T00:40:18 ::authors ssirca
# ::snt Myc-V12-RAC1 and Myc-V12-CDC42 were nucleofected into immortalized wild-type, p110α-knockout, and p110β-knockout MEFs, along with a kinase-dead AKT reporter construct.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_427.txt
(s / smr-empty)

# ::id PMC_369_0480.428 ::date 2016-07-28T00:48:01 ::authors ssirca
# ::snt The next day, cells were serum starved and harvested for western blot.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_428.txt
(s / smr-empty)

# ::id PMC_369_0480.429 ::date 2016-07-28T00:48:45 ::authors ssirca
# ::snt Myc-V12-RAC1, Myc-V12-CDC42, or Myc-V12-HRAS were nucleofected into wild-type and p110β-RBD-DM MEFs as described in (H).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_429.txt
(s / smr-empty)

# ::id PMC_369_0480.430 ::date 2016-07-28T00:51:01 ::authors ssirca
# ::snt See also Figure S4 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_430.txt
(s / smr-empty)

# ::id PMC_369_0480.431 ::date 2016-07-28T00:51:32 ::authors ssirca
# ::snt RAC Activates p110β Downstream of GPCRs
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_431.txt
(a / add-modification-00
      :ARG0 (e / enzyme :name (n / name :op1 "RAC")
            :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
      :ARG1 (p / protein :name (n2 / name :op1 "p110β")
            :xref (x2 / xref :value "UNIPROT:PK3CB_HUMAN")))

# ::id PMC_369_0480.432 ::date 2016-07-28T00:54:59 ::authors ssirca
# ::snt Primary wild-type and homozygous p110β-RBD-DM MEFs were serum starved and stimulated with LPA for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_432.txt
(s / smr-empty)

# ::id PMC_369_0480.433 ::date 2016-07-28T00:55:58 ::authors ssirca
# ::snt Primary wild-type and p110β-RBD-DM MEFs were serum starved and stimulated with LPA (10 μM) for indicated time periods.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_433.txt
(s / smr-empty)

# ::id PMC_369_0480.434 ::date 2016-07-28T00:57:42 ::authors ssirca
# ::snt Immortalized wild-type, p110α-knockout, p110β-knockout, and p110β-RBD-DM MEFs were serum starved and stimulated with indicated doses of LPA for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_434.txt
(s / smr-empty)

# ::id PMC_369_0480.435 ::date 2016-07-28T00:58:31 ::authors ssirca
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1, CDC42 or both.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user ssirca ::file PMC_369_0480_435.txt
(s / smr-empty)

# ::id PMC_369_0480.436 ::date 2016-07-27T11:23:07 ::authors nnistor
# ::snt Serum-starved cells were stimulated with LPA (10 μM) or S1P (1 μM) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_436.txt
(s / smr-empty)

# ::id PMC_369_0480.437 ::date 2016-07-27T11:25:35 ::authors nnistor
# ::snt Immortalized wild-type MEFs were serum starved, preincubated with EHT1864 for 30 min, and stimulated with LPA (10 μM) or S1P (1 μM) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_437.txt
(s / smr-empty)

# ::id PMC_369_0480.438 ::date 2016-07-27T11:26:37 ::authors nnistor
# ::snt Serum-starved wild-type and p110β-RBD-DM MEFs were stimulated with LPA (10 μM) for indicated periods of time.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_438.txt
(s / smr-empty)

# ::id PMC_369_0480.439 ::date 2016-07-27T11:27:07 ::authors nnistor
# ::snt RAC⋅GTP and total RAC were measured as described in the Extended Experimental Procedures (n = 3; mean with SEM).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_439.txt
(s / smr-empty)

# ::id PMC_369_0480.440 ::date 2016-07-27T11:27:38 ::authors nnistor
# ::snt See also Figure S5 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_440.txt
(s / smr-empty)

# ::id PMC_369_0480.441 ::date 2016-07-27T11:28:09 ::authors nnistor
# ::snt Dock180/Elmo1 Activate RAC Downstream of GPCRs and Upstream of p110β
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_441.txt
(a / add-modification-00
      :ARG0 (m / macro-molecular-complex
            :part (p2 / protein :name (n / name :op1 "Dock180")
                  :xref (x / xref :value "UNIPROT:DOCK1_HUMAN"))
            :part (p3 / protein :name (n2 / name :op1 "Elmo1")
                  :xref (x2 / xref :value "UNIPROT:ELMO1_HUMAN")))
      :ARG1 (e / enzyme :name (n3 / name :op1 "RAC")
            :xref (x3 / xref :value "UNIPROT:RAC1_HUMAN"))
      :manner (p / phosphorylate-01))

# ::id PMC_369_0480.443 ::date 2016-07-27T11:36:12 ::authors nnistor
# ::snt A total of 48 hr after transfection, serum-starved cells were stimulated with LPA (10 μM) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_443.txt
(s / smr-empty)

# ::id PMC_369_0480.445 ::date 2016-07-27T11:37:08 ::authors nnistor
# ::snt Then 48 hr after transfection, serum-starved cells were stimulated with LPA (10 μM) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_445.txt
(s / smr-empty)

# ::id PMC_369_0480.446 ::date 2016-07-27T11:37:35 ::authors nnistor
# ::snt Immortalized wild-type MEFs, transfected with scrambled duplex or Dock180-specific siRNA pools, were stimulated with LPA (10 μM) or EGF (10 ng/ml) for 20 s and active RAC was quantified (n = 4; mean with SEM; t test; bottom: a representative experiment).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_446.txt
(s / smr-empty)

# ::id PMC_369_0480.447 ::date 2016-07-27T11:38:10 ::authors nnistor
# ::snt Immortalized MEFs were preincubated with PTX (200 ng/ml, 16 hr) or GDC0941 (10 μM, 1 hr) and stimulated with LPA (10 μM) for the indicated time periods (n = 4; mean with SEM; one-way ANOVA; bottom: representative lysates).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_447.txt
(s / smr-empty)

# ::id PMC_369_0480.448 ::date 2016-07-27T11:38:42 ::authors nnistor
# ::snt GST-tagged full-length Elmo1 and fragments as shown (schematic) were incubated with lysates from COS7 cells expressing Gβ 2 and Gγ 1 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_448.txt
(s / smr-empty)

# ::id PMC_369_0480.449 ::date 2016-07-27T11:39:20 ::authors nnistor
# ::snt Bound Gβ was detected by western blot.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user nnistor ::file PMC_369_0480_449.txt
(b / bind-01
      :ARG1 (p / protein-segment :name (n / name :op1 "Gβ"))
      :ARG2 (p2 / protein))

# ::id PMC_369_0480.450 ::date 2016-07-27T11:39:55 ::authors nnistor
# ::snt See text for details.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_450.txt
(s / smr-empty)

# ::id PMC_369_0480.451 ::date 2016-07-27T11:40:21 ::authors nnistor
# ::snt See also Figure S6 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_451.txt
(s / smr-empty)

# ::id PMC_369_0480.453 ::date 2016-07-27T11:40:45 ::authors nnistor
# ::snt Migration of wild-type and p110β-RBD-DM MEFs in gradients of LPA and PDGF was assessed in transwell filter assays (n = 3; mean with SD; one-way ANOVA).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user nnistor ::file PMC_369_0480_453.txt
(m / multi-index-card
      :card1 (t / translocate-01
            :ARG1 (c / cell-line :name (n / name :op1 "MEF")
                  :xref (x / xref :value "Wt MEF:CVCL_L690")
                  :mod (w / wild-type))
            :ARG2 (m2 / molecular-physical-entity :name (n2 / name :op1 "LPA")
                  :xref (x2 / xref :value "PUBCHEM:5497152")))
      :card2 (t2 / translocate-01
            :ARG1 (c2 / cell-line :name (n3 / name :op1 "MEF")
                  :xref (x4 / xref :value "Wt MEF:CVCL_L690")
                  :mod (w2 / wild-type))
            :ARG2 (p / protein :name (n4 / name :op1 "PDGF")
                  :xref (x3 / xref :value "UNIPROT:PGFRB_HUMAN")))
      :card3 (t3 / translocate-01
            :ARG1 (c3 / cell-line :name (n5 / name :op1 "MEF"))
            :ARG2 (m3 / molecular-physical-entity :name (n6 / name :op1 "LPA")
                  :xref (x5 / xref :value "PUBCHEM:5497152")))
      :card4 (t4 / translocate-01
            :ARG1 (c4 / cell-line :name (n7 / name :op1 "MEF"))
            :ARG2 (p2 / protein :name (n8 / name :op1 "PDGF")
                  :xref (x6 / xref :value "UNIPROT:PGFRB_HUMAN"))))

# ::id PMC_369_0480.454 ::date 2016-07-27T12:00:10 ::authors nnistor
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting Dock180, Elmo1, or RAC1.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_454.txt
(s / smr-empty)

# ::id PMC_369_0480.455 ::date 2016-07-27T12:02:34 ::authors nnistor
# ::snt Migration in gradients of LPA and PDGF was assessed in transwell filter assays and cell numbers were normalized to control conditions (n = 4; mean with SEM; one-way ANOVA).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_455.txt
(m / multi-index-card
      :card1 (t / translocate-01
            :ARG2 (m2 / molecular-physical-entity :name (n / name :op1 "LPA")
                  :xref (x / xref :value "PUBCHEM:5497152")))
      :card2 (t2 / translocate-01
            :ARG2 (p / protein :name (n2 / name :op1 "PDGF")
                  :xref (x2 / xref :value "UNIPROT:PGFRB_HUMAN"))))

# ::id PMC_369_0480.456 ::date 2016-07-27T12:14:30 ::authors nnistor
# ::snt Wild-type and homozygous p110β-RBD-DM mice were treated with a single intratracheal dose of bleomycin (1.25 U/kg) and observed for 14 days (n = 16 mice per genotype; Mantel-Cox test).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_456.txt
(s / smr-empty)

# ::id PMC_369_0480.457 ::date 2016-07-27T12:15:05 ::authors nnistor
# ::snt Wild-type and p110β-RBD-DM mice received a single intratracheal dose of saline (n = 3 per genotype) or bleomycin (n = 10 per genotype) and weights were taken 14 days later (mean ±SEM; one-way ANOVA).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_457.txt
(s / smr-empty)

# ::id PMC_369_0480.458 ::date 2016-07-27T12:18:46 ::authors nnistor
# ::snt Representative lung areas from wild-type and homozygous p110β-RBD-DM mice 14 days after treatment with intratracheal bleomycin (×4 magnification).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_458.txt
(s / smr-empty)

# ::id PMC_369_0480.459 ::date 2016-07-27T12:19:20 ::authors nnistor
# ::snt Top: H&E; middle: IHC for α-SMA; bottom: Sirius red.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_459.txt
(s / smr-empty)

# ::id PMC_369_0480.460 ::date 2016-07-27T12:21:17 ::authors nnistor
# ::snt Lungs were analyzed by H&E 14 days after bleomycin challenge.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user nnistor ::file PMC_369_0480_460.txt
(s / smr-empty)

# ::id PMC_369_0480.461 ::date 2016-07-27T12:21:45 ::authors nnistor
# ::snt Multiple nonoverlapping areas of representative sections from each lung were photographed and transparent (white) areas were quantified using Nikon NIS elements software (mean ±SEM; one-way ANOVA; see Figure S7 C for raw data).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_461.txt
(s / smr-empty)

# ::id PMC_369_0480.462 ::date 2016-07-27T12:27:52 ::authors nnistor
# ::snt Lungs were analyzed by immunohistochemistry for smooth muscle antigen (α-SMA) 14 days after bleomycin challenge.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_462.txt
(s / smr-empty)

# ::id PMC_369_0480.463 ::date 2016-07-27T12:28:21 ::authors nnistor
# ::snt Multiple nonoverlapping areas of representative sections from each lung were photographed and SMA-positive (brown) areas were quantified using Nikon NIS elements software (mean ±SEM; one-way ANOVA; see Figure S7 D for raw data).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_463.txt
(s / smr-empty)

# ::id PMC_369_0480.464 ::date 2016-07-27T12:28:57 ::authors nnistor
# ::snt See also Figure S7 .
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_464.txt
(s / smr-empty)

# ::id PMC_369_0480.465 ::date 2016-07-27T12:29:27 ::authors nnistor
# ::snt PI 3-Kinase p110β Is Unable to Interact with RAS, Related to Figure 1
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_369_0480_465.txt
(b / bind-01 :polarity -
      :ARG1 (e / enzyme :name (n2 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:PK3CB_HUMAN")
            :part-of (m / macro-molecular-complex :name (n / name :op1 "PI 3-Kinase")))
      :ARG2 (p3 / protein-family :name (n3 / name :op1 "RAS")))

# ::id PMC_369_0480.466 ::date 2016-07-27T12:33:55 ::authors nnistor
# ::snt Constitutively active mutants of HRAS, KRAS and NRAS were expressed in COS7 cells along with empty vector, p110α/p85 or p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_369_0480_466.txt
(m / multi-index-card
      :card1 (a / add-modification-00
            :ARG1 (e / enzyme :name (n / name :op1 "HRAS")
                  :xref (x / xref :value "UNIPROT:RASH_HUMAN")
                  :ARG2-of (m2 / mutate-01))
            :location (c / cell-line :name (n2 / name :op1 "COS7")
                  :xref (x4 / xref :value "COS7:CVCL_0224"))
            :manner (p / phosphorylate-01))
      :card2 (a2 / add-modification-00
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "KRAS")
                  :xref (x2 / xref :value "UNIPROT:RASK_HUMAN")
                  :ARG2-of (m3 / mutate-01))
            :location (c2 / cell-line :name (n4 / name :op1 "COS7")
                  :xref (x5 / xref :value "COS7:CVCL_0224"))
            :manner (p2 / phosphorylate-01))
      :card3 (a3 / add-modification-00
            :ARG1 (e3 / enzyme :name (n5 / name :op1 "NRAS")
                  :xref (x3 / xref :value "UNIPROT:RASN_HUMAN")
                  :ARG2-of (m4 / mutate-01))
            :location (c3 / cell-line :name (n6 / name :op1 "COS7")
                  :xref (x6 / xref :value "COS7:CVCL_0224"))
            :manner (p3 / phosphorylate-01)))

# ::id PMC_369_0480.468 ::date 2016-07-27T12:36:40 ::authors nnistor
# ::snt Wild-type p110β or p110β-RBD-DM were expressed at low levels in COS7 cells, along with p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user nnistor ::file PMC_369_0480_468.txt
(s / smr-empty)

# ::id PMC_369_0480.470 ::date 2016-07-27T12:37:20 ::authors nnistor
# ::snt Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr, myristoylated p110β.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_470.txt
(s / smr-empty)

# ::id PMC_369_0480.471 ::date 2016-07-27T12:38:17 ::authors nnistor
# ::snt cDNAs encoding all 34 murine members of the RAS subfamily of small GTPases (RFGs) were cloned into pGEX-2T and verified by sequencing.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_471.txt
(s / smr-empty)

# ::id PMC_369_0480.472 ::date 2016-07-27T12:39:34 ::authors nnistor
# ::snt GST-tagged RFGs were expressed in E.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_472.txt
(s / smr-empty)

# ::id PMC_369_0480.473 ::date 2016-07-27T12:40:07 ::authors nnistor
# ::snt coli , purified on glutathione agarose, loaded with GDP/GTPγS in vitro and incubated with lysates from transfected COS7 cells, expressing FLAG-p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_473.txt
(s / smr-empty)

# ::id PMC_369_0480.474 ::date 2016-07-27T12:41:31 ::authors nnistor
# ::snt GST-tagged RFGs were purified from E.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_474.txt
(s / smr-empty)

# ::id PMC_369_0480.475 ::date 2016-07-27T12:43:13 ::authors nnistor
# ::snt coli lysates and loaded with GDP/GTPγS in vitro.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_475.txt
(s / smr-empty)

# ::id PMC_369_0480.476 ::date 2016-07-27T12:43:47 ::authors nnistor
# ::snt FLAG-tagged p110α, p110γ and p110δ were expressed in COS7 cells along with their respective regulatory subunits p85 or p101.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Jul 27, 2016 ::user nnistor ::file PMC_369_0480_476.txt
(s / smr-empty)

# ::id PMC_369_0480.477 ::date 2016-07-27T12:44:22 ::authors nnistor
# ::snt COS7 cell lysates were incubated with GTPases for 1 hr and bound p110 was detected by western blot for FLAG.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user nnistor ::file PMC_369_0480_477.txt
(b / bind-01
      :ARG1 (p / protein :name (n / name :op1 "p110")
            :xref (x / xref :value "UNIPROT:PK3CA_HUMAN"))
      :ARG2 (p2 / protein)
      :location (c / cell-line :name (n2 / name :op1 "COS7")
            :xref (x2 / xref :value "COS7:CVCL_0224")))

# ::id PMC_369_0480.478 ::date 2016-07-27T12:45:20 ::authors nnistor
# ::snt RAC and CDC42 Directly Bind and Active p110β, Related to Figure 2
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_369_0480_478.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG2 (e3 / enzyme :name (n2 / name :op1 "p110β")
                  :xref (x5 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card2 (b2 / bind-01
            :ARG0 (p2 / protein :name (n3 / name :op1 "CDC42")
                  :xref (x3 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (e6 / enzyme :name (n4 / name :op1 "p110β")
                  :xref (x6 / xref :value "UNIPROT:PK3CB_HUMAN")))
      :card3 (a / add-modification-00
            :ARG0 (e2 / enzyme :name (n5 / name :op1 "RAC")
                  :xref (x2 / xref :value "UNIPROT:RAC1_HUMAN"))
            :ARG1 (e5 / enzyme :name (n6 / name :op1 "p110β")
                  :xref (x7 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :manner (p5 / phosphorylate-01))
      :card4 (a2 / add-modification-00
            :ARG0 (p7 / protein :name (n7 / name :op1 "CDC42")
                  :xref (x4 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG1 (e4 / enzyme :name (n8 / name :op1 "p110β")
                  :xref (x8 / xref :value "UNIPROT:PK3CB_HUMAN"))
            :manner (p6 / phosphorylate-01)))

# ::id PMC_369_0480.479 ::date 2016-07-27T12:47:13 ::authors nnistor
# ::snt Left: GST-tagged wild-type and D33I mutant HRAS were expressed in E.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_369_0480_479.txt
(s / smr-empty)

# ::id PMC_369_0480.480 ::date 2016-07-27T12:47:30 ::authors nnistor
# ::snt coli , purified on glutathione agarose beads, loaded with GDP/GTPγS in vitro, and incubated with lysates from transfected COS7 cells expressing FLAG-p110α/p85 or FLAG-p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Jul 28, 2016 ::user nnistor ::file PMC_369_0480_480.txt
(s / smr-empty)

# ::id PMC_369_0480.481 ::date 2016-07-27T12:47:48 ::authors nnistor
# ::snt Right: GST-tagged wild-type and I37D mutant DIRAS1 were probed for binding FLAG-p110α/p85 or FLAG-p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_369_0480_481.txt
(m / multi-index-card
      :card1 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "DIRAS1")
                  :xref (x / xref :value "UNIPROT:DIRA1_HUMAN")
                  :mod (w / wild-type))
            :ARG2 (m2 / macro-molecular-complex
                  :part (e8 / enzyme :name (n2 / name :op1 "p110α")
                        :xref (x6 / xref :value "UNIPROT:PK3CA_HUMAN"))
                  :part (p2 / protein :name (n3 / name :op1 "p85")
                        :xref (x9 / xref :value "UNIPROT:P85A_HUMAN")))
            :mode (h / hypothesis))
      :card2 (b2 / bind-01
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "DIRAS1")
                  :ARG2-of (m3 / mutate-01 :value "I37D")
                  :xref (x2 / xref :value "UNIPROT:DIRA1_HUMAN"))
            :ARG2 (m4 / macro-molecular-complex
                  :part (e7 / enzyme :name (n5 / name :op1 "p110α")
                        :xref (x5 / xref :value "UNIPROT:PK3CA_HUMAN"))
                  :part (p4 / protein :name (n6 / name :op1 "p85")
                        :xref (x10 / xref :value "UNIPROT:P85A_HUMAN")))
            :mode (h2 / hypothesis))
      :card3 (b3 / bind-01
            :ARG1 (e3 / enzyme :name (n7 / name :op1 "DIRAS1")
                  :xref (x3 / xref :value "UNIPROT:DIRA1_HUMAN")
                  :mod (w2 / wild-type))
            :ARG2 (m5 / macro-molecular-complex
                  :part (e6 / enzyme :name (n8 / name :op1 "p110β")
                        :xref (x7 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :part (p6 / protein :name (n9 / name :op1 "p85")
                        :xref (x11 / xref :value "UNIPROT:P85A_HUMAN")))
            :mode (h3 / hypothesis))
      :card4 (b4 / bind-01
            :ARG1 (e4 / enzyme :name (n10 / name :op1 "DIRAS1")
                  :ARG2-of (m6 / mutate-01 :value "I37D")
                  :xref (x4 / xref :value "UNIPROT:DIRA1_HUMAN"))
            :ARG2 (m7 / macro-molecular-complex
                  :part (e5 / enzyme :name (n11 / name :op1 "p110β")
                        :xref (x8 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :part (p8 / protein :name (n12 / name :op1 "p85")
                        :xref (x12 / xref :value "UNIPROT:P85A_HUMAN")))
            :mode (h4 / hypothesis)))

# ::id PMC_369_0480.482 ::date 2016-07-27T12:48:11 ::authors nnistor
# ::snt Bound p110 was identified by western blot for FLAG.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_369_0480_482.txt
(s / smr-empty)

# ::id PMC_369_0480.483 ::date 2016-07-30T14:01:01 ::authors amoldovan
# ::snt GST pulldown assay assessing binding of purified recombinant p110β/p85 complexes to immobilized, GDP-/GTPγS-loaded DIRAS1.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user amoldovan ::file PMC_369_0480_483.txt
(m2 / multi-index-card
      :card1 (b / bind-01
            :ARG1 (m / macro-molecular-complex
                  :part (e / enzyme :name (n / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :part (p2 / protein :name (n2 / name :op1 "p85")
                        :xref (x2 / xref :value "UNIPROT:P85A_HUMAN")))
            :ARG2 (p3 / protein :name (n3 / name :op1 "DIRAS1")
                  :xref (x3 / xref :value "UNIPROT:DIRA1_HUMAN")
                  :ARG2-of (b2 / bind-01
                        :ARG1 (s / small-molecule :name (n4 / name :op1 "GDP")
                              :xref (x4 / xref :value "PUBCHEM:8977")))))
      :card2 (b3 / bind-01
            :ARG1 (m3 / macro-molecular-complex
                  :part (e2 / enzyme :name (n5 / name :op1 "p110β")
                        :xref (x6 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :part (p5 / protein :name (n6 / name :op1 "p85")
                        :xref (x7 / xref :value "UNIPROT:P85A_HUMAN")))
            :ARG2 (p6 / protein :name (n7 / name :op1 "DIRAS1")
                  :xref (x5 / xref :value "UNIPROT:DIRA1_HUMAN")
                  :ARG2-of (b4 / bind-01
                        :ARG1 (s2 / small-molecule :name (n8 / name :op1 "GTPγS")
                              :xref (x8 / xref :value "PUBCHEM:1764"))))))

# ::id PMC_369_0480.484 ::date 2016-07-30T14:54:10 ::authors amoldovan
# ::snt Lanes 1/2: p85/p110β wild-type; Lanes 3/4: Δp85/p110β wild-type; Lanes 5/6: p85/p110β-RBD-DM.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_484.txt
(s / smr-empty)

# ::id PMC_369_0480.485 ::date 2016-07-30T14:57:05 ::authors amoldovan
# ::snt Δp85 is depicted in Figure 3 C.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_485.txt
(s / smr-empty)

# ::id PMC_369_0480.486 ::date 2016-07-30T14:57:34 ::authors amoldovan
# ::snt Color-coded amino acid sequence alignment of the G2 boxes of indicated RHO GTPases, frame highlights RAC1-I33 residue.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_486.txt
(s / smr-empty)

# ::id PMC_369_0480.487 ::date 2016-07-30T14:59:51 ::authors amoldovan
# ::snt Purified recombinant, GST-tagged and GDP/GTPγS-loaded RHO subfamily GTPases were incubated with lysates from COS7 cells expressing FLAG-p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_487.txt
(s / smr-empty)

# ::id PMC_369_0480.488 ::date 2016-07-30T15:00:38 ::authors amoldovan
# ::snt Purified recombinant wild-type RAC1 and a RAC1-I33D mutant were compared for GTP-dependent binding to purified recombinant p110β/p85 (50 nM).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_488.txt
(s / smr-empty)

# ::id PMC_369_0480.489 ::date 2016-07-30T15:01:20 ::authors amoldovan
# ::snt Representative experiment and quantification of two independent experiments are shown (mean and SEM).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_489.txt
(s / smr-empty)

# ::id PMC_369_0480.490 ::date 2016-07-30T15:02:10 ::authors amoldovan
# ::snt 11 selected RHO family GTPases were expressed in E.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_490.txt
(s / smr-empty)

# ::id PMC_369_0480.491 ::date 2016-07-30T15:03:45 ::authors amoldovan
# ::snt coli , purified on glutathione agarose beads and loaded with GDP/GTPγS in vitro.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_491.txt
(s / smr-empty)

# ::id PMC_369_0480.492 ::date 2016-07-30T15:04:18 ::authors amoldovan
# ::snt HRAS was included as positive control.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_492.txt
(s / smr-empty)

# ::id PMC_369_0480.493 ::date 2016-07-30T15:05:11 ::authors amoldovan
# ::snt Pulldown was made from a lysate of transfected COS7 cells expressing FLAG-p110α/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_493.txt
(s / smr-empty)

# ::id PMC_369_0480.494 ::date 2016-07-30T15:05:48 ::authors amoldovan
# ::snt Constitutively active mutants of RAC1 and CDC42 (Myc-tagged) were expressed in COS7 cells along with empty vector, FLAG-p110β/p85 or FLAG-p110β-RBD-DM/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_494.txt
(s / smr-empty)

# ::id PMC_369_0480.495 ::date 2016-07-31T20:13:49 ::authors amoldovan
# ::snt Constitutively active mutants of RAC1, CDC42 and RHOA (Myc-tagged) were expressed in COS7 cells along with empty vector or FLAG-p110β/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_495.txt
(s / smr-empty)

# ::id PMC_369_0480.497 ::date 2016-07-30T15:07:56 ::authors amoldovan
# ::snt Representative lipid kinase assay assessing the effect of increasing concentrations of purified recombinant GTPγS-loaded RAC1 and CDC42 on the activity of purified recombinant p110α/p85 protein complexes.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_497.txt
(s / smr-empty)

# ::id PMC_369_0480.498 ::date 2016-07-30T15:08:23 ::authors amoldovan
# ::snt Constitutively active mutants of RAC1 and CDC42 (Myc-tagged) were expressed in COS7 cells along with empty vector, FLAG-tagged p110α/p85, p110γ/p101 or p110δ/p85.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_498.txt
(s / smr-empty)

# ::id PMC_369_0480.500 ::date 2016-07-31T20:15:36 ::authors amoldovan
# ::snt RAC and CDC42 Are Interactors of the p110β RAS-Binding Domain, Related to Figure 3
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user amoldovan ::file PMC_369_0480_500.txt
(m / multi-index-card
      :card1 (b3 / bind-01
            :ARG1 (p / protein-family :name (n / name :op1 "RAC"))
            :ARG2 (p3 / protein-segment
                  :part-of (e / enzyme :name (n3 / name :op1 "p110β")
                        :xref (x3 / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :ARG2-of (b / bind-01
                        :ARG1 (p5 / protein-family :name (n4 / name :op1 "RAS")))))
      :card2 (b4 / bind-01
            :ARG1 (p2 / protein :name (n2 / name :op1 "CDC42")
                  :xref (x2 / xref :value "UNIPROT:CDC42_HUMAN"))
            :ARG2 (p6 / protein-segment
                  :part-of (e2 / enzyme :name (n5 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
                  :ARG2-of (b2 / bind-01
                        :ARG1 (p8 / protein-family :name (n6 / name :op1 "RAS"))))))

# ::id PMC_369_0480.501 ::date 2016-07-31T20:32:44 ::authors amoldovan
# ::snt 43 single point mutations of 37 RBD residues were introduced by site-directed mutagenesis.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user amoldovan ::file PMC_369_0480_501.txt
(s / smr-empty)

# ::id PMC_369_0480.502 ::date 2016-07-31T20:38:27 ::authors amoldovan
# ::snt Mutants were expressed in COS7 cells, along with p85, and lysates were incubated with GST-tagged, GTPγS-loaded RAC1 and CDC42.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_502.txt
(s / smr-empty)

# ::id PMC_369_0480.503 ::date 2016-07-30T15:09:40 ::authors amoldovan
# ::snt Bound p110β was detected by western blot for FLAG.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_503.txt
(s / smr-empty)

# ::id PMC_369_0480.504 ::date 2016-07-30T15:10:08 ::authors amoldovan
# ::snt Mutants with reduced protein expression levels were deemed unstable and excluded from experiments.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_504.txt
(s / smr-empty)

# ::id PMC_369_0480.505 ::date 2016-07-30T15:10:48 ::authors amoldovan
# ::snt Point mutations made are listed along with their impact on binding to RAC1 and CDC42 (+, no effect on binding; (+), reduced binding; −, complete or near complete loss of binding; unst., unstable protein).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_505.txt
(s / smr-empty)

# ::id PMC_369_0480.506 ::date 2016-07-30T15:11:44 ::authors amoldovan
# ::snt Top: the differential power recorded directly over time; bottom: thermal energy (H) over molar ratio.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_506.txt
(s / smr-empty)

# ::id PMC_369_0480.507 ::date 2016-07-30T15:12:29 ::authors amoldovan
# ::snt RAC/CDC42 Binding to p110β Regulates PI3K Activity In Vivo, Related to Figure 4
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user amoldovan ::file PMC_369_0480_507.txt
(i2 / increase-01
      :ARG0 (b / bind-01
            :ARG1 (m / macro-molecular-complex
                  :part (p / protein-family :name (n / name :op1 "RAC"))
                  :part (p2 / protein :name (n2 / name :op1 "CDC42")
                        :xref (x / xref :value "UNIPROT:CDC42_HUMAN")))
            :ARG2 (e / enzyme :name (n3 / name :op1 "p110β")
                  :xref (x2 / xref :value "UNIRPOT:PK3CB_HUMAN")))
      :ARG1 (a / add-modification-00
            :ARG0 (p6 / protein)
            :ARG1 (m2 / macro-molecular-complex :name (n4 / name :op1 "PI3K"))
            :manner (p4 / phosphorylate-01)))

# ::id PMC_369_0480.508 ::date 2016-07-30T15:13:28 ::authors amoldovan
# ::snt An FRT-flanked neomycin selection cassette was inserted into murine genomic DNA provided by a BAC clone, immediately downstream of Pik3cb exon 6, using Red/ET recombination technology (Genebridges).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_508.txt
(s / smr-empty)

# ::id PMC_369_0480.509 ::date 2016-07-30T15:13:55 ::authors amoldovan
# ::snt Selection cassette and flanking arms of genomic DNA were sub-cloned and mutations (★) introduced by site-directed mutagenesis.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_509.txt
(s / smr-empty)

# ::id PMC_369_0480.510 ::date 2016-07-30T15:14:25 ::authors amoldovan
# ::snt Arrows indicate priming sites for ES cell screening and genotyping.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_510.txt
(s / smr-empty)

# ::id PMC_369_0480.511 ::date 2016-07-30T15:15:01 ::authors amoldovan
# ::snt The neomycin selection cassette was later removed by crosses of heterozygous p110β-RBD-DM mice with FLPe mice.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_511.txt
(s / smr-empty)

# ::id PMC_369_0480.512 ::date 2016-07-30T15:16:19 ::authors amoldovan
# ::snt Homologous recombination in ES cells was confirmed by long genomic PCR bridging the entire targeting region (top, targeted allele 10kb, wild-type allele 8.5kb).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_512.txt
(s / smr-empty)

# ::id PMC_369_0480.513 ::date 2016-07-30T15:22:37 ::authors amoldovan
# ::snt After FLP recombination, MEFs (middle) and mice (bottom) were genotyped using primer pairs flanking the remaining FRT adjacent to exon 6.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_513.txt
(s / smr-empty)

# ::id PMC_369_0480.514 ::date 2016-07-30T15:24:00 ::authors amoldovan
# ::snt Genomic DNA from heterozygous and homozygous p110β-RBD-DM mice was isolated and exon 6 was PCR amplified and sequenced using standard techniques.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_514.txt
(s / smr-empty)

# ::id PMC_369_0480.515 ::date 2016-07-30T15:25:27 ::authors amoldovan
# ::snt Wild-type and homozygous p110β-RBD-DM MEFs were maintained in 0%, 1% and 10% FCS, respectively.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_515.txt
(s / smr-empty)

# ::id PMC_369_0480.516 ::date 2016-07-30T15:26:46 ::authors amoldovan
# ::snt Lysates were made for western blot analysis.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_516.txt
(s / smr-empty)

# ::id PMC_369_0480.518 ::date 2016-07-30T15:27:40 ::authors amoldovan
# ::snt The coprecipitation of p110α and p110β along with p85 was assessed by western blot.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_518.txt
(s / smr-empty)

# ::id PMC_369_0480.519 ::date 2016-07-30T15:28:58 ::authors amoldovan
# ::snt Immortalized p110α lox/lox ;CreER +/− and p110β lox/lox ;CreER +/− MEFs were treated with 4-hydroxytamoxifen (1 μM) for 3 consecutive days, prior to use in experiments.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_519.txt
(s / smr-empty)

# ::id PMC_369_0480.520 ::date 2016-07-30T15:29:35 ::authors amoldovan
# ::snt RAC Activates p110β Downstream of G Protein-Coupled Receptors, Related to Figure 5
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Tue Aug 2, 2016 ::user amoldovan ::file PMC_369_0480_520.txt
(a / add-modification-00
      :ARG0 (p2 / protein-family :name (n / name :op1 "RAC"))
      :ARG1 (e / enzyme :name (n2 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:PK3CB_HUMAN"))
      :manner (p / phosphorylate-01))

# ::id PMC_369_0480.521 ::date 2016-07-30T15:30:52 ::authors amoldovan
# ::snt Primary wild-type and homozygous p110β-RBD-DM MEFs were serum-starved and stimulated with sphingosine 1-phosphate (S1P) at indicated doses.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_521.txt
(s / smr-empty)

# ::id PMC_369_0480.523 ::date 2016-07-30T15:31:46 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were serum starved overnight and stimulated with EGF, LPA or S1P for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_523.txt
(s / smr-empty)

# ::id PMC_369_0480.524 ::date 2016-07-30T15:32:18 ::authors amoldovan
# ::snt Pertussis toxin (PTX, 200 ng/ml) was added 16 prior to stimulation where indicated.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_524.txt
(s / smr-empty)

# ::id PMC_369_0480.525 ::date 2016-07-30T15:32:47 ::authors amoldovan
# ::snt Primary wild-type and p110β-RBD-DM MEFs were serum-starved and stimulated with EGF, PDGF or insulin at indicated doses.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_525.txt
(s / smr-empty)

# ::id PMC_369_0480.527 ::date 2016-07-31T21:15:46 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific individual siRNA oligonucleotides targeting RAC1 or CDC42.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_527.txt
(s / smr-empty)

# ::id PMC_369_0480.528 ::date 2016-07-30T15:40:45 ::authors amoldovan
# ::snt 48 hr after transfection, serum-starved cells were stimulated with LPA (10 μM) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_528.txt
(s / smr-empty)

# ::id PMC_369_0480.529 ::date 2016-07-30T15:47:14 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1 or CDC42.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_529.txt
(s / smr-empty)

# ::id PMC_369_0480.530 ::date 2016-07-31T21:17:52 ::authors amoldovan
# ::snt Serum-starved cells were stimulated with EGF (10 ng/ml), PDGF (10 ng/ml) or insulin (5 μg/ml) for 5 min, before they were harvested for western blot.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_530.txt
(s / smr-empty)

# ::id PMC_369_0480.531 ::date 2016-07-31T21:18:24 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were serum-starved and incubated with EHT1864 at the indicated doses for 30 min, before they were stimulated with EGF (10 ng/ml), PDGF (10 ng/ml) or insulin (5 μg/ml) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_531.txt
(s / smr-empty)

# ::id PMC_369_0480.532 ::date 2016-07-31T21:18:58 ::authors amoldovan
# ::snt Dock180/Elmo1 Activate RAC Downstream of GPCRs and Upstream of p110β, Related to Figure 6
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_532.txt
(a / add-modification-00
      :ARG0 (m / macro-molecular-complex
            :part (p2 / protein :name (n / name :op1 "Dock180")
                  :xref (x / xref :value "UNIRPOT:DOCK1_HUMAN"))
            :part (p3 / protein :name (n2 / name :op1 "Elmo1")
                  :xref (x2 / xref :value "UNIPROT:ELMO1_HUMAN")))
      :ARG1 (p4 / protein-family :name (n3 / name :op1 "RAC"))
      :manner (p / phosphorylate-01))

# ::id PMC_369_0480.537 ::date 2016-07-31T21:22:44 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or siRNA pools targeting Dock180 or Elmo1.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_537.txt
(s / smr-empty)

# ::id PMC_369_0480.538 ::date 2016-07-31T21:23:32 ::authors amoldovan
# ::snt Cells were serum starved and stimulated with EGF (10 ng/ml), PDGF (10 ng/ml) or insulin (5 μg/ml) for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_538.txt
(s / smr-empty)

# ::id PMC_369_0480.539 ::date 2016-07-31T21:24:02 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific individual siRNA oligonucleotides targeting Dock180.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_539.txt
(s / smr-empty)

# ::id PMC_369_0480.541 ::date 2016-07-31T21:24:33 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific single siRNA oligonucleotides targeting Elmo1.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_541.txt
(s / smr-empty)

# ::id PMC_369_0480.543 ::date 2016-07-30T15:34:13 ::authors amoldovan
# ::snt RNA was extracted in parallel experiments and Elmo1 mRNA levels were compared by qPCR (mean with SEM).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_543.txt
(s / smr-empty)

# ::id PMC_369_0480.544 ::date 2016-07-30T15:35:20 ::authors amoldovan
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting Elmo1 or Elmo2, and serum-starved cells were stimulated with LPA for 5 min.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_544.txt
(s / smr-empty)

# ::id PMC_369_0480.545 ::date 2016-07-30T15:36:23 ::authors amoldovan
# ::snt Elmo1/Elmo2 mRNA levels were assessed by qPCR (mean with SEM).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sat Jul 30, 2016 ::user amoldovan ::file PMC_369_0480_545.txt
(s / smr-empty)

# ::id PMC_369_0480.547 ::date 2016-07-30T15:37:37 ::authors amoldovan
# ::snt p110β-RBD-DM Mice Are Protected from Bleomycin-Induced Lung Fibrosis, Related to Figure 7
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Sun Jul 31, 2016 ::user amoldovan ::file PMC_369_0480_547.txt
(s / smr-empty)

# ::id PMC_434_5513.0 ::date 2016-08-01T10:32:32
# ::snt Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_0.txt
(i2 / increase-01
      :ARG0 (e / enzyme :name (n / name :op1 "MAP" :op2 "kinase" :op3 "phosphatase" :op4 "3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN"))
      :ARG1 (d / decrease-01
            :ARG0 (e2 / enzyme :name (n2 / name :op1 "Ras")
                  :ARG1-of (a / add-modification-00
                        :manner (p / phosphorylate-01)))
            :ARG1 (e3 / enzyme :name (n3 / name :op1 "Erk" :op2 "MAP" :op3 "kinase")
                  :xref (x2 / xref :value "UNIPROT:MK01_HUMAN")))
      :location (c / cell-line :name (n4 / name :op1 "NIH3T3")
            :xref (x3 / xref :value "NIH3T3:CVCL_0594")))

# ::id PMC_434_5513.2 ::date 2016-08-01T10:42:18
# ::snt The Ras/Raf/MEK/Erk signaling pathway is important for regulation of cell growth, proliferation, differentiation, survival, and apoptosis in response to a variety of extracellular stimuli.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_2.txt
(s / smr-empty)

# ::id PMC_434_5513.3 ::date 2016-08-01T10:43:07
# ::snt Lack of Erk MAPK activation is observed in several cancer cells despite active activation of Ras.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_3.txt
(a / add-modification-00 :polarity -
      :ARG0 (a2 / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
            :manner p)
      :ARG1 (a3 / add-modification-00
            :ARG0 (p3 / protein)
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk" :op2 "MAPK")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN"))
            :manner p)
      :manner (p / phosphorylate-01)
      :location (c / cell))

# ::id PMC_434_5513.4 ::date 2016-08-01T10:46:28
# ::snt However, little is known about the modulation of Erk1/2 activity by active Ras.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_4.txt
(i2 / increase-01
      :ARG0 (e / enzyme :name (n / name :op1 "Ras")
            :ARG1-of (a / add-modification-00
                  :manner (p / phosphorylate-01)))
      :ARG1 (a2 / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk1/2")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN"))))

# ::id PMC_434_5513.5 ::date 2016-08-01T10:48:26
# ::snt Here, we show that overexpression of active H-Ras (H-RasG12R) in NIH3T3 fibroblasts impaired FGF2-induced Erk1/2 phosphorylation, as compared to wild-type cells.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_5.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (e / enzyme :name (n / name :op1 "H-Ras")
                  :xref (x / xref :value "UNIPROT:RASH_HUMAN")
                  :ARG1-of (a / add-modification-00
                        :manner (p / phosphorylate-01)))
            :ARG1 (i2 / increase-01
                  :ARG0 (p2 / protein :name (n3 / name :op1 "FGF2")
                        :xref (x3 / xref :value "UNIPROT:FGF2_HUMAN"))
                  :ARG1 (a2 / add-modification-00
                        :ARG0 (p3 / protein)
                        :ARG1 (e2 / enzyme :name (n4 / name :op1 "Erk1/2")
                              :xref (x4 / xref :value "UNIPROT:MK01_HUMAN"))
                        :manner p))
            :location (c / cell-line :name (n2 / name :op1 "NIH3T3")
                  :xref (x2 / xref :value "NIH3T3:CVCL_0594")))
      :card2 (d2 / decrease-01 :polarity -
            :ARG0 (e3 / enzyme :name (n5 / name :op1 "H-Ras")
                  :xref (x5 / xref :value "UNIPROT:RASH_HUMAN")
                  :ARG1-of (a4 / add-modification-00
                        :manner (p5 / phosphorylate-01)))
            :ARG1 (i3 / increase-01
                  :ARG0 (p4 / protein :name (n6 / name :op1 "FGF2")
                        :xref (x6 / xref :value "UNIPROT:FGF2_HUMAN"))
                  :ARG1 (a3 / add-modification-00
                        :ARG0 (p6 / protein)
                        :ARG1 (e4 / enzyme :name (n7 / name :op1 "Erk1/2")
                              :xref (x7 / xref :value "UNIPROT:MK01_HUMAN"))
                        :manner p5))
            :location (c2 / cell
                  :mod (w / wild-type))))

# ::id PMC_434_5513.6 ::date 2016-08-01T11:00:47
# ::snt Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 (MKP3) mRNA expression, a negative regulator of Erk MAPK.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_6.txt
(i2 / increase-01
      :ARG0 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
            :manner (p2 / phosphorylate-01))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "MAP" :op2 "kinase" :op3 "phosphatase" :op4 "3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN")
            :ARG0-of (d / decrease-01
                  :ARG1 (e3 / enzyme :name (n3 / name :op1 "Erk" :op2 "MAPK")
                        :xref (x2 / xref :value "UNIPROT:MK01_HUMAN")))))

# ::id PMC_434_5513.7 ::date 2016-08-01T11:03:11
# ::snt Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway abrogated active Ras-induced up-regulation of MKP3 expression, leading to the rescue of Erk1/2 phosphorylation.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_7.txt
(d / decrease-01
      :ARG0 (p / pathway :name (n / name :op1 "PI3K/Akt"))
      :ARG1 (i2 / increase-01
            :ARG0 (e / enzyme :name (n2 / name :op1 "Ras")
                  :ARG1-of (a / add-modification-00
                        :manner (p2 / phosphorylate-01)))
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "MKP3")
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN"))))

# ::id PMC_434_5513.8 ::date 2016-08-01T11:09:27
# ::snt Our results demonstrated that the Ras/Raf/MEK/Erk signaling cascade is negatively regulated by the PI3K/Aktdependent transcriptional activation of the MKP3 gene.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_8.txt
(d / decrease-01
      :ARG0 (i2 / increase-01
            :ARG0 (m / macro-molecular-complex
                  :part (e / enzyme :name (n / name :op1 "PI3K")
                        :xref (x2 / xref :value "UNIPROT:P85A_HUMAN"))
                  :part (e2 / enzyme :name (n2 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN")))
            :ARG1 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (g / gene :name (n3 / name :op1 "MKP3")
                        :xref (x3 / xref :value "HGNC:17007"))
                  :manner (p2 / phosphorylate-01)))
      :ARG1 (p3 / pathway :name (n4 / name :op1 "Ras/Raf/MEK/Erk")))

# ::id PMC_434_5513.26 ::date 2016-08-01T11:19:25
# ::snt We previously described a NIH3T3 cell line (NIH3T3tet-on/HRasG12R), in which the expression of active Ras (H-RasG12R) can be induced by addition of doxycycline (20) .
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_26.txt
(i2 / increase-01
      :ARG0 (s / small-molecule :name (n / name :op1 "doxycycline")
            :xref (x / xref :value "PUBCHEM:54671203"))
      :ARG1 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (e / enzyme :name (n2 / name :op1 "H-Ras")
                  :xref (x2 / xref :value "UNIPROT:RASH_HUMAN")
                  :ARG2-of (m / mutate-01 :value "G12R"))
            :manner (p2 / phosphorylate-01))
      :location (c / cell-line :name (n3 / name :op1 "NIH3T3")
            :xref (x3 / xref :value "NIH3T3:CVCL_0594")))

# ::id PMC_434_5513.27 ::date 2016-08-01T11:23:14
# ::snt In this model system, the active Ras protein was detectable 24 h after the addition of 2 μg/ml doxycycline ( Fig. 1 A).
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_27.txt
(s / smr-empty)

# ::id PMC_434_5513.28 ::date 2016-08-01T11:23:57
# ::snt Despite the continual increase in the level of active Ras, the levels of Erk1/2 phosphorylation gradually decreased after peaking at 12 h after doxycycline addition.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_28.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                  :ARG1-of (a / add-modification-00
                        :manner (p / phosphorylate-01))))
      :card2 (d / decrease-01
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk1/2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p3 / phosphorylate-01)))
      :card3 (i3 / increase-01
            :ARG0 (s / small-molecule :name (n3 / name :op1 "doxycycline")
                  :xref (x2 / xref :value "PUBCHEM:54671203"))
            :ARG1 (a3 / add-modification-00
                  :ARG0 (p5 / protein)
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "Erk1/2")
                        :xref (x3 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p4 / phosphorylate-00))))

# ::id PMC_434_5513.29 ::date 2016-08-01T11:33:17
# ::snt However, Akt and Raf1, an upstream kinase of Erk1/2, phosphorylation was still increased due to expression of active Ras.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_29.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (e / enzyme :name (n / name :op1 "Ras")
                  :ARG1-of (a / add-modification-00
                        :manner (p / phosphorylate-01)))
            :ARG1 (a2 / add-modification-00
                  :ARG0 (p2 / protein)
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN"))
                  :manner p))
      :card2 (i3 / increase-01
            :ARG0 (e3 / enzyme :name (n3 / name :op1 "Ras")
                  :ARG1-of (a3 / add-modification-00
                        :manner (p3 / phosphorylate-01)))
            :ARG1 (a4 / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (e4 / enzyme :name (n4 / name :op1 "Raf1")
                        :xref (x2 / xref :value "UNIPROT:RAF1_HUMAN"))
                  :manner p3)))

# ::id PMC_434_5513.30 ::date 2016-08-01T11:39:25
# ::snt To determine whether growth factor stimulation of Erk1/2 could also be affected due to sustained activation of Ras, NIH3T3tet-on/H-RasG12R cells were cultured in medium containing 0.5% serum in both the absence and presence of doxycycline, and then stimulated with FGF2 for 30 min ( Fig. 1 B).
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_30.txt
(i2 / increase-01
      :ARG0 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
            :manner (p / phosphorylate-01))
      :ARG1 (i3 / increase-01
            :ARG0 (m / molecular-physical-entity :name (n2 / name :op1 "growth" :op2 "factor"))
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "Erk1/2")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN")))
      :mode (h / hypothesis))

# ::id PMC_434_5513.31 ::date 2016-08-01T11:48:11
# ::snt The level of Erk1/2 phosphorylation was increased by FGF2 in both untreated and treated cells with doxycycline for 12 h, but not in cells treated with doxycycline for 48 h, although the basal Erk1/2 phosphorylation level was similar to that in cells treated with doxycycline for 12 h.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_31.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "FGF2")
            :xref (x / xref :value "UNIPROT:FGF2_HUMAN"))
      :ARG1 (a / add-modification-00
            :ARG0 (p2 / protein)
            :ARG1 (e / enzyme :name (n2 / name :op1 "Erk1/2")
                  :xref (x2 / xref :value "UNIPROT:MK01_HUMAN"))
            :manner (p3 / phosphorylate-01)))

# ::id PMC_434_5513.32 ::date 2016-08-01T11:53:46
# ::snt Furthermore, the phosphorylation of Erk1/2 down-stream targets, such as p90 ribosomal S6 kinase (RSK; MAPKAPK1A) and transcription factor Elk-1, was not increased by FGF2 in cells treated with doxycycline for 48 h.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_32.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (p / protein :name (n / name :op1 "FGF2")
                  :xref (x / xref :value "UNIPROT:FGF2_HUMAN"))
            :ARG1 (e / enzyme :name (n2 / name :op1 "p90" :op2 "ribosomal" :op3 "S6" :op4 "kinase")
                  :xref (x2 / xref :value "UNIPROT:KS6A1_HUMAN"))
            :location (c / cell))
      :card2 (i3 / increase-01 :polarity -
            :ARG0 (p2 / protein :name (n3 / name :op1 "FGF2")
                  :xref (x4 / xref :value "UNIPROT:KS6A1_HUMAN"))
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "Elk-1")
                  :xref (x3 / xref :value "UNIPROT:ELK1_HUMAN"))
            :location (c2 / cell)))

# ::id PMC_434_5513.33 ::date 2016-08-01T12:20:54
# ::snt Effect of sustained active Ras expression on Erk1/2 downregulation.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_33.txt
(d / decrease-01
      :ARG0 (e / enzyme :name (n / name :op1 "Ras")
            :ARG1-of (a / add-modification-00
                  :manner (p / phosphorylate-01)))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk1/2")
            :xref (x / xref :value "UNIPROT:MK01_HUMAN")))

# ::id PMC_434_5513.35 ::date 2016-08-01T12:23:11
# ::snt We next assessed the nuclear translocation of phosphorylated Erk1/2 following doxycycline treatment.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_35.txt
(t / translocate-01
      :ARG0 (s / small-molecule :name (n / name :op1 "doxycycline")
            :xref (x / xref :value "PUBCHEM:54671203"))
      :ARG1 (e / enzyme :name (n2 / name :op1 "Erk1/2")
            :xref (x2 / xref :value "UNIPROT:MK01_HUMAN")
            :ARG1-of (a / add-modification-00
                  :manner (p / phosphorylate-01)))
      :ARG2 (n3 / nucleus))

# ::id PMC_434_5513.36 ::date 2016-08-01T12:26:00
# ::snt Phopho-Erk1/2 immunoreactivity was highly enriched in the nucleus following FGF2 treatment in control cultures.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_36.txt
(i2 / increase-01
      :ARG0 (p / protein :name (n / name :op1 "FGF2")
            :xref (x / xref :value "UNIPROT:FGF2_HUMAN"))
      :ARG1 (e / enzyme :name (n2 / name :op1 "Erk1/2")
            :ARG1-of (a / add-modification-00
                  :manner (p2 / phosphorylate-01))
            :xref (x2 / xref :value "UNIPROT:MK01_HUMAN")))

# ::id PMC_434_5513.37 ::date 2016-08-01T12:28:22
# ::snt In contrast, Erk1/2 phosphorylation was marked in the cytosol, but sparse in the nucleus of doxycycline-treated cells ( Fig. 2 ).
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_37.txt
(s / smr-empty)

# ::id PMC_434_5513.38 ::date 2016-08-01T12:28:59
# ::snt These results suggest that prolonged Ras activation impairs the nuclear levels of phosphorylated Erk1/2 in NIH3T3 cells.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_38.txt
(d / decrease-01
      :ARG0 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
            :manner (p2 / phosphorylate-01))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk1/2")
            :xref (x / xref :value "UNIPROT:MK01_HUMAN")
            :ARG1-of (a2 / add-modification-00
                  :manner (p3 / phosphorylate-01)))
      :location (c / cell-line :name (n3 / name :op1 "NIH3T3")
            :xref (x2 / xref :value "NIH3T3:CVCL_0594")))

# ::id PMC_434_5513.39 ::date 2016-08-01T12:31:11
# ::snt Effect of sustained active Ras expression on the nuclear localization of phosphorylated Erk1/2.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_39.txt
(a / add-modification-00
      :ARG0 (e / enzyme :name (n / name :op1 "Ras")
            :ARG1-of (a2 / add-modification-00
                  :manner (p / phosphorylate-01)))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk1/2")
            :xref (x / xref :value "UNIPROT:MK01_HUMAN")
            :ARG1-of a2))

# ::id PMC_434_5513.40 ::date 2016-08-01T12:33:16
# ::snt NIH3T3tet-on/H-RasG12R cells were cultured on glass slides and either left untreated (− Doxy ) or treated (+ Doxy ) with doxycycline (2 μg/ml) for 24 h, followed by serum starvation with 0.5% serum for an additional 24 h in the absence or presence of doxycycline.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_40.txt
(s / smr-empty)

# ::id PMC_434_5513.44 ::date 2016-08-01T12:33:52
# ::snt Stained cells were immediately observed under an EVOSf1 Ⓡ fluorescence microscope (Advance Microscopy Group).
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_44.txt
(s / smr-empty)

# ::id PMC_434_5513.45 ::date 2016-08-01T12:34:19
# ::snt MKP3 is a Thr/Tyr dual-specific phosphatase of Erk1/2 that prevents nuclear translocation of Erk1/2 (18) .
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_45.txt
(t / translocate-01 :polarity -
      :ARG0 (e / enzyme :name (n / name :op1 "MKP3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN"))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk1/2")
            :xref (x2 / xref :value "UNIPROT:MK01_HUMAN"))
      :ARG2 (n3 / nucleus))

# ::id PMC_434_5513.46 ::date 2016-08-01T12:37:18
# ::snt It has been reported that MKP3 is induced by Erk1/2 upon fibroblast growth factor 2 (FGF2) stimulation in NIH3T3 cells (21) , suggesting that growth factor-induced Erk1/2 activity could be controlled by negative feedback loops via Erk1/2-specific MKP3 expression.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_46.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (p / protein :name (n / name :op1 "fibroblast" :op2 "growth" :op3 "factor" :op4 "2")
                  :xref (x / xref :value "UNIPROT:FGF2_HUMAN"))
            :ARG1 (i3 / increase-01
                  :ARG0 (e2 / enzyme :name (n3 / name :op1 "Erk1/2")
                        :xref (x3 / xref :value "UNIPROT:MK01_HUMAN"))
                  :ARG1 (e / enzyme :name (n2 / name :op1 "MKP3")
                        :xref (x2 / xref :value "UNIPROT:DUS6_HUMAN")))
            :location (c / cell-line :name (n4 / name :op1 "NIH3T3")
                  :xref (x4 / xref :value "NIH3T3:CVCL_0594")))
      :card2 (i4 / increase-01
            :ARG0 (p2 / protein :name (n5 / name :op1 "fibroblast" :op2 "growth" :op3 "factor" :op4 "2")
                  :xref (x5 / xref :value "UNIPROT:FGF2_HUMAN"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (e3 / enzyme :name (n6 / name :op1 "Erk1/2")
                        :xref (x6 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p4 / phosphorylate-01))))

# ::id PMC_434_5513.47 ::date 2016-08-01T12:37:42
# ::snt To investigate whether sustained Ras activation impairs phosphorylated Erk1/2 levels in the nucleus through induction of MKP3, NIH3T3tet-on/H-RasG12R cells were exposed to doxycycline and MKP3 mRNA levels were examined by Northern blot analysis.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_47.txt
(i2 / increase-01
      :ARG0 (e / enzyme :name (n / name :op1 "MKP3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN"))
      :ARG1 (d / decrease-01
            :ARG0 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "Ras"))
                  :manner (p2 / phosphorylate-01))
            :ARG1 (e3 / enzyme :name (n3 / name :op1 "Erk1/2")
                  :xref (x2 / xref :value "UNIPROT:MK01_HUMAN")
                  :ARG2-of (p3 / phosphorylate-01))
            :location (n4 / nucleus))
      :mode (h / hypothesis))

# ::id PMC_434_5513.48 ::date 2016-08-01T12:38:02
# ::snt A time kinetic study showed that MKP3 mRNA was detectable within 3 h after doxycycline addition ( Fig. 3 A).
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_48.txt
(s / smr-empty)

# ::id PMC_434_5513.49 ::date 2016-08-01T12:38:31
# ::snt MKP3 protein was also increased by doxycycline treatment and coincided with a reduction in Erk1/2 phosphorylation ( Fig. 3 B).
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_49.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (s / small-molecule :name (n / name :op1 "doxycycline")
                  :xref (x / xref :value "PUBCHEM:54671203"))
            :ARG1 (e / enzyme :name (n2 / name :op1 "MKP3")
                  :xref (x2 / xref :value "UNIPROT:DUS6_HUMAN")))
      :card2 (d / decrease-01
            :ARG1 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (e2 / enzyme :name (n3 / name :op1 "Erk1/2")
                        :xref (x3 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p2 / phosphorylate-01))))

# ::id PMC_434_5513.50 ::date 2016-08-01T12:40:46
# ::snt To determine whether induction of MKP3 mRNA by active Ras occurred at the transcriptional level, the 5'-regulatory region of the MKP3 gene (nucleotides from −1597 to −10 relative to the transcription start site) was isolated and sub-cloned into a pGL3-Luc reporter vector.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_50.txt
(i2 / increase-01
      :ARG0 (e / enzyme :name (n / name :op1 "Ras")
            :ARG1-of (a / add-modification-00
                  :manner (p / phosphorylate-01)))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "MKP3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN"))
      :mode (h / hypothesis))

# ::id PMC_434_5513.52 ::date 2016-08-01T12:41:14
# ::snt Thus, long-term activation of the Ras signaling pathway up-regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_52.txt
(i2 / increase-01
      :ARG0 (a / add-modification-00
            :ARG0 (p / protein)
            :ARG1 (p2 / pathway :name (n / name :op1 "Ras"))
            :manner (p3 / phosphorylate-01))
      :ARG1 (e / enzyme :name (n2 / name :op1 "MKP3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN"))
      :location (c / cell-line :name (n3 / name :op1 "NIH3T3")
            :xref (x2 / xref :value "NIH3T3:CVCL_0594")))

# ::id PMC_434_5513.55 ::date 2016-08-01T12:45:22
# ::snt After 24 h, the cells were treated with doxycycline (2 μg/ml) for an additional 24 h.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_55.txt
(s / smr-empty)

# ::id PMC_434_5513.57 ::date 2016-08-01T12:45:49
# ::snt Active Ras can stimulate multiple effector pathways, including Raf and PI3K (22) .
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_57.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (e / enzyme :name (n / name :op1 "Ras")
                  :ARG1-of (a / add-modification-00
                        :manner (p / phosphorylate-01)))
            :ARG1 (p2 / pathway :name (n2 / name :op1 "Ras")))
      :card2 (i3 / increase-01
            :ARG0 (e2 / enzyme :name (n3 / name :op1 "Ras")
                  :ARG1-of (a2 / add-modification-00
                        :manner (p3 / phosphorylate-01)))
            :ARG1 (p4 / pathway :name (n4 / name :op1 "PI3K"))))

# ::id PMC_434_5513.58 ::date 2016-08-01T12:51:05
# ::snt Numerous reports have demonstrated that MKP3 expression is dependent on Erk1/2 activity in several cell types, including NIH3T3, human pancreatic cancer, and non-small-cell lung cancer cells (21 , 23 - 25) .
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_58.txt
(m / multi-index-card
      :card1 (i2 / increase-01
            :ARG0 (a / add-modification-00
                  :ARG0 (p / protein)
                  :ARG1 (e / enzyme :name (n / name :op1 "Erk1/2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p2 / phosphorylate-01))
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "MKP3")
                  :xref (x2 / xref :value "UNIPROT:DUS6_HUMAN"))
            :location (c / cell-line :name (n3 / name :op1 "NIH3T3")
                  :xref (x3 / xref :value "NIH3T3:CVCL_0594")))
      :card2 (i3 / increase-01
            :ARG0 (a2 / add-modification-00
                  :ARG0 (p4 / protein)
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "Erk1/2")
                        :xref (x4 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p3 / phosphorylate-01))
            :ARG1 (e4 / enzyme :name (n5 / name :op1 "MKP3")
                  :xref (x5 / xref :value "UNIPROT:DUS6_HUMAN"))
            :location (c2 / cell))
      :card3 (i4 / increase-01
            :ARG0 (a3 / add-modification-00
                  :ARG0 (p6 / protein)
                  :ARG1 (e5 / enzyme :name (n6 / name :op1 "Erk1/2")
                        :xref (x6 / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p5 / phosphorylate-01))
            :ARG1 (e6 / enzyme :name (n7 / name :op1 "MKP3")
                  :xref (x7 / xref :value "UNIPROT:DUS6_HUMAN"))
            :location (c3 / cell-line :name (n8 / name :op1 "NSCLC")
                  :xref (x8 / xref :value "NSCLC:CVCL_H623"))))

# ::id PMC_434_5513.59 ::date 2016-08-01T12:51:31
# ::snt The PI3K pathway also inhibits Erk1/2 activity through up-regulation of MKP3 expression in response to FGF8 stimulation during limb development (26) .
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_59.txt
(m / multi-index-card
      :card1 (d / decrease-01
            :ARG0 (p / pathway :name (n / name :op1 "PI3K"))
            :ARG1 (a / add-modification-00
                  :ARG0 (p3 / protein)
                  :ARG1 (e / enzyme :name (n2 / name :op1 "Erk1/2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN"))
                  :manner (p2 / phosphorylate-01)))
      :card2 (i3 / increase-01
            :ARG0 (p4 / protein :name (n3 / name :op1 "FGF8")
                  :xref (x2 / xref :value "UNIPROT:FGF8_HUMAN"))
            :ARG1 (e2 / enzyme :name (n4 / name :op1 "MKP3")
                  :xref (x3 / xref :value "UNIPROT:DUS6_HUMAN"))))

# ::id PMC_434_5513.60 ::date 2016-08-01T12:51:50
# ::snt These studies have suggested that multiple signaling pathways are involved in MKP3 expression.
# ::save-date Mon Aug 1, 2016 ::user nnistor ::file PMC_434_5513_60.txt
(s / smr-empty)

# ::id PMC_434_5513.61 ::date 2016-08-01T12:52:21
# ::snt To determine the downstream signaling pathway of active Ras involved in MKP3 expression, we utilized pharmacological inhibitors.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_61.txt
(s / smr-empty)

# ::id PMC_434_5513.62 ::date 2016-08-01T12:52:53
# ::snt Treatment with either the PI3K inhibitor (LY294002) or the Akt inhibitor (API-2) blocked doxycycline-induced accumulation of MKP3, which led to the partial recovery of the phosphorylation status of Erk1/2 ( Fig. 4 A), suggesting the existence of an alternative mechanism.
# ::save-date Tue Aug 2, 2016 ::user nnistor ::file PMC_434_5513_62.txt
(m / multi-index-card
      :card1 (i2 / increase-01 :polarity -
            :ARG0 (s / small-molecule :name (n / name :op1 "LY294002")
                  :xref (x3 / xref :value "CHEBI:65329"))
            :ARG1 (i3 / increase-01
                  :ARG0 (s2 / small-molecule :name (n2 / name :op1 "doxycycline")
                        :xref (x / xref :value "PUBCHEM:54671203"))
                  :ARG1 (e / enzyme :name (n3 / name :op1 "MKP3")
                        :xref (x2 / xref :value "UNIPROT:DUS6_HUMAN"))))
      :card2 (i4 / increase-01 :polarity -
            :ARG0 (s3 / small-molecule :name (n4 / name :op1 "API-2")
                  :xref (x4 / xref :value "CHEBI:65310"))
            :ARG1 (i5 / increase-01
                  :ARG0 (s4 / small-molecule :name (n5 / name :op1 "doxycycline")
                        :xref (x5 / xref :value "PUBCHEM:54671203"))
                  :ARG1 (e2 / enzyme :name (n6 / name :op1 "MKP3")
                        :xref (x6 / xref :value "UNIPROT:DUS6_HUMAN")))))
